

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1  
2 An act relating to controlled substances; creating s.  
3 456.0301, F.S.; requiring certain boards to require  
4 certain registered practitioners to complete a  
5 specified board-approved continuing education course  
6 to obtain authorization to prescribe controlled  
7 substances as part of biennial license renewal and  
8 before a specified date; providing course  
9 requirements; providing that the course may be offered  
10 in a distance learning format and requiring that it be  
11 included within required continuing education hours;  
12 prohibiting the Department of Health from renewing the  
13 license of a prescriber under specified circumstances;  
14 specifying a deadline for course completion; providing  
15 an exception from the course requirements for certain  
16 licensees; requiring such licensees to submit  
17 confirmation of course completion; authorizing certain  
18 boards to adopt rules; amending s. 456.072, F.S.;  
19 authorizing disciplinary action against practitioners  
20 for violating specified provisions relating to  
21 controlled substances; amending s. 456.44, F.S.;  
22 defining the term "acute pain"; requiring the  
23 applicable boards to adopt rules establishing certain  
24 guidelines for prescribing controlled substances for  
25 acute pain; providing that the failure of a prescriber

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

26 | to follow specified guidelines is grounds for  
27 | disciplinary action; limiting opioid drug  
28 | prescriptions for the treatment of acute pain to a  
29 | specified period under certain circumstances;  
30 | authorizing such prescriptions for an extended period  
31 | if specified requirements are met; requiring a  
32 | prescriber who prescribes an opioid drug for the  
33 | treatment of pain other than acute pain to include a  
34 | specific indication on the prescription; requiring a  
35 | prescriber who prescribes an opioid drug for the  
36 | treatment of pain related to a traumatic injury with a  
37 | specified Injury Severity Score to concurrently  
38 | prescribe an emergency opioid antagonist; amending ss.  
39 | 458.3265 and 459.0137, F.S.; requiring pain management  
40 | clinics to register with the department or hold a  
41 | valid certificate of exemption; requiring certain  
42 | clinics to apply to the department for a certificate  
43 | of exemption; providing requirements for such  
44 | certificates; requiring the department to adopt rules  
45 | necessary to administer such exemptions; amending s.  
46 | 465.0155, F.S.; providing requirements for pharmacists  
47 | for the dispensing of controlled substances to persons  
48 | not known to them; defining the term "proper  
49 | identification"; amending s. 465.0276, F.S.;

50 | prohibiting the dispensing of certain controlled

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

51 substances in an amount that exceeds a 3-day supply  
52 unless certain criteria are met; providing an  
53 exception for the dispensing of certain controlled  
54 substances by a practitioner to the practitioner's own  
55 patients for the medication-assisted treatment of  
56 opiate addiction; providing requirements for  
57 practitioners for the dispensing of controlled  
58 substances to persons not known to them; defining the  
59 term "proper identification"; amending s. 893.03,  
60 F.S.; correcting a cross-reference; conforming the  
61 state controlled substances schedule to the federal  
62 controlled substances schedule; amending s. 893.04,  
63 F.S.; authorizing a pharmacist to dispense controlled  
64 substances upon receipt of an electronic prescription  
65 if certain conditions are met; amending s. 893.055,  
66 F.S.; revising and providing definitions; revising  
67 requirements for the prescription drug monitoring  
68 program; authorizing rulemaking; requiring dispensers  
69 to report information to the department for each  
70 controlled substance dispensed; providing  
71 applicability; requiring the department to maintain an  
72 electronic system for certain purposes which meets  
73 specified requirements; requiring certain information  
74 to be reported to the system by a specified time;  
75 specifying direct access to system information;

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

76 | authorizing the department to enter into reciprocal  
77 | agreements or contracts to share prescription drug  
78 | monitoring information with certain entities;  
79 | providing requirements for such agreements;  
80 | authorizing the department to enter into agreements or  
81 | contracts for secure connections with practitioner  
82 | electronic systems; requiring specified persons to  
83 | consult the system for certain purposes within a  
84 | specified time; providing exceptions to the duty of  
85 | specified persons to consult the system under certain  
86 | circumstances; requiring the department to issue  
87 | citations to prescribers or dispensers who fail to  
88 | meet specified requirements relating to consulting the  
89 | system; providing a system for discipline of specified  
90 | persons for failing to meet such requirements;  
91 | prohibiting a person from failing to report the  
92 | dispensing of a controlled substance when required to  
93 | do so; specifying penalties; authorizing the  
94 | department to enter into agreements or contracts for  
95 | specified purposes; providing for the release of  
96 | information obtained by the system; allowing specified  
97 | persons to have direct access to information for the  
98 | purpose of reviewing the controlled drug prescription  
99 | history of a patient; providing prescriber or  
100 | dispenser immunity from liability for review of

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

101 patient history when acting in good faith; providing  
102 construction; prohibiting the department from  
103 specified uses of funds; requiring the department to  
104 conduct or participate in studies for specified  
105 purposes; requiring an annual report to be submitted  
106 to the Governor and Legislature by a specified date;  
107 providing report requirements; authorizing the  
108 department to establish a certain direct-support  
109 organization for specified purposes; defining the term  
110 "direct-support organization"; requiring a direct-  
111 support organization to operate under written contract  
112 with the department; providing contract requirements;  
113 requiring the direct-support organization to obtain  
114 written approval from the department for specified  
115 purposes; providing for an independent annual  
116 financial audit by the direct-support organization;  
117 providing that copies of such audit be provided to  
118 specified entities; authorizing the department to  
119 adopt certain rules relating to resources used by the  
120 direct-support organization; providing for future  
121 repeal of provisions relating to the direct-support  
122 organization; requiring the department to adopt rules  
123 to implement the system; amending s. 893.0551, F.S.;  
124 revising provisions concerning the release of  
125 information held by the prescription drug monitoring

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

126 program; amending s. 893.13, F.S.; correcting cross-  
 127 references; increasing the severity of a felony for a  
 128 health care practitioner who provides or a person who  
 129 obtains certain controlled substances that are not  
 130 medically necessary under certain circumstances;  
 131 amending s. 893.147, F.S.; prohibiting any person from  
 132 possessing, purchasing, delivering, selling, or  
 133 possessing with intent to sell or deliver a tableting  
 134 machine, an encapsulating machine, or controlled  
 135 substance counterfeiting materials with knowledge,  
 136 intent, or reasonable cause to believe that it will be  
 137 used to manufacture a controlled substance or  
 138 counterfeit controlled substance; providing an  
 139 exception for persons who meet certain criteria;  
 140 defining terms; providing criminal penalties for  
 141 persons who violate specified provisions relating to  
 142 tableting machines, encapsulating machines, and  
 143 controlled substance counterfeiting materials;  
 144 amending ss. 458.331, 459.015, 463.0055, 782.04,  
 145 893.135, and 921.0022, F.S.; correcting cross-  
 146 references; conforming provisions to changes made by  
 147 the act; providing appropriations; providing effective  
 148 dates.

149  
 150 Be It Enacted by the Legislature of the State of Florida:

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

151  
152           Section 1. Section 456.0301, Florida Statutes, is created  
153 to read:  
154           456.0301 Requirement for instruction on controlled  
155 substance prescribing.-  
156           (1) (a) The appropriate board shall require each person  
157 registered with the United States Drug Enforcement  
158 Administration and authorized to prescribe controlled substances  
159 pursuant to 21 U.S.C. s. 822 to complete a board-approved 2-hour  
160 continuing education course on prescribing controlled substances  
161 offered by a statewide professional association of physicians in  
162 this state that is accredited to provide educational activities  
163 designated for the American Medical Association Physician's  
164 Recognition Award Category 1 Credit or the American Osteopathic  
165 Category 1-A continuing medical education credit as part of  
166 biennial license renewal. The course must include information on  
167 the current standards for prescribing controlled substances,  
168 particularly opiates; alternatives to these standards;  
169 nonpharmacological therapies; prescribing emergency opioid  
170 antagonists; and the risks of opioid addiction following all  
171 stages of treatment in the management of acute pain. The course  
172 may be offered in a distance learning format and must be  
173 included within the number of continuing education hours  
174 required by law. The department may not renew the license of any  
175 prescriber registered with the United States Drug Enforcement

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

176 Administration to prescribe controlled substances who has failed  
 177 to complete the course. The course must be completed by January  
 178 31, 2019, and at each subsequent renewal. This paragraph does  
 179 not apply to a licensee who is required by his or her applicable  
 180 practice act to complete a minimum of 2 hours of continuing  
 181 education on the safe and effective prescribing of controlled  
 182 substances.

183 (b) Each practitioner required to complete the course  
 184 required in paragraph (a) shall submit confirmation of having  
 185 completed such course when applying for biennial license  
 186 renewal.

187 (c) Each licensing board that requires a licensee to  
 188 complete an educational course pursuant to this subsection must  
 189 include the hours required for completion of the course in the  
 190 total hours of continuing education required by law for such  
 191 profession unless the continuing education requirements for such  
 192 profession consist of fewer than 30 hours biennially.

193 (2) Each board may adopt rules to administer this section.

194 Section 2. Paragraph (gg) of subsection (1) of section  
 195 456.072, Florida Statutes, is amended to read:

196 456.072 Grounds for discipline; penalties; enforcement.—

197 (1) The following acts shall constitute grounds for which  
 198 the disciplinary actions specified in subsection (2) may be  
 199 taken:

200 (gg) Engaging in a pattern of practice when prescribing

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

201 medicinal drugs or controlled substances which demonstrates a  
202 lack of reasonable skill or safety to patients, a violation of  
203 ~~any provision of this chapter or ss. 893.055 and 893.0551~~, a  
204 violation of the applicable practice act, or a violation of any  
205 rules adopted under this chapter or the applicable practice act  
206 of the prescribing practitioner. Notwithstanding s. 456.073(13),  
207 the department may initiate an investigation and establish such  
208 a pattern from billing records, data, or any other information  
209 obtained by the department.

210 Section 3. Paragraphs (a) through (g) of subsection (1) of  
211 section 456.44, Florida Statutes, are redesignated as paragraphs  
212 (b) through (h), respectively, a new paragraph (a) is added to  
213 that subsection, subsection (3) of that section is amended, and  
214 subsections (4), (5), and (6) are added to that section, to  
215 read:

216 456.44 Controlled substance prescribing.—

217 (1) DEFINITIONS.—As used in this section, the term:

218 (a) "Acute pain" means the normal, predicted,  
219 physiological, and time-limited response to an adverse chemical,  
220 thermal, or mechanical stimulus associated with surgery, trauma,  
221 or acute illness. The term does not include pain related to:

222 1. Cancer.

223 2. A terminal condition. For purposes of this  
224 subparagraph, the term "terminal condition" means a progressive  
225 disease or medical or surgical condition that causes significant

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

226 functional impairment, is not considered by a treating physician  
227 to be reversible without the administration of life-sustaining  
228 procedures, and will result in death within 1 year after  
229 diagnosis if the condition runs its normal course.

230 3. Palliative care to provide relief of symptoms related  
231 to an incurable, progressive illness or injury.

232 4. A traumatic injury with an Injury Severity Score of 9  
233 or greater.

234 (3) STANDARDS OF PRACTICE FOR TREATMENT OF CHRONIC  
235 NONMALIGNANT PAIN.—The standards of practice in this section do  
236 not supersede the level of care, skill, and treatment recognized  
237 in general law related to health care licensure.

238 (a) A complete medical history and a physical examination  
239 must be conducted before beginning any treatment and must be  
240 documented in the medical record. The exact components of the  
241 physical examination shall be left to the judgment of the  
242 registrant who is expected to perform a physical examination  
243 proportionate to the diagnosis that justifies a treatment. The  
244 medical record must, at a minimum, document the nature and  
245 intensity of the pain, current and past treatments for pain,  
246 underlying or coexisting diseases or conditions, the effect of  
247 the pain on physical and psychological function, a review of  
248 previous medical records, previous diagnostic studies, and  
249 history of alcohol and substance abuse. The medical record shall  
250 also document the presence of one or more recognized medical

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

251 indications for the use of a controlled substance. Each  
252 registrant must develop a written plan for assessing each  
253 patient's risk of aberrant drug-related behavior, which may  
254 include patient drug testing. Registrants must assess each  
255 patient's risk for aberrant drug-related behavior and monitor  
256 that risk on an ongoing basis in accordance with the plan.

257 (b) Each registrant must develop a written individualized  
258 treatment plan for each patient. The treatment plan shall state  
259 objectives that will be used to determine treatment success,  
260 such as pain relief and improved physical and psychosocial  
261 function, and shall indicate if any further diagnostic  
262 evaluations or other treatments are planned. After treatment  
263 begins, the registrant shall adjust drug therapy to the  
264 individual medical needs of each patient. Other treatment  
265 modalities, including a rehabilitation program, shall be  
266 considered depending on the etiology of the pain and the extent  
267 to which the pain is associated with physical and psychosocial  
268 impairment. The interdisciplinary nature of the treatment plan  
269 shall be documented.

270 (c) The registrant shall discuss the risks and benefits of  
271 the use of controlled substances, including the risks of abuse  
272 and addiction, as well as physical dependence and its  
273 consequences, with the patient, persons designated by the  
274 patient, or the patient's surrogate or guardian if the patient  
275 is incompetent. The registrant shall use a written controlled

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

276 substance agreement between the registrant and the patient  
277 outlining the patient's responsibilities, including, but not  
278 limited to:

279 1. Number and frequency of controlled substance  
280 prescriptions and refills.

281 2. Patient compliance and reasons for which drug therapy  
282 may be discontinued, such as a violation of the agreement.

283 3. An agreement that controlled substances for the  
284 treatment of chronic nonmalignant pain shall be prescribed by a  
285 single treating registrant unless otherwise authorized by the  
286 treating registrant and documented in the medical record.

287 (d) The patient shall be seen by the registrant at regular  
288 intervals, not to exceed 3 months, to assess the efficacy of  
289 treatment, ensure that controlled substance therapy remains  
290 indicated, evaluate the patient's progress toward treatment  
291 objectives, consider adverse drug effects, and review the  
292 etiology of the pain. Continuation or modification of therapy  
293 shall depend on the registrant's evaluation of the patient's  
294 progress. If treatment goals are not being achieved, despite  
295 medication adjustments, the registrant shall reevaluate the  
296 appropriateness of continued treatment. The registrant shall  
297 monitor patient compliance in medication usage, related  
298 treatment plans, controlled substance agreements, and  
299 indications of substance abuse or diversion at a minimum of 3-  
300 month intervals.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

301 (e) The registrant shall refer the patient as necessary  
302 for additional evaluation and treatment in order to achieve  
303 treatment objectives. Special attention shall be given to those  
304 patients who are at risk for misusing their medications and  
305 those whose living arrangements pose a risk for medication  
306 misuse or diversion. The management of pain in patients with a  
307 history of substance abuse or with a comorbid psychiatric  
308 disorder requires extra care, monitoring, and documentation and  
309 requires consultation with or referral to an addiction medicine  
310 specialist or a psychiatrist.

311 (f) A registrant must maintain accurate, current, and  
312 complete records that are accessible and readily available for  
313 review and comply with the requirements of this section, the  
314 applicable practice act, and applicable board rules. The medical  
315 records must include, but are not limited to:

- 316 1. The complete medical history and a physical  
317 examination, including history of drug abuse or dependence.
- 318 2. Diagnostic, therapeutic, and laboratory results.
- 319 3. Evaluations and consultations.
- 320 4. Treatment objectives.
- 321 5. Discussion of risks and benefits.
- 322 6. Treatments.
- 323 7. Medications, including date, type, dosage, and quantity  
324 prescribed.
- 325 8. Instructions and agreements.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

326           9. Periodic reviews.

327           10. Results of any drug testing.

328           11. A photocopy of the patient's government-issued photo  
329 identification.

330           12. If a written prescription for a controlled substance  
331 is given to the patient, a duplicate of the prescription.

332           13. The registrant's full name presented in a legible  
333 manner.

334           (g) A registrant shall immediately refer patients with  
335 signs or symptoms of substance abuse to a board-certified pain  
336 management physician, an addiction medicine specialist, or a  
337 mental health addiction facility as it pertains to drug abuse or  
338 addiction unless the registrant is a physician who is board-  
339 certified or board-eligible in pain management. Throughout the  
340 period of time before receiving the consultant's report, a  
341 prescribing registrant shall clearly and completely document  
342 medical justification for continued treatment with controlled  
343 substances and those steps taken to ensure medically appropriate  
344 use of controlled substances by the patient. Upon receipt of the  
345 consultant's written report, the prescribing registrant shall  
346 incorporate the consultant's recommendations for continuing,  
347 modifying, or discontinuing controlled substance therapy. The  
348 resulting changes in treatment shall be specifically documented  
349 in the patient's medical record. Evidence or behavioral  
350 indications of diversion shall be followed by discontinuation of

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

351 controlled substance therapy, and the patient shall be  
352 discharged, and all results of testing and actions taken by the  
353 registrant shall be documented in the patient's medical record.  
354

355 This subsection does not apply to a board-eligible or board-  
356 certified anesthesiologist, physiatrist, rheumatologist, or  
357 neurologist, or to a board-certified physician who has surgical  
358 privileges at a hospital or ambulatory surgery center and  
359 primarily provides surgical services. This subsection does not  
360 apply to a board-eligible or board-certified medical specialist  
361 who has also completed a fellowship in pain medicine approved by  
362 the Accreditation Council for Graduate Medical Education or the  
363 American Osteopathic Association, or who is board eligible or  
364 board certified in pain medicine by the American Board of Pain  
365 Medicine, the American Board of Interventional Pain Physicians,  
366 the American Association of Physician Specialists, or a board  
367 approved by the American Board of Medical Specialties or the  
368 American Osteopathic Association and performs interventional  
369 pain procedures of the type routinely billed using surgical  
370 codes. This subsection does not apply to a registrant who  
371 prescribes medically necessary controlled substances for a  
372 patient during an inpatient stay in a hospital licensed under  
373 chapter 395.

374 (4) STANDARDS OF PRACTICE FOR TREATMENT OF ACUTE PAIN.—The  
375 applicable boards shall adopt rules establishing guidelines for

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

376 prescribing controlled substances for acute pain, including  
 377 evaluation of the patient, creation and maintenance of a  
 378 treatment plan, obtaining informed consent and agreement for  
 379 treatment, periodic review of the treatment plan, consultation,  
 380 medical record review, and compliance with controlled substance  
 381 laws and regulations. Failure of a prescriber to follow such  
 382 guidelines constitutes grounds for disciplinary action pursuant  
 383 to s. 456.072(1)(gg), punishable as provided in s. 456.072(2).

384 (5) PRESCRIPTION SUPPLY.—

385 (a) For the treatment of acute pain, a prescription for an  
 386 opioid drug listed as a Schedule II controlled substance in s.  
 387 893.03 or 21 U.S.C. s. 812 may not exceed a 3-day supply, except  
 388 that up to a 7-day supply may be prescribed if:

389 1. The prescriber, in his or her professional judgment,  
 390 believes that more than a 3-day supply of such an opioid is  
 391 medically necessary to treat the patient's pain as an acute  
 392 medical condition;

393 2. The prescriber indicates "ACUTE PAIN EXCEPTION" on the  
 394 prescription; and

395 3. The prescriber adequately documents in the patient's  
 396 medical records the acute medical condition and lack of  
 397 alternative treatment options that justify deviation from the 3-  
 398 day supply limit established in this subsection.

399 (b) For the treatment of pain other than acute pain, a  
 400 prescriber must indicate "NONACUTE PAIN" on a prescription for

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

401 an opioid drug listed as a Schedule II controlled substance in  
 402 s. 893.03 or 21 U.S.C. s. 812.

403 (6) EMERGENCY OPIOID ANTAGONIST.—For the treatment of pain  
 404 related to a traumatic injury with an Injury Severity Score of 9  
 405 or greater, a prescriber who prescribes a Schedule II controlled  
 406 substance listed in s. 893.03 or 21 U.S.C. s. 812 must  
 407 concurrently prescribe an emergency opioid antagonist, as  
 408 defined in s. 381.887(1).

409 Section 4. Effective January 1, 2019, present subsections  
 410 (2) through (5) of section 458.3265, Florida Statutes, are  
 411 renumbered as subsections (3) through (6), respectively,  
 412 paragraphs (a) and (g) of subsection (1), paragraph (a) of  
 413 present subsection (2), paragraph (a) of present subsection (3),  
 414 and paragraph (a) of present subsection (4) of that section are  
 415 amended, and a new subsection (2) is added to that section, to  
 416 read:

417 458.3265 Pain-management clinics.—

418 (1) REGISTRATION.—

419 (a)1. As used in this section, the term:

420 a. "Board eligible" means successful completion of an  
 421 anesthesia, physical medicine and rehabilitation, rheumatology,  
 422 or neurology residency program approved by the Accreditation  
 423 Council for Graduate Medical Education or the American  
 424 Osteopathic Association for a period of 6 years from successful  
 425 completion of such residency program.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

426           b. "Chronic nonmalignant pain" means pain unrelated to  
 427 cancer which persists beyond the usual course of disease or the  
 428 injury that is the cause of the pain or more than 90 days after  
 429 surgery.

430           c. "Pain-management clinic" or "clinic" means any publicly  
 431 or privately owned facility:

432           (I) That advertises in any medium for any type of pain-  
 433 management services; or

434           (II) Where in any month a majority of patients are  
 435 prescribed opioids, benzodiazepines, barbiturates, or  
 436 carisoprodol for the treatment of chronic nonmalignant pain.

437           2. Each pain-management clinic must register with the  
 438 department or hold a valid certificate of exemption pursuant to  
 439 subsection (2).

440           3. The following clinics are exempt from the registration  
 441 requirement of paragraphs (c)-(m) and must apply to the  
 442 department for a certificate of exemption unless:

443           a. A ~~That~~ clinic ~~is~~ licensed as a facility pursuant to  
 444 chapter 395;

445           b. A clinic in which the majority of the physicians who  
 446 provide services in the clinic primarily provide surgical  
 447 services;

448           c. A ~~The~~ clinic ~~is~~ owned by a publicly held corporation  
 449 whose shares are traded on a national exchange or on the over-  
 450 the-counter market and whose total assets at the end of the

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

451 corporation's most recent fiscal quarter exceeded \$50 million;

452 d. A ~~The~~ clinic ~~is~~ affiliated with an accredited medical  
453 school at which training is provided for medical students,  
454 residents, or fellows;

455 e. A ~~The~~ clinic that does not prescribe controlled  
456 substances for the treatment of pain;

457 f. A ~~The~~ clinic ~~is~~ owned by a corporate entity exempt from  
458 federal taxation under 26 U.S.C. s. 501(c)(3);

459 g. A ~~The~~ clinic ~~is~~ wholly owned and operated by one or  
460 more board-eligible or board-certified anesthesiologists,  
461 physiatrists, rheumatologists, or neurologists; or

462 h. A ~~The~~ clinic ~~is~~ wholly owned and operated by a  
463 physician multispecialty practice where one or more board-  
464 eligible or board-certified medical specialists, who have also  
465 completed fellowships in pain medicine approved by the  
466 Accreditation Council for Graduate Medical Education or who are  
467 also board-certified in pain medicine by the American Board of  
468 Pain Medicine or a board approved by the American Board of  
469 Medical Specialties, the American Association of Physician  
470 Specialists, or the American Osteopathic Association, perform  
471 interventional pain procedures of the type routinely billed  
472 using surgical codes.

473 (g) The department may revoke the clinic's certificate of  
474 registration and prohibit all physicians associated with that  
475 pain-management clinic from practicing at that clinic location

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

476 based upon an annual inspection and evaluation of the factors  
 477 described in subsection (4) ~~(3)~~.

478 (2) CERTIFICATE OF EXEMPTION.—

479 (a) A pain management clinic claiming an exemption from  
 480 the registration requirements of subsection (1) must apply for a  
 481 certificate of exemption on a form adopted in rule by the  
 482 department. The form must require the applicant to provide:

483 1. The name or names under which the applicant does  
 484 business.

485 2. The address at which the pain management clinic is  
 486 located.

487 3. The specific exemption the applicant is claiming with  
 488 supporting documentation.

489 4. Any other information deemed necessary by the  
 490 department.

491 (b) The department must approve or deny the certificate  
 492 within 30 days after the receipt of a complete application.

493 (c) The certificate of exemption must be renewed  
 494 biennially, except that the department may issue the initial  
 495 certificates of exemption for up to 3 years in order to stagger  
 496 renewal dates.

497 (d) A certificateholder must prominently display the  
 498 certificate of exemption and make it available to the department  
 499 or the board upon request.

500 (e) A new certificate of exemption is required for a

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

501 change of address and is not transferable. A certificate of  
502 exemption is valid only for the applicant, qualifying owners,  
503 licenses, registrations, certifications, and services provided  
504 under a specific statutory exemption and is valid only to the  
505 specific exemption claimed and granted.

506 (f) A certificateholder must notify the department at  
507 least 60 days before any anticipated relocation or name change  
508 of the pain management clinic or a change of ownership.

509 (g) If a pain management clinic no longer qualifies for a  
510 certificate of exemption, the certificateholder must notify the  
511 department within 3 days after becoming aware that the clinic no  
512 longer qualifies for a certificate of exemption and register as  
513 a pain management clinic under subsection (1) or cease  
514 operations.

515 (3) ~~(2)~~ PHYSICIAN RESPONSIBILITIES.—These responsibilities  
516 apply to any physician who provides professional services in a  
517 pain-management clinic that is required to be registered in  
518 subsection (1).

519 (a) A physician may not practice medicine in a pain-  
520 management clinic, as described in subsection (5) ~~(4)~~, if the  
521 pain-management clinic is not registered with the department as  
522 required by this section. Any physician who qualifies to  
523 practice medicine in a pain-management clinic pursuant to rules  
524 adopted by the Board of Medicine as of July 1, 2012, may  
525 continue to practice medicine in a pain-management clinic as

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

526 long as the physician continues to meet the qualifications set  
527 forth in the board rules. A physician who violates this  
528 paragraph is subject to disciplinary action by his or her  
529 appropriate medical regulatory board.

530 (4)~~(3)~~ INSPECTION.—

531 (a) The department shall inspect the pain-management  
532 clinic annually, including a review of the patient records, to  
533 ensure that it complies with this section and the rules of the  
534 Board of Medicine adopted pursuant to subsection (5) ~~(4)~~ unless  
535 the clinic is accredited by a nationally recognized accrediting  
536 agency approved by the Board of Medicine.

537 (5)~~(4)~~ RULEMAKING.—

538 (a) The department shall adopt rules necessary to  
539 administer the registration, exemption, and inspection of pain-  
540 management clinics which establish the specific requirements,  
541 procedures, forms, and fees.

542 Section 5. Effective January 1, 2019, present subsections  
543 (2) through (5) of section 459.0137, Florida Statutes, are  
544 renumbered as subsections (3) through (6), respectively,  
545 paragraphs (a) and (g) of subsection (1), paragraph (a) of  
546 present subsection (2), paragraph (a) of present subsection (3),  
547 and paragraph (a) of present subsection (4) of that section are  
548 amended, and a new subsection (2) is added to that section, to  
549 read:

550 459.0137 Pain-management clinics.—

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

551 (1) REGISTRATION.—

552 (a)1. As used in this section, the term:

553 a. "Board eligible" means successful completion of an  
 554 anesthesia, physical medicine and rehabilitation, rheumatology,  
 555 or neurology residency program approved by the Accreditation  
 556 Council for Graduate Medical Education or the American  
 557 Osteopathic Association for a period of 6 years from successful  
 558 completion of such residency program.

559 b. "Chronic nonmalignant pain" means pain unrelated to  
 560 cancer which persists beyond the usual course of disease or the  
 561 injury that is the cause of the pain or more than 90 days after  
 562 surgery.

563 c. "Pain-management clinic" or "clinic" means any publicly  
 564 or privately owned facility:

565 (I) That advertises in any medium for any type of pain-  
 566 management services; or

567 (II) Where in any month a majority of patients are  
 568 prescribed opioids, benzodiazepines, barbiturates, or  
 569 carisoprodol for the treatment of chronic nonmalignant pain.

570 2. Each pain-management clinic must register with the  
 571 department or hold a valid certificate of exemption pursuant to  
 572 subsection (2).

573 3. The following clinics are exempt from the registration  
 574 requirement of paragraphs (c)-(m) and must apply to the  
 575 department for a certificate of exemption unless:

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 576           a. A ~~The~~ clinic ~~is~~ licensed as a facility pursuant to  
577 chapter 395;
- 578           b. A clinic in which the majority of the physicians who  
579 provide services in the clinic primarily provide surgical  
580 services;
- 581           c. A ~~The~~ clinic ~~is~~ owned by a publicly held corporation  
582 whose shares are traded on a national exchange or on the over-  
583 the-counter market and whose total assets at the end of the  
584 corporation's most recent fiscal quarter exceeded \$50 million;
- 585           d. A ~~The~~ clinic ~~is~~ affiliated with an accredited medical  
586 school at which training is provided for medical students,  
587 residents, or fellows;
- 588           e. A ~~The~~ clinic that does not prescribe controlled  
589 substances for the treatment of pain;
- 590           f. A ~~The~~ clinic ~~is~~ owned by a corporate entity exempt from  
591 federal taxation under 26 U.S.C. s. 501(c)(3);
- 592           g. A ~~The~~ clinic ~~is~~ wholly owned and operated by one or  
593 more board-eligible or board-certified anesthesiologists,  
594 psychiatrists, rheumatologists, or neurologists; or
- 595           h. A ~~The~~ clinic ~~is~~ wholly owned and operated by a  
596 physician multispecialty practice where one or more board-  
597 eligible or board-certified medical specialists, who have also  
598 completed fellowships in pain medicine approved by the  
599 Accreditation Council for Graduate Medical Education or the  
600 American Osteopathic Association or who are also board-certified

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

601 in pain medicine by the American Board of Pain Medicine or a  
 602 board approved by the American Board of Medical Specialties, the  
 603 American Association of Physician Specialists, or the American  
 604 Osteopathic Association, perform interventional pain procedures  
 605 of the type routinely billed using surgical codes.

606 (g) The department may revoke the clinic's certificate of  
 607 registration and prohibit all physicians associated with that  
 608 pain-management clinic from practicing at that clinic location  
 609 based upon an annual inspection and evaluation of the factors  
 610 described in subsection (4) ~~(3)~~.

611 (2) CERTIFICATE OF EXEMPTION.—

612 (a) A pain management clinic claiming an exemption from  
 613 the registration requirements of subsection (1) must apply for a  
 614 certificate of exemption on a form adopted in rule by the  
 615 department. The form must require the applicant to provide:

616 1. The name or names under which the applicant does  
 617 business.

618 2. The address at which the pain management clinic is  
 619 located.

620 3. The specific exemption the applicant is claiming with  
 621 supporting documentation.

622 4. Any other information deemed necessary by the  
 623 department.

624 (b) The department must approve or deny the certificate  
 625 within 30 days after the receipt of a complete application.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

626 (c) The certificate of exemption must be renewed  
 627 biennially, except that the department may issue the initial  
 628 certificates of exemption for up to 3 years in order to stagger  
 629 renewal dates.

630 (d) A certificateholder must prominently display the  
 631 certificate of exemption and make it available to the department  
 632 or the board upon request.

633 (e) A new certificate of exemption is required for a  
 634 change of address and is not transferable. A certificate of  
 635 exemption is valid only for the applicant, qualifying owners,  
 636 licenses, registrations, certifications, and services provided  
 637 under a specific statutory exemption and is valid only to the  
 638 specific exemption claimed and granted.

639 (f) A certificateholder must notify the department at  
 640 least 60 days before any anticipated relocation or name change  
 641 of the pain management clinic or a change of ownership.

642 (g) If a pain management clinic no longer qualifies for a  
 643 certificate of exemption, the certificateholder must notify the  
 644 department within 3 days after becoming aware that the clinic no  
 645 longer qualifies for a certificate of exemption and register as  
 646 a pain management clinic under subsection (1) or cease  
 647 operations.

648 (3) ~~(2)~~ PHYSICIAN RESPONSIBILITIES.—These responsibilities  
 649 apply to any osteopathic physician who provides professional  
 650 services in a pain-management clinic that is required to be

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

651 registered in subsection (1).

652 (a) An osteopathic physician may not practice medicine in  
653 a pain-management clinic, as described in subsection (5) ~~(4)~~, if  
654 the pain-management clinic is not registered with the department  
655 as required by this section. Any physician who qualifies to  
656 practice medicine in a pain-management clinic pursuant to rules  
657 adopted by the Board of Osteopathic Medicine as of July 1, 2012,  
658 may continue to practice medicine in a pain-management clinic as  
659 long as the physician continues to meet the qualifications set  
660 forth in the board rules. An osteopathic physician who violates  
661 this paragraph is subject to disciplinary action by his or her  
662 appropriate medical regulatory board.

663 (4) ~~(3)~~ INSPECTION.—

664 (a) The department shall inspect the pain-management  
665 clinic annually, including a review of the patient records, to  
666 ensure that it complies with this section and the rules of the  
667 Board of Osteopathic Medicine adopted pursuant to subsection (5)  
668 ~~(4)~~ unless the clinic is accredited by a nationally recognized  
669 accrediting agency approved by the Board of Osteopathic  
670 Medicine.

671 (5) ~~(4)~~ RULEMAKING.—

672 (a) The department shall adopt rules necessary to  
673 administer the registration, exemption, and inspection of pain-  
674 management clinics which establish the specific requirements,  
675 procedures, forms, and fees.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

676 Section 6. Section 465.0155, Florida Statutes, is amended  
677 to read:

678 465.0155 Standards of practice.—

679 (1) Consistent with the provisions of this act, the board  
680 shall adopt by rule standards of practice relating to the  
681 practice of pharmacy which shall be binding on every state  
682 agency and shall be applied by such agencies when enforcing or  
683 implementing any authority granted by any applicable statute,  
684 rule, or regulation, whether federal or state.

685 (2)(a) Before dispensing a controlled substance to a  
686 person not known to the pharmacist, the pharmacist must require  
687 the person purchasing, receiving, or otherwise acquiring the  
688 controlled substance to present valid photographic  
689 identification or other verification of his or her identity. If  
690 the person does not have proper identification, the pharmacist  
691 may verify the validity of the prescription and the identity of  
692 the patient with the prescriber or his or her authorized agent.  
693 Verification of health plan eligibility through a real-time  
694 inquiry or adjudication system is considered to be proper  
695 identification.

696 (b) This subsection does not apply in an institutional  
697 setting or to a long-term care facility, including, but not  
698 limited to, an assisted living facility or a hospital to which  
699 patients are admitted.

700 (c) As used in this subsection, the term "proper

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

701 identification" means an identification that is issued by a  
 702 state or the Federal Government containing the person's  
 703 photograph, printed name, and signature or a document considered  
 704 acceptable under 8 C.F.R. s. 274a.2(b)(1)(v)(A) and (B).

705 Section 7. Paragraph (b) of subsection (1) of section  
 706 465.0276, Florida Statutes, is amended, and paragraph (d) is  
 707 added to subsection (2) of that section, to read:

708 465.0276 Dispensing practitioner.—

709 (1)

710 (b) A practitioner registered under this section may not  
 711 dispense a controlled substance listed in Schedule II or  
 712 Schedule III as provided in s. 893.03. This paragraph does not  
 713 apply to:

714 1. The dispensing of complimentary packages of medicinal  
 715 drugs which are labeled as a drug sample or complimentary drug  
 716 as defined in s. 499.028 to the practitioner's own patients in  
 717 the regular course of her or his practice without the payment of  
 718 a fee or remuneration of any kind, whether direct or indirect,  
 719 as provided in subsection (4).

720 2. The dispensing of controlled substances in the health  
 721 care system of the Department of Corrections.

722 3. The dispensing of a controlled substance listed in  
 723 Schedule II or Schedule III in connection with the performance  
 724 of a surgical procedure.

725 a. For an opioid drug listed as a Schedule II controlled

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

726 substance in s. 893.03 or 21 U.S.C. s. 812:

727 (I) For the treatment of acute pain, the amount dispensed  
728 pursuant to this subparagraph may not exceed a 3-day supply, or  
729 a 7-day supply if the criteria in s. 456.44(5)(a) are met.

730 (II) For the treatment of pain other than acute pain, a  
731 practitioner must indicate "NONACUTE PAIN" on a prescription.

732 (III) For the treatment of pain related to a traumatic  
733 injury with an Injury Severity Score of 9 or greater, a  
734 practitioner must concurrently prescribe an emergency opioid  
735 antagonist, as defined in s. 381.887(1).

736 b. For a controlled substance listed in Schedule III, the  
737 amount dispensed pursuant to ~~this~~ this the subparagraph may not  
738 exceed a 14-day supply.

739 c. The exception in this subparagraph ~~exception~~ does not  
740 allow for the dispensing of a controlled substance listed in  
741 Schedule II or Schedule III more than 14 days after the  
742 performance of the surgical procedure.

743 d. For purposes of this subparagraph, the term "surgical  
744 procedure" means any procedure in any setting which involves, or  
745 reasonably should involve:

746 (I) ~~a.~~ Perioperative medication and sedation that allows  
747 the patient to tolerate unpleasant procedures while maintaining  
748 adequate cardiorespiratory function and the ability to respond  
749 purposefully to verbal or tactile stimulation and makes intra-  
750 and postoperative monitoring necessary; or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

751            ~~(II) b.~~ The use of general anesthesia or major conduction  
 752 anesthesia and preoperative sedation.

753            4. The dispensing of a controlled substance listed in  
 754 Schedule II or Schedule III pursuant to an approved clinical  
 755 trial. For purposes of this subparagraph, the term "approved  
 756 clinical trial" means a clinical research study or clinical  
 757 investigation that, in whole or in part, is state or federally  
 758 funded or is conducted under an investigational new drug  
 759 application that is reviewed by the United States Food and Drug  
 760 Administration.

761            5. The dispensing of methadone in a facility licensed  
 762 under s. 397.427 where medication-assisted treatment for opiate  
 763 addiction is provided.

764            6. The dispensing of a controlled substance listed in  
 765 Schedule II or Schedule III to a patient of a facility licensed  
 766 under part IV of chapter 400.

767            7. The dispensing of controlled substances listed in  
 768 Schedule II or Schedule III which have been approved by the  
 769 United States Food and Drug Administration for the purpose of  
 770 treating opiate addictions, including, but not limited to,  
 771 buprenorphine and buprenorphine combination products, by a  
 772 practitioner authorized under 21 U.S.C. s. 823, as amended, to  
 773 the practitioner's own patients for the medication-assisted  
 774 treatment of opiate addiction.

775            (2) A practitioner who dispenses medicinal drugs for human

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

776 consumption for fee or remuneration of any kind, whether direct  
777 or indirect, must:

778 (d)1. Before dispensing a controlled substance to a person  
779 not known to the dispenser, require the person purchasing,  
780 receiving, or otherwise acquiring the controlled substance to  
781 present valid photographic identification or other verification  
782 of his or her identity. If the person does not have proper  
783 identification, the dispenser may verify the validity of the  
784 prescription and the identity of the patient with the prescriber  
785 or his or her authorized agent. Verification of health plan  
786 eligibility through a real-time inquiry or adjudication system  
787 is considered to be proper identification.

788 2. This paragraph does not apply in an institutional  
789 setting or to a long-term care facility, including, but not  
790 limited to, an assisted living facility or a hospital to which  
791 patients are admitted.

792 3. As used in this paragraph, the term "proper  
793 identification" means an identification that is issued by a  
794 state or the Federal Government containing the person's  
795 photograph, printed name, and signature or a document considered  
796 acceptable under 8 C.F.R. s. 274a.2(b)(1)(v)(A) and (B).

797 Section 8. Paragraph (c) of subsection (1) and subsections  
798 (2) through (5) of section 893.03, Florida Statutes, are amended  
799 to read:

800 893.03 Standards and schedules.—The substances enumerated

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

801 in this section are controlled by this chapter. The controlled  
 802 substances listed or to be listed in Schedules I, II, III, IV,  
 803 and V are included by whatever official, common, usual,  
 804 chemical, trade name, or class designated. The provisions of  
 805 this section shall not be construed to include within any of the  
 806 schedules contained in this section any excluded drugs listed  
 807 within the purview of 21 C.F.R. s. 1308.22, styled "Excluded  
 808 Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical  
 809 Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted  
 810 Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt  
 811 Anabolic Steroid Products."

812 (1) SCHEDULE I.—A substance in Schedule I has a high  
 813 potential for abuse and has no currently accepted medical use in  
 814 treatment in the United States and in its use under medical  
 815 supervision does not meet accepted safety standards. The  
 816 following substances are controlled in Schedule I:

817 (c) Unless specifically excepted or unless listed in  
 818 another schedule, any material, compound, mixture, or  
 819 preparation that contains any quantity of the following  
 820 hallucinogenic substances or that contains any of their salts,  
 821 isomers, including optical, positional, or geometric isomers,  
 822 homologues, nitrogen-heterocyclic analogs, esters, ethers, and  
 823 salts of isomers, homologues, nitrogen-heterocyclic analogs,  
 824 esters, or ethers, if the existence of such salts, isomers, and  
 825 salts of isomers is possible within the specific chemical

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 826 designation or class description:
- 827 1. Alpha-Ethyltryptamine.
- 828 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2-
- 829 oxazoline).
- 830 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
- 831 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 832 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 833 6. Bufotenine.
- 834 7. Cannabis.
- 835 8. Cathinone.
- 836 9. DET (Diethyltryptamine).
- 837 10. 2,5-Dimethoxyamphetamine.
- 838 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
- 839 12. DMT (Dimethyltryptamine).
- 840 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
- 841 analog of phencyclidine).
- 842 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
- 843 15. N-Ethylamphetamine.
- 844 16. Fenethylamine.
- 845 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 846 18. Ibogaine.
- 847 19. LSD (Lysergic acid diethylamide).
- 848 20. Mescaline.
- 849 21. Methcathinone.
- 850 22. 5-Methoxy-3,4-methylenedioxyamphetamine.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 851           23. PMA (4-Methoxyamphetamine).
- 852           24. PMMA (4-Methoxymethamphetamine).
- 853           25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 854           26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 855           27. MDA (3,4-Methylenedioxyamphetamine).
- 856           28. JB-336 (N-Methyl-3-piperidyl benzilate).
- 857           29. N,N-Dimethylamphetamine.
- 858           30. Parahexyl.
- 859           31. Peyote.
- 860           32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine  
861 analog of phencyclidine).
- 862           33. Psilocybin.
- 863           34. Psilocyn.
- 864           35. *Salvia divinorum*, except for any drug product approved  
865 by the United States Food and Drug Administration which contains  
866 *Salvia divinorum* or its isomers, esters, ethers, salts, and  
867 salts of isomers, esters, and ethers, if the existence of such  
868 isomers, esters, ethers, and salts is possible within the  
869 specific chemical designation.
- 870           36. Salvinorin A, except for any drug product approved by  
871 the United States Food and Drug Administration which contains  
872 Salvinorin A or its isomers, esters, ethers, salts, and salts of  
873 isomers, esters, and ethers, if the existence of such isomers,  
874 esters, ethers, and salts is possible within the specific  
875 chemical designation.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 876 |           37. Xylazine.
- 877 |           38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
- 878 | (Thiophene analog of phencyclidine).
- 879 |           39. 3,4,5-Trimethoxyamphetamine.
- 880 |           40. Methyldone (3,4-Methylenedioxyethcathinone).
- 881 |           41. MDPV (3,4-Methylenedioxypropionylphenone).
- 882 |           42. Methyldone.
- 883 |           43. Methoxyethcathinone.
- 884 |           44. Fluoroethcathinone.
- 885 |           45. Methylethcathinone.
- 886 |           46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-
- 887 | yl)phenol) and its dimethyloctyl (C8) homologue.
- 888 |           47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
- 889 | (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
- 890 | ol].
- 891 |           48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
- 892 |           49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
- 893 |           50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-
- 894 | naphthoyl)indole).
- 895 |           51. BZP (Benzylpiperazine).
- 896 |           52. Fluorophenylpiperazine.
- 897 |           53. Methylphenylpiperazine.
- 898 |           54. Chlorophenylpiperazine.
- 899 |           55. Methoxyphenylpiperazine.
- 900 |           56. DBZP (1,4-Dibenzylpiperazine).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 901           57.   TFMPP (Trifluoromethylphenylpiperazine).
- 902           58.   MBDB (Methylbenzodioxolylbutanamine) or (3,4-
- 903 Methylendioxy-N-methylbutanamine).
- 904           59.   5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
- 905           60.   5-Hydroxy-N-methyltryptamine.
- 906           61.   5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
- 907           62.   5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
- 908           63.   Methyltryptamine.
- 909           64.   5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
- 910           65.   5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
- 911           66.   Tyramine (4-Hydroxyphenethylamine).
- 912           67.   5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
- 913           68.   DiPT (N,N-Diisopropyltryptamine).
- 914           69.   DPT (N,N-Dipropyltryptamine).
- 915           70.   4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
- 916           71.   5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
- 917           72.   DOI (4-Iodo-2,5-dimethoxyamphetamine).
- 918           73.   DOC (4-Chloro-2,5-dimethoxyamphetamine).
- 919           74.   2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 920           75.   2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 921           76.   2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 922           77.   2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
- 923           78.   2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
- 924           79.   2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 925           80.   2C-I (4-Iodo-2,5-dimethoxyphenethylamine).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 926           81. Butylone (3,4-Methylenedioxy-alpha-
- 927 methylaminobutyrophenone).
- 928           82. Ethcathinone.
- 929           83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
- 930           84. Naphyrone (Naphthylpyrovalerone).
- 931           85. Dimethylone (3,4-Methylenedioxy-N,N-
- 932 dimethylcathinone).
- 933           86. 3,4-Methylenedioxy-N,N-diethylcathinone.
- 934           87. 3,4-Methylenedioxy-propiofenone.
- 935           88. 3,4-Methylenedioxy-alpha-bromopropiofenone.
- 936           89. 3,4-Methylenedioxy-propiofenone-2-oxime.
- 937           90. 3,4-Methylenedioxy-N-acetylcathinone.
- 938           91. 3,4-Methylenedioxy-N-acetylmethcathinone.
- 939           92. 3,4-Methylenedioxy-N-acetylethcathinone.
- 940           93. Bromomethcathinone.
- 941           94. Buphedrone (alpha-Methylamino-butyrophenone).
- 942           95. Eutylone (3,4-Methylenedioxy-alpha-
- 943 ethylaminobutyrophenone).
- 944           96. Dimethylcathinone.
- 945           97. Dimethylmethcathinone.
- 946           98. Pentylone (3,4-Methylenedioxy-alpha-
- 947 methylaminovalerophenone).
- 948           99. MDPPP (3,4-Methylenedioxy-alpha-
- 949 pyrrolidinopropiofenone).
- 950           100. MDPBP (3,4-Methylenedioxy-alpha-

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 951 pyrrolidinobutyrophenone).
- 952 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
- 953 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
- 954 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
- 955 (Benocyclidine).
- 956 104. F-MABP (Fluoromethylaminobutyrophenone).
- 957 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
- 958 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
- 959 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
- 960 108. Me-EABP (Methylethylaminobutyrophenone).
- 961 109. Etizolam.
- 962 110. PPP (Pyrrolidinopropiophenone).
- 963 111. PBP (Pyrrolidinobutyrophenone).
- 964 112. PVP (Pyrrolidinovalerophenone) or
- 965 (Pyrrolidinopentiophenone).
- 966 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
- 967 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
- 968 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
- 969 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
- 970 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
- 971 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
- 972 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
- 973 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
- 974 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-
- 975 methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 976 | 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).  
 977 | 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).  
 978 | 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).  
 979 | 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).  
 980 | 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).  
 981 | 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).  
 982 | 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).  
 983 | 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).  
 984 | 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
 985 | (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-  
 986 | ol).  
 987 | 131. HU-308 ([ (1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-  
 988 | methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-  
 989 | enyl] methanol).  
 990 | 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-  
 991 | methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-  
 992 | 1,4-dione).  
 993 | 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).  
 994 | 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-  
 995 | undecanamide).  
 996 | 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-  
 997 | undecanamide).  
 998 | 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-  
 999 | methyloctan-2-yl)phenol).  
 1000 | 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1001 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
- 1002 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
- 1003 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
- 1004 methoxyphenylacetyl)indole).
- 1005 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
- 1006 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
- 1007 naphthalenylmethanone).
- 1008 142. WIN55,212-3 ([ (3S)-2,3-Dihydro-5-methyl-3-(4-
- 1009 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
- 1010 naphthalenylmethanone).
- 1011 143. Pentedrone (alpha-Methylaminovalerophenone).
- 1012 144. Fluoroamphetamine.
- 1013 145. Fluoromethamphetamine.
- 1014 146. Methoxetamine.
- 1015 147. Methiopropamine.
- 1016 148. Methylbuphedrone (Methyl-alpha-
- 1017 methylaminobutyrophenone).
- 1018 149. APB ((2-Aminopropyl)benzofuran).
- 1019 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
- 1020 151. UR-144 (1-Pentyl-3-(2,2,3,3-
- 1021 tetramethylcyclopropanoyl)indole).
- 1022 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
- 1023 tetramethylcyclopropanoyl)indole).
- 1024 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-
- 1025 tetramethylcyclopropanoyl)indole).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1026 | 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-  
 1027 | carboxamide).
- 1028 | 155. AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-  
 1029 | iodobenzoyl)indole).
- 1030 | 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-  
 1031 | carboxamide).
- 1032 | 157. URB-597 ((3'-(Aminocarbonyl)[1,1'-biphenyl]-3-yl)-  
 1033 | cyclohexylcarbamate).
- 1034 | 158. URB-602 ([1,1'-Biphenyl]-3-yl-carbamic acid,  
 1035 | cyclohexyl ester).
- 1036 | 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1-  
 1037 | benzoxazin-4-one).
- 1038 | 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
- 1039 | 161. 2C-H (2,5-Dimethoxyphenethylamine).
- 1040 | 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
- 1041 | 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
- 1042 | 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-  
 1043 | methoxybenzyl)]phenethylamine).
- 1044 | 165. MDMA (3,4-Methylenedioxyamphetamine).
- 1045 | 166. PB-22 (8-Quinoliny 1-pentylindole-3-carboxylate).
- 1046 | 167. Fluoro PB-22 (8-Quinoliny 1-(fluoropentyl)indole-3-  
 1047 | carboxylate).
- 1048 | 168. BB-22 (8-Quinoliny 1-(cyclohexylmethyl)indole-3-  
 1049 | carboxylate).
- 1050 | 169. Fluoro AKB48 (N-Adamant-1-yl 1-

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1051 (fluoropentyl)indazole-3-carboxamide).
- 1052 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
- 1053 pentylindazole-3-carboxamide).
- 1054 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
- 1055 (4-fluorobenzyl)indazole-3-carboxamide).
- 1056 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-
- 1057 1-pentylindazole-3-carboxamide).
- 1058 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
- 1059 yl)-1-(fluoropentyl)indole-3-carboxamide).
- 1060 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-
- 1061 methoxybenzyl)]phenethylamine).
- 1062 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-
- 1063 methoxybenzyl)]phenethylamine).
- 1064 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
- 1065 (cyclohexylmethyl)indazole-3-carboxamide).
- 1066 177. FUB-PB-22 (8-Quinoliny 1-(4-fluorobenzyl)indole-3-
- 1067 carboxylate).
- 1068 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-
- 1069 (fluoropentyl)indole-3-carboxamide).
- 1070 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-
- 1071 (fluoropentyl)indazole-3-carboxamide).
- 1072 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-
- 1073 naphthoyl)indazole).
- 1074 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl-
- 1075 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1076 | 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9-  
 1077 | (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-  
 1078 | hexahydrobenzo[c]chromen-1-ol).
- 1079 | 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9-  
 1080 | (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-  
 1081 | hexahydrobenzo[c]chromen-1-ol).
- 1082 | 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)-  
 1083 | 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9  
 1084 | diol).
- 1085 | 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6-  
 1086 | dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-  
 1087 | tetrahydro-6aH-benzo[c]chromen-1-ol).
- 1088 | 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-  
 1089 | 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
- 1090 | 187. MAPB ((2-Methylaminopropyl)benzofuran).
- 1091 | 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
- 1092 | 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
- 1093 | 190. Synthetic Cannabinoids.—Unless specifically excepted  
 1094 | or unless listed in another schedule or contained within a  
 1095 | pharmaceutical product approved by the United States Food and  
 1096 | Drug Administration, any material, compound, mixture, or  
 1097 | preparation that contains any quantity of a synthetic  
 1098 | cannabinoid found to be in any of the following chemical class  
 1099 | descriptions, or homologues, nitrogen-heterocyclic analogs,  
 1100 | isomers (including optical, positional, or geometric), esters,

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1101 ethers, salts, and salts of homologues, nitrogen-heterocyclic  
1102 analogs, isomers, esters, or ethers, whenever the existence of  
1103 such homologues, nitrogen-heterocyclic analogs, isomers, esters,  
1104 ethers, salts, and salts of isomers, esters, or ethers is  
1105 possible within the specific chemical class or designation.  
1106 Since nomenclature of these synthetically produced cannabinoids  
1107 is not internationally standardized and may continually evolve,  
1108 these structures or the compounds of these structures shall be  
1109 included under this subparagraph, regardless of their specific  
1110 numerical designation of atomic positions covered, if it can be  
1111 determined through a recognized method of scientific testing or  
1112 analysis that the substance contains properties that fit within  
1113 one or more of the following categories:

1114       a. Tetrahydrocannabinols.—Any tetrahydrocannabinols  
1115 naturally contained in a plant of the genus *Cannabis*, the  
1116 synthetic equivalents of the substances contained in the plant  
1117 or in the resinous extracts of the genus *Cannabis*, or synthetic  
1118 substances, derivatives, and their isomers with similar chemical  
1119 structure and pharmacological activity, including, but not  
1120 limited to, Delta 9 tetrahydrocannabinols and their optical  
1121 isomers, Delta 8 tetrahydrocannabinols and their optical  
1122 isomers, Delta 6a,10a tetrahydrocannabinols and their optical  
1123 isomers, or any compound containing a tetrahydrobenzo[c]chromene  
1124 structure with substitution at either or both the 3-position or  
1125 9-position, with or without substitution at the 1-position with

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1126 hydroxyl or alkoxy groups, including, but not limited to:

1127 (I) Tetrahydrocannabinol.

1128 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-

1129 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-

1130 ol).

1131 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-

1132 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-

1133 ol).

1134 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-

1135 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

1136 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-

1137 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

1138 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-

1139 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

1140 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-

1141 (2,3-dimethylpentan-2-yl)-6a,7,10,10a-

1142 tetrahydrobenzo[c]chromene).

1143 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-

1144 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

1145 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-

1146 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

1147 (X) Parahexyl.

1148 b. Naphthoylindoles, Naphthoylindazoles,

1149 Naphthoylcarbazoles, Naphthylmethylindoles,

1150 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1151 compound containing a naphthoylindole, naphthoylindazole,  
 1152 naphthoylcarbazole, naphthylmethylindole,  
 1153 naphthylmethylindazole, or naphthylmethylcarbazole structure,  
 1154 with or without substitution on the indole, indazole, or  
 1155 carbazole ring to any extent, whether or not substituted on the  
 1156 naphthyl ring to any extent, including, but not limited to:

1157 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).  
 1158 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-  
 1159 naphthoyl)indole).  
 1160 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).  
 1161 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).  
 1162 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).  
 1163 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).  
 1164 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).  
 1165 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).  
 1166 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).  
 1167 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).  
 1168 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).  
 1169 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).  
 1170 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).  
 1171 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-  
 1172 naphthoyl)indole).  
 1173 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).  
 1174 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).  
 1175 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1176 naphthoyl) indole).  
 1177 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-  
 1178 naphthoyl) indole).  
 1179 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl) indole).  
 1180 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl) indole).  
 1181 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl) indole).  
 1182 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1-  
 1183 naphthylmethyl] indole).  
 1184 (XXIII) JWH-193 (1-[2-(4-Morpholinyl) ethyl]-3-(4-methyl-1-  
 1185 naphthoyl) indole).  
 1186 (XXIV) JWH-198 (1-[2-(4-Morpholinyl) ethyl]-3-(4-methoxy-1-  
 1187 naphthoyl) indole).  
 1188 (XXV) JWH-200 (1-[2-(4-Morpholinyl) ethyl]-3-(1-  
 1189 naphthoyl) indole).  
 1190 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl) indole).  
 1191 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl) indole).  
 1192 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-  
 1193 naphthoyl) indole).  
 1194 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl) indole).  
 1195 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl) indole).  
 1196 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl) methyl]-3-(1-  
 1197 naphthoyl) indole).  
 1198 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-  
 1199 naphthoyl) indole).  
 1200 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1201 naphthoyl) indole).

1202 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-

1203 naphthoyl) indole).

1204 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-

1205 naphthoyl) indole).

1206 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl) indole).

1207 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-

1208 naphthoyl) indazole).

1209 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-

1210 naphthoyl) indole).

1211 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-

1212 naphthoyl) indole).

1213 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl) carbazole).

1214 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-

1215 naphthoyl) carbazole).

1216 c. Naphthoylpyrroles.—Any compound containing a

1217 naphthoylpyrrole structure, with or without substitution on the

1218 pyrrole ring to any extent, whether or not substituted on the

1219 naphthyl ring to any extent, including, but not limited to:

1220 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl) pyrrole).

1221 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl) pyrrole).

1222 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl) pyrrole).

1223 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl) pyrrole).

1224 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl) pyrrole).

1225 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1226 naphthoyl)pyrrole).

1227 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-  
1228 naphthoyl)pyrrole).

1229 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-  
1230 naphthoyl)pyrrole).

1231 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-  
1232 naphthoyl)pyrrole).

1233 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-  
1234 naphthoyl)pyrrole).

1235 d. Naphthylmethylenindenes.—Any compound containing a  
1236 naphthylmethylenindene structure, with or without substitution  
1237 at the 3-position of the indene ring to any extent, whether or  
1238 not substituted on the naphthyl ring to any extent, including,  
1239 but not limited to, JWH-176 (3-Pentyl-1-  
1240 (naphthylmethylene)indene).

1241 e. Phenylacetylindoles and Phenylacetylindazoles.—Any  
1242 compound containing a phenylacetylindole or phenylacetylindazole  
1243 structure, with or without substitution on the indole or  
1244 indazole ring to any extent, whether or not substituted on the  
1245 phenyl ring to any extent, including, but not limited to:

1246 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).

1247 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).

1248 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).

1249 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).

1250 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1251 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).

1252 (VII) Cannabipiperidiethanone.

1253 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-  
1254 methoxyphenylacetyl)indole).

1255 f. Cyclohexylphenols.—Any compound containing a  
1256 cyclohexylphenol structure, with or without substitution at the  
1257 5-position of the phenolic ring to any extent, whether or not  
1258 substituted on the cyclohexyl ring to any extent, including, but  
1259 not limited to:

1260 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-  
1261 yl)phenol).

1262 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)  
1263 homologue).

1264 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-  
1265 methyloctan-2-yl)phenol).

1266 g. Benzoylindoles and Benzoylindazoles.—Any compound  
1267 containing a benzoylindole or benzoylindazole structure, with or  
1268 without substitution on the indole or indazole ring to any  
1269 extent, whether or not substituted on the phenyl ring to any  
1270 extent, including, but not limited to:

1271 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).

1272 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

1273 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-  
1274 iodo-5-nitrobenzoyl)indole).

1275 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1276 (4-methoxybenzoyl) indole).
- 1277 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
- 1278 iodobenzoyl) indole).
- 1279 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl) indole).
- 1280 (VII) RCS-4 C4 homologue (1-Butyl-3-(4-
- 1281 methoxybenzoyl) indole).
- 1282 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo-
- 1283 3-(4-methoxybenzoyl) indole).
- 1284 h. Tetramethylcyclopropanoylindoles and
- 1285 Tetramethylcyclopropanoylindazoles.—Any compound containing a
- 1286 tetramethylcyclopropanoylindole or
- 1287 tetramethylcyclopropanoylindazole structure, with or without
- 1288 substitution on the indole or indazole ring to any extent,
- 1289 whether or not substituted on the tetramethylcyclopropyl group
- 1290 to any extent, including, but not limited to:
- 1291 (I) UR-144 (1-Pentyl-3-(2,2,3,3-
- 1292 tetramethylcyclopropanoyl) indole).
- 1293 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
- 1294 tetramethylcyclopropanoyl) indole).
- 1295 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-
- 1296 tetramethylcyclopropanoyl) indole).
- 1297 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-
- 1298 tetramethylcyclopropanoyl) indole).
- 1299 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-
- 1300 tetramethylcyclopropanoyl) indole).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1301 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-  
 1302 tetramethylcyclopropanoyl)indole).
- 1303 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-  
 1304 tetramethylcyclopropanoyl)indole).
- 1305 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-  
 1306 tetramethylcyclopropanoyl)indazole).
- 1307 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-  
 1308 tetramethylcyclopropanoyl)indole).
- 1309 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-  
 1310 tetramethylcyclopropanoyl)indole).
- 1311 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole  
 1312 carboxamides, and Adamantylindazole carboxamides.—Any compound  
 1313 containing an adamantoyl indole, adamantoyl indazole, adamantyl  
 1314 indole carboxamide, or adamantyl indazole carboxamide structure,  
 1315 with or without substitution on the indole or indazole ring to  
 1316 any extent, whether or not substituted on the adamantyl ring to  
 1317 any extent, including, but not limited to:
- 1318 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
- 1319 (II) Fluoro AKB48 (N-Adamant-1-yl 1-  
 1320 (fluoropentyl)indazole-3-carboxamide).
- 1321 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-  
 1322 carboxamide).
- 1323 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-  
 1324 adamantoyl)indole).
- 1325 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1326 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).  
 1327 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-  
 1328 adamantoyl)indole).  
 1329 j. Quinolinyllindolecarboxylates,  
 1330 Quinolinyllindazolecarboxylates, Quinolinyllindolecarboxamides,  
 1331 and Quinolinyllindazolecarboxamides.—Any compound containing a  
 1332 quinolinyllindole carboxylate, quinolinyllindazole carboxylate,  
 1333 isoquinolinyllindole carboxylate, isoquinolinyllindazole  
 1334 carboxylate, quinolinyllindole carboxamide, quinolinyllindazole  
 1335 carboxamide, isoquinolinyllindole carboxamide, or  
 1336 isoquinolinyllindazole carboxamide structure, with or without  
 1337 substitution on the indole or indazole ring to any extent,  
 1338 whether or not substituted on the quinoline or isoquinoline ring  
 1339 to any extent, including, but not limited to:  
 1340 (I) PB-22 (8-Quinolinyll 1-pentylindole-3-carboxylate).  
 1341 (II) Fluoro PB-22 (8-Quinolinyll 1-(fluoropentyl)indole-3-  
 1342 carboxylate).  
 1343 (III) BB-22 (8-Quinolinyll 1-(cyclohexylmethyl)indole-3-  
 1344 carboxylate).  
 1345 (IV) FUB-PB-22 (8-Quinolinyll 1-(4-fluorobenzyl)indole-3-  
 1346 carboxylate).  
 1347 (V) NPB-22 (8-Quinolinyll 1-pentylindazole-3-carboxylate).  
 1348 (VI) Fluoro NPB-22 (8-Quinolinyll 1-(fluoropentyl)indazole-  
 1349 3-carboxylate).  
 1350 (VII) FUB-NPB-22 (8-Quinolinyll 1-(4-fluorobenzyl)indazole-

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1351 3-carboxylate).

1352 (VIII) THJ (8-Quinoliny 1-pentylindazole-3-carboxamide).

1353 (IX) Fluoro THJ (8-Quinoliny 1-(fluoropentyl)indazole-3-

1354 carboxamide).

1355 k. Naphthylindolecarboxylates and

1356 Naphthylindazolecarboxylates.—Any compound containing a

1357 naphthylindole carboxylate or naphthylindazole carboxylate

1358 structure, with or without substitution on the indole or

1359 indazole ring to any extent, whether or not substituted on the

1360 naphthyl ring to any extent, including, but not limited to:

1361 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-

1362 carboxylate).

1363 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-

1364 carboxylate).

1365 (III) Fluoro SDB-005 (1-Naphthalenyl 1-

1366 (fluoropentyl)indazole-3-carboxylate).

1367 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-

1368 carboxylate).

1369 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-

1370 carboxylate).

1371 1. Naphthylindole carboxamides and Naphthylindazole

1372 carboxamides.—Any compound containing a naphthylindole

1373 carboxamide or naphthylindazole carboxamide structure, with or

1374 without substitution on the indole or indazole ring to any

1375 extent, whether or not substituted on the naphthyl ring to any

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1376 extent, including, but not limited to:

1377 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).

1378 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-

1379 (fluoropentyl)indole-3-carboxamide).

1380 (III) Chloro-NNEI (N-Naphthalen-1-yl 1-

1381 (chloropentyl)indole-3-carboxamide).

1382 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-

1383 carboxamide).

1384 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1-

1385 (fluoropentyl)indazole-3-carboxamide).

1386 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl

1387 indazole carboxamides, Alkylcarbonyl indole carboxylates, and

1388 Alkylcarbonyl indazole carboxylates.—Any compound containing an

1389 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,

1390 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-

1391 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an

1392 indole carboxamide, indazole carboxamide, indole carboxylate, or

1393 indazole carboxylate, with or without substitution on the indole

1394 or indazole ring to any extent, whether or not substituted on

1395 the alkylcarbonyl group to any extent, including, but not

1396 limited to:

1397 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-

1398 pentylindole-3-carboxamide).

1399 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-

1400 yl)-1-(fluoropentyl)indole-3-carboxamide).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1401 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-  
 1402 1-(fluoropentyl)indole-3-carboxamide).
- 1403 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
 1404 pentylindazole-3-carboxamide).
- 1405 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-  
 1406 yl)-1-(fluoropentyl)indazole-3-carboxamide).
- 1407 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-  
 1408 1-pentylindazole-3-carboxamide).
- 1409 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-  
 1410 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
- 1411 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-  
 1412 1-(4-fluorobenzyl)indazole-3-carboxamide).
- 1413 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
 1414 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
- 1415 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
 1416 (cyclohexylmethyl)indazole-3-carboxamide).
- 1417 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-  
 1418 1-(cyclohexylmethyl)indazole-3-carboxamide).
- 1419 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
 1420 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
- 1421 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-  
 1422 pentylindazole-3-carboxamide).
- 1423 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-  
 1424 1-(fluoropentyl)indazole-3-carboxamide).
- 1425 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1426 fluorobenzyl) indazole-3-carboxamide) .
- 1427 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
- 1428 2-yl)-1-(cyclohexylmethyl) indazole-3-carboxamide) .
- 1429 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-
- 1430 oxobutan-2-yl)-1-(4-fluorobenzyl) indazole-3-carboxamide) .
- 1431 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
- 1432 2-yl)-1-(cyclohexylmethyl) indole-3-carboxamide) .
- 1433 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-
- 1434 fluoropentyl) indole-3-carboxamide) .
- 1435 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-
- 1436 fluoropentyl) indazole-3-carboxamide) .
- 1437 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-
- 1438 (cyclohexylmethyl) indazole-3-carboxamide) .
- 1439 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-
- 1440 fluorobenzyl) indazole-3-carboxamide) .
- 1441 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
- 1442 2-yl)-1-(cyclohexylmethyl) indazole-3-carboxylate) .
- 1443 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.-
- 1444 Any compound containing a N-(2-phenylpropan-2-yl) indole
- 1445 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
- 1446 structure, with or without substitution on the indole or
- 1447 indazole ring to any extent, whether or not substituted on the
- 1448 phenyl ring of the cumyl group to any extent, including, but not
- 1449 limited to:
- 1450 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1451 carboxamide).

1452 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-

1453 (fluoropentyl)indole-3-carboxamide).

1454 o. Other Synthetic Cannabinoids.—Any material, compound,

1455 mixture, or preparation that contains any quantity of a

1456 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:

1457 (I) With or without modification or replacement of a

1458 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage

1459 between either two core rings, or linkage between a core ring

1460 and group structure, with or without the addition of a carbon or

1461 replacement of a carbon;

1462 (II) With or without replacement of a core ring or group

1463 structure, whether or not substituted on the ring or group

1464 structures to any extent; and

1465 (III) Is a cannabinoid receptor agonist, unless

1466 specifically excepted or unless listed in another schedule or

1467 contained within a pharmaceutical product approved by the United

1468 States Food and Drug Administration.

1469 191. Substituted Cathinones.—Unless specifically excepted,

1470 listed in another schedule, or contained within a pharmaceutical

1471 product approved by the United States Food and Drug

1472 Administration, any material, compound, mixture, or preparation,

1473 including its salts, isomers, esters, or ethers, and salts of

1474 isomers, esters, or ethers, whenever the existence of such salts

1475 is possible within any of the following specific chemical

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1476 designations:

1477       a. Any compound containing a 2-amino-1-phenyl-1-propanone

1478 structure;

1479       b. Any compound containing a 2-amino-1-naphthyl-1-

1480 propanone structure; or

1481       c. Any compound containing a 2-amino-1-thiophenyl-1-

1482 propanone structure,

1483

1484 whether or not the compound is further modified:

1485       (I) With or without substitution on the ring system to any

1486 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,

1487 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused

1488 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide

1489 substituents;

1490       (II) With or without substitution at the 3-propanone

1491 position with an alkyl substituent or removal of the methyl

1492 group at the 3-propanone position;

1493       (III) With or without substitution at the 2-amino nitrogen

1494 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or

1495 not further substituted in the ring system; or

1496       (IV) With or without inclusion of the 2-amino nitrogen

1497 atom in a cyclic structure, including, but not limited to:

1498       (A) Methcathinone.

1499       (B) Ethcathinone.

1500       (C) Methydone (3,4-Methylenedioxy-methcathinone).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1501 (D) 2,3-Methylenedioxy-methcathinone.
- 1502 (E) MDPV (3,4-Methylenedioxy-pyrovalerone).
- 1503 (F) Methylenedioxy-methcathinone.
- 1504 (G) Methoxy-methcathinone.
- 1505 (H) Fluoro-methcathinone.
- 1506 (I) Methylethcathinone.
- 1507 (J) Butylone (3,4-Methylenedioxy-alpha-
- 1508 methylenedioxy-methylamino-2-phenylethylamine).
- 1509 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
- 1510 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
- 1511 (M) Naphyrone (Naphthylpyrovalerone).
- 1512 (N) Bromo-methcathinone.
- 1513 (O) Buphedrone (alpha-Methylamino-2-phenylethylamine).
- 1514 (P) Eutylone (3,4-Methylenedioxy-alpha-
- 1515 ethylamino-2-phenylethylamine).
- 1516 (Q) Dimethylcathinone.
- 1517 (R) Dimethylmethcathinone.
- 1518 (S) Pentylone (3,4-Methylenedioxy-alpha-
- 1519 methylamino-2-phenylethylamine).
- 1520 (T) Penthedrone (alpha-Methylamino-2-phenylethylamine).
- 1521 (U) MDPPP (3,4-Methylenedioxy-alpha-
- 1522 pyrrolidinopropylphenone).
- 1523 (V) MDPBP (3,4-Methylenedioxy-alpha-
- 1524 pyrrolidinobutylphenone).
- 1525 (W) MPPP (Methyl-alpha-pyrrolidinopropylphenone).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1526 (X) PPP (Pyrrolidinopropiophenone).
- 1527 (Y) PVP (Pyrrolidinovalerophenone) or
- 1528 (Pyrrolidinopentiophenone).
- 1529 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
- 1530 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
- 1531 (BB) F-MABP (Fluoromethylaminobutyrophenone).
- 1532 (CC) Me-EABP (Methylethylaminobutyrophenone).
- 1533 (DD) PBP (Pyrrolidinobutyrophenone).
- 1534 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
- 1535 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
- 1536 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
- 1537 (HH) Dimethylone (3,4-Methylenedioxy-N,N-
- 1538 dimethylcathinone).
- 1539 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
- 1540 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
- 1541 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
- 1542 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
- 1543 (MM) Methylbuphedrone (Methyl-alpha-
- 1544 methylaminobutyrophenone).
- 1545 (NN) Methyl-alpha-methylaminohexanophenone.
- 1546 (OO) N-Ethyl-N-methylcathinone.
- 1547 (PP) PHP (Pyrrolidinohexanophenone).
- 1548 (QQ) PV8 (Pyrrolidinoheptanophenone).
- 1549 (RR) Chloromethcathinone.
- 1550 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1551           192. Substituted Phenethylamines.—Unless specifically  
 1552           excepted or unless listed in another schedule, or contained  
 1553           within a pharmaceutical product approved by the United States  
 1554           Food and Drug Administration, any material, compound, mixture,  
 1555           or preparation, including its salts, isomers, esters, or ethers,  
 1556           and salts of isomers, esters, or ethers, whenever the existence  
 1557           of such salts is possible within any of the following specific  
 1558           chemical designations, any compound containing a phenethylamine  
 1559           structure, without a beta-keto group, and without a benzyl group  
 1560           attached to the amine group, whether or not the compound is  
 1561           further modified with or without substitution on the phenyl ring  
 1562           to any extent with alkyl, alkylthio, nitro, alkoxy, thio,  
 1563           halide, fused alkylenedioxy, fused furan, fused benzofuran,  
 1564           fused dihydrofuran, or fused tetrahydropyran substituents,  
 1565           whether or not further substituted on a ring to any extent, with  
 1566           or without substitution at the alpha or beta position by any  
 1567           alkyl substituent, with or without substitution at the nitrogen  
 1568           atom, and with or without inclusion of the 2-amino nitrogen atom  
 1569           in a cyclic structure, including, but not limited to:  
 1570           a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).  
 1571           b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).  
 1572           c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).  
 1573           d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).  
 1574           e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).  
 1575           f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1576 | g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 1577 | h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
- 1578 | i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
- 1579 | j. 2C-H (2,5-Dimethoxyphenethylamine).
- 1580 | k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
- 1581 | l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
- 1582 | m. MDMA (3,4-Methylenedioxyamphetamine).
- 1583 | n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
- 1584 | Methylenedioxy-N-methylbutanamine).
- 1585 | o. MDA (3,4-Methylenedioxyamphetamine).
- 1586 | p. 2,5-Dimethoxyamphetamine.
- 1587 | q. Fluoroamphetamine.
- 1588 | r. Fluoromethamphetamine.
- 1589 | s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 1590 | t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 1591 | u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
- 1592 | v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
- 1593 | w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
- 1594 | x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 1595 | y. PMA (4-Methoxyamphetamine).
- 1596 | z. N-Ethylamphetamine.
- 1597 | aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 1598 | bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
- 1599 | cc. PMMA (4-Methoxymethamphetamine).
- 1600 | dd. N,N-Dimethylamphetamine.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1601 ee. 3,4,5-Trimethoxyamphetamine.
- 1602 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
- 1603 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
- 1604 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
- 1605 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
- 1606 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 1607 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 1608 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 1609 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 1610 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
- 1611 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
- 1612 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
- 1613 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
- 1614 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
- 1615 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-
- 1616 dihydrobenzofuran),

1617  
 1618 which does not include phenethylamine, mescaline as described in  
 1619 subparagraph 20., substituted cathinones as described in  
 1620 subparagraph 191., N-Benzyl phenethylamine compounds as  
 1621 described in subparagraph 193., or methamphetamine as described  
 1622 in subparagraph (2)(c)5. ~~(2)(e)4.~~

1623 193. N-Benzyl Phenethylamine Compounds.—Unless  
 1624 specifically excepted or unless listed in another schedule, or  
 1625 contained within a pharmaceutical product approved by the United

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1626 States Food and Drug Administration, any material, compound,  
 1627 mixture, or preparation, including its salts, isomers, esters,  
 1628 or ethers, and salts of isomers, esters, or ethers, whenever the  
 1629 existence of such salts is possible within any of the following  
 1630 specific chemical designations, any compound containing a  
 1631 phenethylamine structure without a beta-keto group, with  
 1632 substitution on the nitrogen atom of the amino group with a  
 1633 benzyl substituent, with or without substitution on the phenyl  
 1634 or benzyl ring to any extent with alkyl, alkoxy, thio,  
 1635 alkylthio, halide, fused alkylenedioxy, fused furan, fused  
 1636 benzofuran, or fused tetrahydropyran substituents, whether or  
 1637 not further substituted on a ring to any extent, with or without  
 1638 substitution at the alpha position by any alkyl substituent,  
 1639 including, but not limited to:

- 1640 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-  
 1641 methoxybenzyl)]phenethylamine).
- 1642 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-  
 1643 hydroxybenzyl)]phenethylamine).
- 1644 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-  
 1645 fluorobenzyl)]phenethylamine).
- 1646 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-  
 1647 methylenedioxybenzyl)]phenethylamine).
- 1648 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-  
 1649 methoxybenzyl)]phenethylamine).
- 1650 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1651 hydroxybenzyl) ]phenethylamine) .
- 1652       g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-
- 1653 fluorobenzyl) ]phenethylamine) .
- 1654       h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-
- 1655 methylenedioxybenzyl) ]phenethylamine) .
- 1656       i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-
- 1657 methoxybenzyl) ]phenethylamine) .
- 1658       j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-
- 1659 methoxybenzyl) ]phenethylamine) .
- 1660       k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-
- 1661 methoxybenzyl) ]phenethylamine) .
- 1662       l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-
- 1663 methoxybenzyl) ]phenethylamine) .
- 1664       m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-
- 1665 hydroxybenzyl) ]phenethylamine) .
- 1666       n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-
- 1667 fluorobenzyl) ]phenethylamine) .
- 1668       o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-
- 1669 methylenedioxybenzyl) ]phenethylamine) .
- 1670       p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-
- 1671 methoxybenzyl) ]phenethylamine) .
- 1672       q. 25H-NBOH (2,5-Dimethoxy-[N-(2-
- 1673 hydroxybenzyl) ]phenethylamine) .
- 1674       r. 25H-NBF (2,5-Dimethoxy-[N-(2-
- 1675 fluorobenzyl) ]phenethylamine) .

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1676 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-  
1677 methoxybenzyl)]phenethylamine),  
1678

1679 which does not include substituted cathinones as described in  
1680 subparagraph 191.

1681 194. Substituted Tryptamines.—Unless specifically excepted  
1682 or unless listed in another schedule, or contained within a  
1683 pharmaceutical product approved by the United States Food and  
1684 Drug Administration, any material, compound, mixture, or  
1685 preparation containing a 2-(1H-indol-3-yl)ethanamine, for  
1686 example tryptamine, structure with or without mono- or di-  
1687 substitution of the amine nitrogen with alkyl or alkenyl groups,  
1688 or by inclusion of the amino nitrogen atom in a cyclic  
1689 structure, whether or not substituted at the alpha position with  
1690 an alkyl group, whether or not substituted on the indole ring to  
1691 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy  
1692 groups, including, but not limited to:

- 1693 a. Alpha-Ethyltryptamine.
- 1694 b. Bufotenine.
- 1695 c. DET (Diethyltryptamine).
- 1696 d. DMT (Dimethyltryptamine).
- 1697 e. MET (N-Methyl-N-ethyltryptamine).
- 1698 f. DALT (N,N-Diallyltryptamine).
- 1699 g. EiPT (N-Ethyl-N-isopropyltryptamine).
- 1700 h. MiPT (N-Methyl-N-isopropyltryptamine).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1701 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
- 1702 j. 5-Hydroxy-N-methyltryptamine.
- 1703 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
- 1704 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
- 1705 m. Methyltryptamine.
- 1706 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
- 1707 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
- 1708 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
- 1709 q. DiPT (N,N-Diisopropyltryptamine).
- 1710 r. DPT (N,N-Dipropyltryptamine).
- 1711 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
- 1712 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
- 1713 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
- 1714 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
- 1715 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
- 1716 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
- 1717 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-
- 1718 isopropyltryptamine).
- 1719 z. Methyl-alpha-ethyltryptamine.
- 1720 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
- 1721
- 1722 which does not include tryptamine, psilocyn as described in
- 1723 subparagraph 34., or psilocybin as described in subparagraph 33.
- 1724 195. Substituted Phenylcyclohexylamines.—Unless
- 1725 specifically excepted or unless listed in another schedule, or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1726 contained within a pharmaceutical product approved by the United  
 1727 States Food and Drug Administration, any material, compound,  
 1728 mixture, or preparation containing a phenylcyclohexylamine  
 1729 structure, with or without any substitution on the phenyl ring,  
 1730 any substitution on the cyclohexyl ring, any replacement of the  
 1731 phenyl ring with a thiophenyl or benzothiophenyl ring, with or  
 1732 without substitution on the amine with alkyl, dialkyl, or alkoxy  
 1733 substituents, inclusion of the nitrogen in a cyclic structure,  
 1734 or any combination of the above, including, but not limited to:

- 1735 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP  
 1736 (Benocyclidine).
- 1737 b. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog  
 1738 of phencyclidine).
- 1739 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine  
 1740 analog of phencyclidine).
- 1741 d. PCPr (Phenylcyclohexylpropylamine).
- 1742 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene  
 1743 analog of phencyclidine).
- 1744 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
- 1745 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
- 1746 h. Methoxetamine.
- 1747 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
- 1748 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
- 1749 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
- 1750 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1751 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
- 1752 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
- 1753 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
- 1754 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
- 1755 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
- 1756 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
- 1757 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2-
- 1758 piperidinylidene]-benzenesulfonamide.
- 1759 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-
- 1760 piperidinylidene]-benzenesulfonamide.
- 1761 198. AH-7921, 3,4-dichloro-N-[[1-
- 1762 (dimethylamino)cyclohexyl]methyl]-benzamide.
- 1763 199. U47700, trans-3,4-dichloro-N-[2-
- 1764 (dimethylamino)cyclohexyl]-N-methyl-benzamide.
- 1765 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,
- 1766 dihydrochloride.
- 1767 (2) SCHEDULE II.—A substance in Schedule II has a high
- 1768 potential for abuse and has a currently accepted but severely
- 1769 restricted medical use in treatment in the United States, and
- 1770 abuse of the substance may lead to severe psychological or
- 1771 physical dependence. The following substances are controlled in
- 1772 Schedule II:
- 1773 (a) Unless specifically excepted or unless listed in
- 1774 another schedule, any of the following substances, whether
- 1775 produced directly or indirectly by extraction from substances of

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1776 | vegetable origin or independently by means of chemical  
 1777 | synthesis:  
 1778 |       1. Opium and any salt, compound, derivative, or  
 1779 | preparation of opium, except nalmefene or isoquinoline alkaloids  
 1780 | of opium, including, but not limited to the following:  
 1781 |       a. Raw opium.  
 1782 |       b. Opium extracts.  
 1783 |       c. Opium fluid extracts.  
 1784 |       d. Powdered opium.  
 1785 |       e. Granulated opium.  
 1786 |       f. Tincture of opium.  
 1787 |       g. Codeine.  
 1788 |       h. Dihydroetorphine.  
 1789 |       ~~i.h.~~ Ethylmorphine.  
 1790 |       ~~j.i.~~ Etorphine hydrochloride.  
 1791 |       ~~k.j.~~ Hydrocodone and hydrocodone combination products.  
 1792 |       ~~l.k.~~ Hydromorphone.  
 1793 |       ~~m.l.~~ Levo-alphaacetylmethadol (also known as levo-alpha-  
 1794 | acetylmethadol, levomethadyl acetate, or LAAM).  
 1795 |       ~~n.m.~~ Metopon (methyldihydromorphinone).  
 1796 |       ~~o.n.~~ Morphine.  
 1797 |       p. Oripavine.  
 1798 |       ~~q.o.~~ Oxycodone.  
 1799 |       ~~r.p.~~ Oxymorphone.  
 1800 |       ~~s.q.~~ Thebaine.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1801           2. Any salt, compound, derivative, or preparation of a  
 1802 substance which is chemically equivalent to or identical with  
 1803 any of the substances referred to in subparagraph 1., except  
 1804 that these substances shall not include the isoquinoline  
 1805 alkaloids of opium.

1806           3. Any part of the plant of the species *Papaver*  
 1807 *somniferum*, L.

1808           4. Cocaine or ecgonine, including any of their  
 1809 stereoisomers, and any salt, compound, derivative, or  
 1810 preparation of cocaine or ecgonine, except that these substances  
 1811 shall not include ioflupane I 123.

1812           (b) Unless specifically excepted or unless listed in  
 1813 another schedule, any of the following substances, including  
 1814 their isomers, esters, ethers, salts, and salts of isomers,  
 1815 esters, and ethers, whenever the existence of such isomers,  
 1816 esters, ethers, and salts is possible within the specific  
 1817 chemical designation:

- 1818           1. Alfentanil.
- 1819           2. Alphaprodine.
- 1820           3. Anileridine.
- 1821           4. Bezitramide.
- 1822           5. Bulk propoxyphene (nondosage forms).
- 1823           6. Carfentanil.
- 1824           7. Dihydrocodeine.
- 1825           8. Diphenoxylate.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1826 | 9. Fentanyl.
- 1827 | 10. Isomethadone.
- 1828 | 11. Levomethorphan.
- 1829 | 12. Levorphanol.
- 1830 | 13. Metazocine.
- 1831 | 14. Methadone.
- 1832 | 15. Methadone-Intermediate,4-cyano-2-
- 1833 | dimethylamino-4,4-diphenylbutane.
- 1834 | 16. Moramide-Intermediate,2-methyl-
- 1835 | 3-morpholino-1,1-diphenylpropane-carboxylic acid.
- 1836 | 17. Nabilone.
- 1837 | 18. Pethidine (meperidine).
- 1838 | 19. Pethidine-Intermediate-A,4-cyano-1-
- 1839 | methyl-4-phenylpiperidine.
- 1840 | 20. Pethidine-Intermediate-B,ethyl-4-
- 1841 | phenylpiperidine-4-carboxylate.
- 1842 | 21. Pethidine-Intermediate-C,1-methyl-4- phenylpiperidine-
- 1843 | 4-carboxylic acid.
- 1844 | 22. Phenazocine.
- 1845 | 23. Phencyclidine.
- 1846 | 24. 1-Phenylcyclohexylamine.
- 1847 | 25. Piminodine.
- 1848 | 26. 1-Piperidinocyclohexanecarbonitrile.
- 1849 | 27. Racemethorphan.
- 1850 | 28. Racemorphan.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1851 29. Remifentanil.

1852 ~~30.29.~~ Sufentanil.

1853 31. Tapentadol.

1854 32. Thiafentanil.

1855 (c) Unless specifically excepted or unless listed in  
 1856 another schedule, any material, compound, mixture, or  
 1857 preparation which contains any quantity of the following  
 1858 substances, including their salts, isomers, optical isomers,  
 1859 salts of their isomers, and salts of their optical isomers:

1860 1. Amobarbital.

1861 2. Amphetamine.

1862 3. Glutethimide.

1863 4. Lisdexamfetamine.

1864 ~~5.4.~~ Methamphetamine.

1865 ~~6.5.~~ Methylphenidate.

1866 ~~7.6.~~ Pentobarbital.

1867 ~~8.7.~~ Phenmetrazine.

1868 ~~9.8.~~ Phenylacetone.

1869 ~~10.9.~~ Secobarbital.

1870 (d) Dronabinol (synthetic THC) in oral solution in a drug  
 1871 product approved by the United States Food and Drug  
 1872 Administration.

1873 (3) SCHEDULE III.—A substance in Schedule III has a  
 1874 potential for abuse less than the substances contained in  
 1875 Schedules I and II and has a currently accepted medical use in

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1876 treatment in the United States, and abuse of the substance may  
 1877 lead to moderate or low physical dependence or high  
 1878 psychological dependence or, in the case of anabolic steroids,  
 1879 may lead to physical damage. The following substances are  
 1880 controlled in Schedule III:

1881 (a) Unless specifically excepted or unless listed in  
 1882 another schedule, any material, compound, mixture, or  
 1883 preparation which contains any quantity of the following  
 1884 substances having a depressant or stimulant effect on the  
 1885 nervous system:

1886 1. Any substance which contains any quantity of a  
 1887 derivative of barbituric acid, including thiobarbituric acid, or  
 1888 any salt of a derivative of barbituric acid or thiobarbituric  
 1889 acid, including, but not limited to, butabarbital and  
 1890 butalbital.

1891 2. Benzphetamine.

1892 3. Buprenorphine.

1893 ~~4.3.~~ Chlorhexadol.

1894 ~~5.4.~~ Chlorphentermine.

1895 ~~6.5.~~ Clortermine.

1896 7. Embutramide.

1897 ~~8.6.~~ Lysergic acid.

1898 ~~9.7.~~ Lysergic acid amide.

1899 ~~10.8.~~ Methyprylon.

1900 11. Perampanel.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1901        12.9. Phendimetrazine.

1902        13.10. Sulfondiethylmethane.

1903        14.11. Sulfonethylmethane.

1904        15.12. Sulfonmethane.

1905        16.13. Tiletamine and zolazepam or any salt thereof.

1906        (b) Nalorphine.

1907        (c) Unless specifically excepted or unless listed in

1908 another schedule, any material, compound, mixture, or

1909 preparation containing limited quantities of any of the

1910 following controlled substances or any salts thereof:

1911            1. Not more than 1.8 grams of codeine per 100 milliliters

1912 or not more than 90 milligrams per dosage unit, with an equal or

1913 greater quantity of an isoquinoline alkaloid of opium.

1914            2. Not more than 1.8 grams of codeine per 100 milliliters

1915 or not more than 90 milligrams per dosage unit, with recognized

1916 therapeutic amounts of one or more active ingredients which are

1917 not controlled substances.

1918            3. Not more than 300 milligrams of hydrocodone per 100

1919 milliliters or not more than 15 milligrams per dosage unit, with

1920 a fourfold or greater quantity of an isoquinoline alkaloid of

1921 opium.

1922            4. Not more than 300 milligrams of hydrocodone per 100

1923 milliliters or not more than 15 milligrams per dosage unit, with

1924 recognized therapeutic amounts of one or more active ingredients

1925 that are not controlled substances.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1926           5. Not more than 1.8 grams of dihydrocodeine per 100  
 1927 milliliters or not more than 90 milligrams per dosage unit, with  
 1928 recognized therapeutic amounts of one or more active ingredients  
 1929 which are not controlled substances.

1930           6. Not more than 300 milligrams of ethylmorphine per 100  
 1931 milliliters or not more than 15 milligrams per dosage unit, with  
 1932 one or more active, nonnarcotic ingredients in recognized  
 1933 therapeutic amounts.

1934           7. Not more than 50 milligrams of morphine per 100  
 1935 milliliters or per 100 grams, with recognized therapeutic  
 1936 amounts of one or more active ingredients which are not  
 1937 controlled substances.

1938  
 1939 For purposes of charging a person with a violation of s. 893.135  
 1940 involving any controlled substance described in subparagraph 3.  
 1941 or subparagraph 4., the controlled substance is a Schedule III  
 1942 controlled substance pursuant to this paragraph but the weight  
 1943 of the controlled substance per milliliters or per dosage unit  
 1944 is not relevant to the charging of a violation of s. 893.135.  
 1945 The weight of the controlled substance shall be determined  
 1946 pursuant to s. 893.135(6).

1947           (d) Anabolic steroids.

1948           1. The term "anabolic steroid" means any drug or hormonal  
 1949 substance, chemically and pharmacologically related to  
 1950 testosterone, other than estrogens, progestins, and

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 1951 corticosteroids, that promotes muscle growth and includes:
- 1952 a. Androsterone.
  - 1953 b. Androsterone acetate.
  - 1954 c. Boldenone.
  - 1955 d. Boldenone acetate.
  - 1956 e. Boldenone benzoate.
  - 1957 f. Boldenone undecylenate.
  - 1958 g. Chlorotestosterone (Clostebol).
  - 1959 h. Dehydrochlormethyltestosterone.
  - 1960 i. Dihydrotestosterone (Stanolone).
  - 1961 j. Drostanolone.
  - 1962 k. Ethylestrenol.
  - 1963 l. Fluoxymesterone.
  - 1964 m. Formebolone (Formebolone).
  - 1965 n. Mesterolone.
  - 1966 o. Methandrostenolone (Methandienone).
  - 1967 p. Methandranone.
  - 1968 q. Methandriol.
  - 1969 r. Methenolone.
  - 1970 s. Methyltestosterone.
  - 1971 t. Mibolerone.
  - 1972 u. Nortestosterone (Nandrolone).
  - 1973 v. Norethandrolone.
  - 1974 w. Nortestosterone decanoate.
  - 1975 x. Nortestosterone phenylpropionate.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

1976 y. Nortestosterone propionate.  
 1977 z. Oxandrolone.  
 1978 aa. Oxymesterone.  
 1979 bb. Oxymetholone.  
 1980 cc. Stanozolol.  
 1981 dd. Testolactone.  
 1982 ee. Testosterone.  
 1983 ff. Testosterone acetate.  
 1984 gg. Testosterone benzoate.  
 1985 hh. Testosterone cypionate.  
 1986 ii. Testosterone decanoate.  
 1987 jj. Testosterone enanthate.  
 1988 kk. Testosterone isocaproate.  
 1989 ll. Testosterone oleate.  
 1990 mm. Testosterone phenylpropionate.  
 1991 nn. Testosterone propionate.  
 1992 oo. Testosterone undecanoate.  
 1993 pp. Trenbolone.  
 1994 qq. Trenbolone acetate.  
 1995 rr. Any salt, ester, or isomer of a drug or substance  
 1996 described or listed in this subparagraph if that salt, ester, or  
 1997 isomer promotes muscle growth.  
 1998 2. The term does not include an anabolic steroid that is  
 1999 expressly intended for administration through implants to cattle  
 2000 or other nonhuman species and that has been approved by the

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2001 United States Secretary of Health and Human Services for such  
2002 administration. However, any person who prescribes, dispenses,  
2003 or distributes such a steroid for human use is considered to  
2004 have prescribed, dispensed, or distributed an anabolic steroid  
2005 within the meaning of this paragraph.

2006 (e) Ketamine, including any isomers, esters, ethers,  
2007 salts, and salts of isomers, esters, and ethers, whenever the  
2008 existence of such isomers, esters, ethers, and salts is possible  
2009 within the specific chemical designation.

2010 (f) Dronabinol (synthetic THC) in sesame oil and  
2011 encapsulated in a soft gelatin capsule in a drug product  
2012 approved by the United States Food and Drug Administration.

2013 (g) Any drug product containing gamma-hydroxybutyric acid,  
2014 including its salts, isomers, and salts of isomers, for which an  
2015 application is approved under s. 505 of the Federal Food, Drug,  
2016 and Cosmetic Act.

2017 (4) (a) SCHEDULE IV.—A substance in Schedule IV has a low  
2018 potential for abuse relative to the substances in Schedule III  
2019 and has a currently accepted medical use in treatment in the  
2020 United States, and abuse of the substance may lead to limited  
2021 physical or psychological dependence relative to the substances  
2022 in Schedule III.

2023 (b) Unless specifically excepted or unless listed in  
2024 another schedule, any material, compound, mixture, or  
2025 preparation which contains any quantity of the following

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2026 substances, including its salts, isomers, and salts of isomers  
 2027 whenever the existence of such salts, isomers, and salts of  
 2028 isomers is possible within the specific chemical designation,  
 2029 are controlled in Schedule IV:

- 2030 1. Alfaxalone.
- 2031 2.~~(a)~~ Alprazolam.
- 2032 3.~~(b)~~ Barbital.
- 2033 4.~~(c)~~ Bromazepam.
- 2034 5.~~(iii)~~ Butorphanol tartrate.
- 2035 6.~~(d)~~ Camazepam.
- 2036 7.~~(jjj)~~ Carisoprodol.
- 2037 8.~~(e)~~ Cathine.
- 2038 9.~~(f)~~ Chloral betaine.
- 2039 10.~~(g)~~ Chloral hydrate.
- 2040 11.~~(h)~~ Chlordiazepoxide.
- 2041 12.~~(i)~~ Clobazam.
- 2042 13.~~(j)~~ Clonazepam.
- 2043 14.~~(k)~~ Clorazepate.
- 2044 15.~~(l)~~ Clotiazepam.
- 2045 16.~~(m)~~ Cloxazolam.
- 2046 17. Dexfenfluramine.
- 2047 18.~~(n)~~ Delorazepam.
- 2048 19. Dichloralphenazone.
- 2049 20.~~(p)~~ Diazepam.
- 2050 21.~~(q)~~ Diethylpropion.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 2051 |        22. Eluxadoline.
- 2052 |        23.~~(r)~~ Estazolam.
- 2053 |        24. Eszopiclone.
- 2054 |        25.~~(s)~~ Ethchlorvynol.
- 2055 |        26.~~(t)~~ Ethinamate.
- 2056 |        27.~~(u)~~ Ethyl loflazepate.
- 2057 |        28.~~(v)~~ Fencamfamin.
- 2058 |        29.~~(w)~~ Fenfluramine.
- 2059 |        30.~~(x)~~ Fenproporex.
- 2060 |        31.~~(y)~~ Fludiazepam.
- 2061 |        32.~~(z)~~ Flurazepam.
- 2062 |        33. Fospropofol.
- 2063 |        34.~~(aa)~~ Halazepam.
- 2064 |        35.~~(bb)~~ Haloxazolam.
- 2065 |        36.~~(cc)~~ Ketazolam.
- 2066 |        37.~~(dd)~~ Loprazolam.
- 2067 |        38.~~(ee)~~ Lorazepam.
- 2068 |        39. Lorcaserin.
- 2069 |        40.~~(ff)~~ Lormetazepam.
- 2070 |        41.~~(gg)~~ Mazindol.
- 2071 |        42.~~(hh)~~ Mebutamate.
- 2072 |        43.~~(ii)~~ Medazepam.
- 2073 |        44.~~(jj)~~ Mefenorex.
- 2074 |        45.~~(kk)~~ Meproamate.
- 2075 |        46.~~(ll)~~ Methohexital.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 2076 |        47.~~(mm)~~ Methylphenobarbital.
- 2077 |        48.~~(nn)~~ Midazolam.
- 2078 |        49. Modafinil.
- 2079 |        50.~~(oo)~~ Nimetazepam.
- 2080 |        51.~~(pp)~~ Nitrazepam.
- 2081 |        52.~~(qq)~~ Nordiazepam.
- 2082 |        53.~~(rr)~~ Oxazepam.
- 2083 |        54.~~(ss)~~ Oxazolam.
- 2084 |        55.~~(tt)~~ Paraldehyde.
- 2085 |        56.~~(uu)~~ Pemoline.
- 2086 |        57.~~(vv)~~ Pentazocine.
- 2087 |        58. Petrichloral.
- 2088 |        59.~~(ww)~~ Phenobarbital.
- 2089 |        60.~~(xx)~~ Phentermine.
- 2090 |        61.~~(yy)~~ Pinazepam.
- 2091 |        62.~~(zz)~~ Pipradrol.
- 2092 |        63.~~(aaa)~~ Prazepam.
- 2093 |        64.~~(o)~~ Propoxyphene (dosage forms).
- 2094 |        65.~~(bbb)~~ Propylhexedrine, excluding any patent or
- 2095 |        proprietary preparation containing propylhexedrine, unless
- 2096 |        otherwise provided by federal law.
- 2097 |        66.~~(ccc)~~ Quazepam.
- 2098 |        67. Sibutramine.
- 2099 |        68.~~(eee)~~ SPA[(-)-1 dimethylamino-1, 2
- 2100 |        diphenylethane].

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2101           69. Suvorexant.  
 2102           70.~~(fff)~~ Temazepam.  
 2103           71.~~(ddd)~~ Tetrazepam.  
 2104           72. Tramadol.  
 2105           73.~~(ggg)~~ Triazolam.  
 2106           74. Zaleplon.  
 2107           75. Zolpidem.  
 2108           76. Zopiclone.  
 2109           77.~~(hhh)~~ Not more than 1 milligram of difenoxin and not  
 2110 less than 25 micrograms of atropine sulfate per dosage unit.  
 2111           (5) SCHEDULE V.—A substance, compound, mixture, or  
 2112 preparation of a substance in Schedule V has a low potential for  
 2113 abuse relative to the substances in Schedule IV and has a  
 2114 currently accepted medical use in treatment in the United  
 2115 States, and abuse of such compound, mixture, or preparation may  
 2116 lead to limited physical or psychological dependence relative to  
 2117 the substances in Schedule IV.  
 2118           (a) Substances controlled in Schedule V include any  
 2119 compound, mixture, or preparation containing any of the  
 2120 following limited quantities of controlled substances, which  
 2121 must ~~shall~~ include one or more active medicinal ingredients that  
 2122 ~~which~~ are not controlled substances in sufficient proportion to  
 2123 confer upon the compound, mixture, or preparation valuable  
 2124 medicinal qualities other than those possessed by the controlled  
 2125 substance alone:

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 2126           1. Not more than 200 milligrams of codeine per 100  
 2127 milliliters or per 100 grams.
- 2128           2. Not more than 100 milligrams of dihydrocodeine per 100  
 2129 milliliters or per 100 grams.
- 2130           3. Not more than 100 milligrams of ethylmorphine per 100  
 2131 milliliters or per 100 grams.
- 2132           4. Not more than 2.5 milligrams of diphenoxylate and not  
 2133 less than 25 micrograms of atropine sulfate per dosage unit.
- 2134           5. Not more than 100 milligrams of opium per 100  
 2135 milliliters or per 100 grams.
- 2136           6. Not more than 0.5 milligrams of difenoxin and not less  
 2137 than 25 micrograms of atropine sulfate per dosage unit.
- 2138           (b) Unless a specific exception exists or unless listed in  
 2139 another schedule, any material, compound, mixture, or  
 2140 preparation that contains any quantity of the following  
 2141 substances is controlled in Schedule V:
- 2142                 1. Brivaracetam.
- 2143                 2. Ezogabine.
- 2144                 3. Lacosamide.
- 2145                 4. Pregabalin ~~Narcotic drugs. Unless specifically excepted~~  
 2146 ~~or unless listed in another schedule, any material, compound,~~  
 2147 ~~mixture, or preparation containing any of the following narcotic~~  
 2148 ~~drugs and their salts: Buprenorphine.~~
- 2149           (c) Stimulants. Unless specifically excepted or unless  
 2150 listed in another schedule, any material, compound, mixture, or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2151 preparation which contains any quantity of the following  
 2152 substances having a stimulant effect on the central nervous  
 2153 system, including its salts, isomers, and salts of isomers:  
 2154 Pyrovalerone.

2155 Section 9. Subsection (1) of section 893.04, Florida  
 2156 Statutes, is amended to read:

2157 893.04 Pharmacist and practitioner.—

2158 (1) A pharmacist, in good faith and in the course of  
 2159 professional practice only, may dispense controlled substances  
 2160 upon a written, ~~or~~ oral, or electronic prescription of a  
 2161 practitioner, under the following conditions:

2162 (a) Oral prescriptions must be promptly reduced to writing  
 2163 by the pharmacist or recorded electronically if permitted by  
 2164 federal law.

2165 (b) The written prescription must be dated and signed by  
 2166 the prescribing practitioner on the day when issued.

2167 (c) There shall appear on the face of the prescription or  
 2168 written record thereof for the controlled substance the  
 2169 following information:

2170 1. The full name and address of the person for whom, or  
 2171 the owner of the animal for which, the controlled substance is  
 2172 dispensed.

2173 2. The full name and address of the prescribing  
 2174 practitioner and the practitioner's federal controlled substance  
 2175 registry number shall be printed thereon.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2176           3. If the prescription is for an animal, the species of  
2177 animal for which the controlled substance is prescribed.

2178           4. The name of the controlled substance prescribed and the  
2179 strength, quantity, and directions for use thereof.

2180           5. The number of the prescription, as recorded in the  
2181 prescription files of the pharmacy in which it is filled.

2182           6. The initials of the pharmacist filling the prescription  
2183 and the date filled.

2184           (d) The prescription shall be retained on file by the  
2185 proprietor of the pharmacy in which it is filled for a period of  
2186 2 years.

2187           (e) Affixed to the original container in which a  
2188 controlled substance is delivered upon a prescription or  
2189 authorized refill thereof, as hereinafter provided, there shall  
2190 be a label bearing the following information:

2191           1. The name and address of the pharmacy from which such  
2192 controlled substance was dispensed.

2193           2. The date on which the prescription for such controlled  
2194 substance was filled.

2195           3. The number of such prescription, as recorded in the  
2196 prescription files of the pharmacy in which it is filled.

2197           4. The name of the prescribing practitioner.

2198           5. The name of the patient for whom, or of the owner and  
2199 species of the animal for which, the controlled substance is  
2200 prescribed.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2201           6. The directions for the use of the controlled substance  
2202 prescribed in the prescription.

2203           7. A clear, concise warning that it is a crime to transfer  
2204 the controlled substance to any person other than the patient  
2205 for whom prescribed.

2206           (f) A prescription for a controlled substance listed in  
2207 Schedule II may be dispensed only upon a written or electronic  
2208 prescription of a practitioner, except that in an emergency  
2209 situation, as defined by regulation of the Department of Health,  
2210 such controlled substance may be dispensed upon oral  
2211 prescription but is limited to a 72-hour supply. A prescription  
2212 for a controlled substance listed in Schedule II may not be  
2213 refilled.

2214           (g) A prescription for a controlled substance listed in  
2215 Schedule III, Schedule IV, or Schedule V may not be filled or  
2216 refilled more than five times within a period of 6 months after  
2217 the date on which the prescription was written unless the  
2218 prescription is renewed by a practitioner.

2219           Section 10. Section 893.055, Florida Statutes, is amended  
2220 to read:

2221           (Substantial rewording of section. See  
2222 s. 893.055, F.S., for present text.)  
2223 893.055 Prescription drug monitoring program.-

2224           (1) As used in this section, the term:

2225           (a) "Active investigation" means an investigation that is

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2226 being conducted with a reasonable, good faith belief that it  
 2227 could lead to the filing of administrative, civil, or criminal  
 2228 proceedings, or that is ongoing and continuing and for which  
 2229 there is a reasonable, good faith anticipation of securing an  
 2230 arrest or prosecution in the foreseeable future.

2231 (b) "Administration" means the obtaining and giving of a  
 2232 single dose of a controlled substance by a legally authorized  
 2233 person to a patient for her or his consumption.

2234 (c) "Controlled substance" means a controlled substance  
 2235 listed in Schedule II, Schedule III, Schedule IV, or Schedule V  
 2236 of s. 893.03 or 21 U.S.C. s. 812.

2237 (d) "Dispense" means the transfer of possession of one or  
 2238 more doses of a controlled substance by a dispenser to the  
 2239 ultimate consumer or to his or her agent.

2240 (e) "Dispenser" means a dispensing health care  
 2241 practitioner, pharmacy, or pharmacist licensed to dispense  
 2242 controlled substances in or into this state.

2243 (f) "Health care practitioner" or "practitioner" means any  
 2244 practitioner licensed under chapter 458, chapter 459, chapter  
 2245 461, chapter 463, chapter 464, chapter 465, or chapter 466.

2246 (g) "Health care regulatory board" has the same meaning as  
 2247 in s. 456.001(1).

2248 (h) "Law enforcement agency" means the Department of Law  
 2249 Enforcement, a sheriff's office in this state, a police  
 2250 department in this state, or a law enforcement agency of the

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2251 Federal Government which enforces the laws of this state or the  
 2252 United States relating to controlled substances and whose agents  
 2253 and officers are empowered by law to conduct criminal  
 2254 investigations and make arrests.

2255 (i) "Pharmacy" includes a community pharmacy, an  
 2256 institutional pharmacy, a nuclear pharmacy, a special pharmacy,  
 2257 or an Internet pharmacy that is licensed by the department under  
 2258 chapter 465 and that dispenses or delivers controlled substances  
 2259 to an individual or address in this state.

2260 (j) "Prescriber" means a prescribing physician,  
 2261 prescribing practitioner, or other prescribing health care  
 2262 practitioner authorized by the laws of this state to order  
 2263 controlled substances.

2264 (k) "Program manager" means an employee of or a person  
 2265 contracted by the department who is designated to ensure the  
 2266 integrity of the prescription drug monitoring program in  
 2267 accordance with the requirements established in this section.

2268 (2) (a) The department shall maintain an electronic system  
 2269 to collect and store controlled substance dispensing information  
 2270 and shall release the information as authorized in this section  
 2271 and s. 893.0551. The electronic system must:

2272 1. Not infringe upon the legitimate prescribing or  
 2273 dispensing of a controlled substance by a prescriber or  
 2274 dispenser acting in good faith and in the course of professional  
 2275 practice.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2276           2. Be consistent with standards of the American Society  
 2277 for Automation in Pharmacy.

2278           3. Comply with the Health Insurance Portability and  
 2279 Accountability Act as it pertains to protected health  
 2280 information, electronic protected health information, and all  
 2281 other relevant state and federal privacy and security laws and  
 2282 regulations.

2283           4. Purge or cause to be purged information in the database  
 2284 that is more than 4 years old.

2285           (b) The department may collaborate with professional  
 2286 health care regulatory boards, appropriate organizations, and  
 2287 other state agencies to identify indicators of controlled  
 2288 substance abuse.

2289           (3) (a) For each controlled substance dispensed to a  
 2290 patient in this state, the following information must be  
 2291 reported by the dispenser to the system as soon thereafter as  
 2292 possible but no later than the close of the next business day  
 2293 after the day the controlled substance is dispensed unless an  
 2294 extension or exemption is approved by the department:

2295           1. The name of the prescribing practitioner, the  
 2296 practitioner's federal Drug Enforcement Administration  
 2297 registration number, the practitioner's National Provider  
 2298 Identification or other appropriate identifier, and the date of  
 2299 the prescription.

2300           2. The date the prescription was filled and the method of

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2301 payment, such as cash by an individual, insurance coverage  
 2302 through a third party, or Medicaid payment. This paragraph does  
 2303 not authorize the department to include individual credit card  
 2304 numbers or other account numbers in the system.

2305 3. The full name, address, telephone number, and date of  
 2306 birth of the person for whom the prescription was written.

2307 4. The name, national drug code, quantity, and strength of  
 2308 the controlled substance dispensed.

2309 5. The full name, federal Drug Enforcement Administration  
 2310 registration number, State of Florida Department of Health  
 2311 issued pharmacy permit number, and address of the pharmacy or  
 2312 other location from which the controlled substance was  
 2313 dispensed. If the controlled substance was dispensed by a  
 2314 practitioner other than a pharmacist, the practitioner's full  
 2315 name, address, federal Drug Enforcement Administration  
 2316 registration number, State of Florida Department of Health  
 2317 issued license number, and National Provider Identification.

2318 6. Whether the drug was dispensed as an initial  
 2319 prescription or a refill, and the number of refills ordered.

2320 7. The name of the individual picking up the controlled  
 2321 substance prescription and type and issuer of the identification  
 2322 provided.

2323 8. Other appropriate identifying information as determined  
 2324 by department rule.

2325 (b) The following acts of administration or dispensing are

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2326 exempt from the reporting requirements of this subsection:  
 2327 1. All acts of administration of a controlled substance.  
 2328 2. The dispensing of a controlled substance in the health  
 2329 care system of the Department of Corrections.  
 2330 3. The dispensing of a controlled substance to a person  
 2331 under the age of 16.  
 2332 (4) The following persons must be provided direct access  
 2333 to information in the system:  
 2334 (a) A prescriber or dispenser or his or her designee.  
 2335 (b) An employee of the United States Department of  
 2336 Veterans Affairs, the United States Department of Defense, or  
 2337 the Indian Health Service who provides health care services  
 2338 pursuant to such employment and who has the authority to  
 2339 prescribe or dispense controlled substances shall have access to  
 2340 the information in the program's system upon verification of  
 2341 employment.  
 2342 (c) The program manager or designated program and support  
 2343 staff to administer the system.  
 2344 1. In order to calculate performance measures pursuant to  
 2345 subsection (14), the program manager or program and support  
 2346 staff members who have been directed by the program manager to  
 2347 calculate performance measures may have direct access to  
 2348 information that contains no identifying information of any  
 2349 patient, physician, health care practitioner, prescriber, or  
 2350 dispenser.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2351        2. The program manager or designated program and support  
2352 staff must provide the department, upon request, data that does  
2353 not contain patient, physician, health care practitioner,  
2354 prescriber, or dispenser identifying information for public  
2355 health care and safety initiatives purposes.

2356        3. The program manager, upon determining a pattern  
2357 consistent with the department's rules established under  
2358 subsection (16), may provide relevant information to the  
2359 prescriber and dispenser.

2360        4. The program manager, upon determining a pattern  
2361 consistent with the rules established under subsection (16) and  
2362 having cause to believe a violation of s. 893.13(7)(a)8.,  
2363 (8)(a), or (8)(b) has occurred, may provide relevant information  
2364 to the applicable law enforcement agency.

2365  
2366 The program manager and designated program and support staff  
2367 must complete a level II background screening.

2368        (5) The following entities may not directly access  
2369 information in the system, but may request information from the  
2370 program manager or designated program and support staff:

2371        (a) The department and its health care regulatory boards,  
2372 as appropriate, for investigations involving licensees  
2373 authorized to prescribe or dispense controlled substances.

2374        (b) The Attorney General for Medicaid fraud cases  
2375 involving prescribed controlled substances.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2376 (c) A law enforcement agency during active investigations  
 2377 of potential criminal activity, fraud, or theft regarding  
 2378 prescribed controlled substances.

2379 (d) A medical examiner when conducting an authorized  
 2380 investigation under s. 406.11, to determine the cause of death  
 2381 of an individual.

2382 (e) An impaired practitioner consultant who is retained by  
 2383 the department under s. 456.076 to review the system information  
 2384 of an impaired practitioner program participant or a referral  
 2385 who has agreed to be evaluated or monitored through the program  
 2386 and who has separately agreed in writing to the consultant's  
 2387 access to and review of such information.

2388 (f) A patient or the legal guardian or designated health  
 2389 care surrogate of an incapacitated patient who submits a written  
 2390 and notarized request that includes the patient's full name,  
 2391 address, phone number, date of birth, and a copy of a  
 2392 government-issued photo identification.

2393 (6) The department may enter into one or more reciprocal  
 2394 agreements or contracts to share prescription drug monitoring  
 2395 information with other states, districts, or territories if the  
 2396 prescription drug monitoring programs of such other states,  
 2397 districts, or territories are compatible with the Florida  
 2398 program.

2399 (a) In determining compatibility, the department shall  
 2400 consider:

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 2401           1. The safeguards for privacy of patient records and the  
 2402 success of the program in protecting patient privacy.
- 2403           2. The persons authorized to view the data collected by  
 2404 the program. Comparable entities and licensed health care  
 2405 practitioners in other states, districts, or territories of the  
 2406 United States, law enforcement agencies, the Attorney General's  
 2407 Medicaid Fraud Control Unit, medical regulatory boards, and, as  
 2408 needed, management staff that have similar duties as management  
 2409 staff who work with the prescription drug monitoring program as  
 2410 authorized in s. 893.0551 are authorized access upon approval by  
 2411 the department.
- 2412           3. The schedules of the controlled substances that are  
 2413 monitored by the program.
- 2414           4. The data reported to or included in the program's  
 2415 system.
- 2416           5. Any implementing criteria deemed essential for a  
 2417 thorough comparison.
- 2418           6. The costs and benefits to the state of sharing  
 2419 prescription information.
- 2420           (b) The department shall assess the prescription drug  
 2421 monitoring program's continued compatibility with other states',  
 2422 districts', or territories' programs every 4 years.
- 2423           (c) Any agreements or contracts for sharing of  
 2424 prescription drug monitoring information between the department  
 2425 and other states, districts, or territories shall contain the

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2426 same restrictions and requirements as this section or s.  
 2427 893.0551, and the information must be provided according to the  
 2428 department's determination of compatibility.

2429 (7) The department may enter into agreements or contracts  
 2430 to establish secure connections between the system and a  
 2431 prescribing or dispensing health care practitioner's electronic  
 2432 health recordkeeping system. The electronic health recordkeeping  
 2433 system owner or license holder will be responsible for ensuring  
 2434 that only authorized individuals have access to prescription  
 2435 drug monitoring program information.

2436 (8) A prescriber or dispenser or a designee of a  
 2437 prescriber or dispenser must consult the system to review a  
 2438 patient's controlled substance dispensing history before  
 2439 prescribing or dispensing a controlled substance for a patient  
 2440 age 16 or older. This requirement does not apply when  
 2441 prescribing or dispensing a nonopioid controlled substance  
 2442 listed in Schedule V of s. 893.03 or 21 U.S.C. 812. For purposes  
 2443 of this subsection, a "nonopioid controlled substance" is a  
 2444 controlled substance that does not contain any amount of a  
 2445 substance listed as an opioid in s. 893.03 or 21 U.S.C. 812.

2446 (a) The duty to consult the system does not apply when the  
 2447 system:

2448 1. Is determined by the department to be nonoperational;

2449 or

2450 2. Cannot be accessed by the prescriber or dispenser or a

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2451 designee of the prescriber or dispenser because of a temporary  
2452 technological or electrical failure.

2453 (b) A prescriber or dispenser or designee of a prescriber  
2454 or dispenser who does not consult the system under this  
2455 subsection shall document the reason he or she did not consult  
2456 the system in the patient's medical record or prescription  
2457 record and shall not prescribe or dispense greater than a 3-day  
2458 supply of a controlled substance to the patient.

2459 (c) The department shall issue a nondisciplinary citation  
2460 to any prescriber or dispenser who fails to consult the system  
2461 as required by this subsection for an initial offense. Each  
2462 subsequent offense is subject to disciplinary action pursuant to  
2463 s. 456.073.

2464 (9) A person who willfully and knowingly fails to report  
2465 the dispensing of a controlled substance as required by this  
2466 section commits a misdemeanor of the first degree, punishable as  
2467 provided in s. 775.082 or s. 775.083.

2468 (10) Information in the prescription drug monitoring  
2469 program's system may be released only as provided in this  
2470 section and s. 893.0551. The content of the system is intended  
2471 to be informational only. Information in the system is not  
2472 subject to discovery or introduction into evidence in any civil  
2473 or administrative action against a prescriber, dispenser,  
2474 pharmacy, or patient arising out of matters that are the subject  
2475 of information in the system. The program manager and authorized

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2476 persons who participate in preparing, reviewing, issuing, or any  
2477 other activity related to management of the system may not be  
2478 permitted or required to testify in any such civil or  
2479 administrative action as to any findings, recommendations,  
2480 evaluations, opinions, or other actions taken in connection with  
2481 management of the system.

2482 (11) A prescriber or dispenser, or his or her designee,  
2483 may have access to the information under this section which  
2484 relates to a patient of that prescriber or dispenser as needed  
2485 for the purpose of reviewing the patient's controlled drug  
2486 prescription history. A prescriber or dispenser acting in good  
2487 faith is immune from any civil, criminal, or administrative  
2488 liability that might otherwise be incurred or imposed for  
2489 receiving or using information from the prescription drug  
2490 monitoring program. This subsection does not create a private  
2491 cause of action, and a person may not recover damages against a  
2492 prescriber or dispenser authorized to access information under  
2493 this subsection for accessing or failing to access such  
2494 information.

2495 (12) (a) All costs incurred by the department in  
2496 administering the prescription drug monitoring program shall be  
2497 funded through federal grants, private funding applied for or  
2498 received by the state, or state funds appropriated in the  
2499 General Appropriations Act. The department may not:

2500 1. Commit funds for the monitoring program without

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2501 ensuring funding is available; or  
 2502 2. Use funds provided, directly or indirectly, by  
 2503 prescription drug manufacturers to implement the program.  
 2504 (b) The department shall cooperate with the direct-support  
 2505 organization established under subsection (15) in seeking  
 2506 federal grant funds, other nonstate grant funds, gifts,  
 2507 donations, or other private moneys for the department if the  
 2508 costs of doing so are immaterial. Immaterial costs include, but  
 2509 are not limited to, the costs of mailing and personnel assigned  
 2510 to research or apply for a grant. The department may  
 2511 competitively procure and contract pursuant to s. 287.057 for  
 2512 any goods and services required by this section.  
 2513 (13) The department shall conduct or participate in  
 2514 studies to examine the feasibility of enhancing the prescription  
 2515 drug monitoring program for the purposes of public health  
 2516 initiatives and statistical reporting. Such studies shall  
 2517 respect the privacy of the patient, the prescriber, and the  
 2518 dispenser. Such studies may be conducted by the department or a  
 2519 contracted vendor in order to:  
 2520 (a) Improve the quality of health care services and safety  
 2521 by improving prescribing and dispensing practices for controlled  
 2522 substances;  
 2523 (b) Take advantage of advances in technology;  
 2524 (c) Reduce duplicative prescriptions and the  
 2525 overprescribing of controlled substances; and

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2526 (d) Reduce drug abuse.  
 2527 (14) The department shall annually report on performance  
 2528 measures to the Governor, the President of the Senate, and the  
 2529 Speaker of the House of Representatives by December 1.

2530 Performance measures may include, but are not limited to, the  
 2531 following outcomes:

2532 (a) Reduction of the rate of inappropriate use of  
 2533 controlled substances through department education and safety  
 2534 efforts.

2535 (b) Reduction of the quantity of controlled substances  
 2536 obtained by individuals attempting to engage in fraud and  
 2537 deceit.

2538 (c) Increased coordination among partners participating in  
 2539 the prescription drug monitoring program.

2540 (d) Involvement of stakeholders in achieving improved  
 2541 patient health care and safety and reduction of controlled  
 2542 substance abuse and controlled substance diversion.

2543 (15) The department may establish a direct-support  
 2544 organization to provide assistance, funding, and promotional  
 2545 support for the activities authorized for the prescription drug  
 2546 monitoring program.

2547 (a) As used in this subsection, the term "direct-support  
 2548 organization" means an organization that is:

2549 1. A Florida corporation not for profit incorporated under  
 2550 chapter 617, exempted from filing fees, and approved by the

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2551 Department of State.

2552 2. Organized and operated to conduct programs and  
 2553 activities; raise funds; request and receive grants, gifts, and  
 2554 bequests of money; acquire, receive, hold, and invest, in its  
 2555 own name, securities, funds, objects of value, or other  
 2556 property, either real or personal; and make expenditures or  
 2557 provide funding to or for the direct or indirect benefit of the  
 2558 department in the furtherance of the prescription drug  
 2559 monitoring program.

2560 (b) The State Surgeon General shall appoint a board of  
 2561 directors for the direct-support organization.

2562 1. The board of directors shall consist of no fewer than  
 2563 five members who shall serve at the pleasure of the State  
 2564 Surgeon General.

2565 2. The State Surgeon General shall provide guidance to  
 2566 members of the board to ensure that moneys received by the  
 2567 direct-support organization are not received from inappropriate  
 2568 sources. Inappropriate sources include, but are not limited to,  
 2569 donors, grantors, persons, prescription drug manufacturers, or  
 2570 organizations that may monetarily or substantively benefit from  
 2571 the purchase of goods or services by the department in  
 2572 furtherance of the prescription drug monitoring program.

2573 (c) The direct-support organization shall operate under  
 2574 written contract with the department. The contract must, at a  
 2575 minimum, provide for:

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2576 1. Approval of the articles of incorporation and bylaws of  
2577 the direct-support organization by the department.

2578 2. Submission of an annual budget for the approval of the  
2579 department.

2580 3. The reversion, without penalty, to the department's  
2581 grants and donations trust fund for the administration of the  
2582 prescription drug monitoring program of all moneys and property  
2583 held in trust by the direct-support organization for the benefit  
2584 of the prescription drug monitoring program if the direct-  
2585 support organization ceases to exist or if the contract is  
2586 terminated.

2587 4. The fiscal year of the direct-support organization,  
2588 which must begin July 1 of each year and end June 30 of the  
2589 following year.

2590 5. The disclosure of the material provisions of the  
2591 contract to donors of gifts, contributions, or bequests,  
2592 including such disclosure on all promotional and fundraising  
2593 publications, and an explanation to such donors of the  
2594 distinction between the department and the direct-support  
2595 organization.

2596 6. The direct-support organization's collecting,  
2597 expending, and providing of funds to the department for the  
2598 development, implementation, and operation of the prescription  
2599 drug monitoring program as described in this section. The  
2600 direct-support organization may collect and expend funds to be

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2601 used for the functions of the direct-support organization's  
2602 board of directors, as necessary and approved by the department.  
2603 In addition, the direct-support organization may collect and  
2604 provide funding to the department in furtherance of the  
2605 prescription drug monitoring program by:

2606 a. Establishing and administering the prescription drug  
2607 monitoring program's electronic system, including hardware and  
2608 software.

2609 b. Conducting studies on the efficiency and effectiveness  
2610 of the program to include feasibility studies as described in  
2611 subsection (13).

2612 c. Providing funds for future enhancements of the program  
2613 within the intent of this section.

2614 d. Providing user training of the prescription drug  
2615 monitoring program, including distribution of materials to  
2616 promote public awareness and education and conducting workshops  
2617 or other meetings for health care practitioners, pharmacists,  
2618 and others as appropriate.

2619 e. Providing funds for travel expenses.

2620 f. Providing funds for administrative costs, including  
2621 personnel, audits, facilities, and equipment.

2622 g. Fulfilling all other requirements necessary to  
2623 implement and operate the program as outlined in this section.

2624 7. Certification by the department that the direct-support  
2625 organization is complying with the terms of the contract in a

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2626 manner consistent with and in furtherance of the goals and  
2627 purposes of the prescription drug monitoring program and in the  
2628 best interests of the state. Such certification must be made  
2629 annually and reported in the official minutes of a meeting of  
2630 the direct-support organization.

2631 (d) The activities of the direct-support organization must  
2632 be consistent with the goals and mission of the department, as  
2633 determined by the department, and in the best interests of the  
2634 state. The direct-support organization must obtain written  
2635 approval from the department for any activities in support of  
2636 the prescription drug monitoring program before undertaking  
2637 those activities.

2638 (e) The direct-support organization shall provide for an  
2639 independent annual financial audit in accordance with s.  
2640 215.981. Copies of the audit shall be provided to the department  
2641 and the Office of Policy and Budget in the Executive Office of  
2642 the Governor.

2643 (f) The direct-support organization may not exercise any  
2644 power under s. 617.0302(12) or (16).

2645 (g) The direct-support organization is not considered a  
2646 lobbying firm within the meaning of s. 11.045.

2647 (h) The department may permit, without charge, appropriate  
2648 use of administrative services, property, and facilities of the  
2649 department by the direct-support organization, subject to this  
2650 section. The use must be directly in keeping with the approved

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2651 purposes of the direct-support organization and may not be made  
2652 at times or places that would unreasonably interfere with  
2653 opportunities for the public to use such facilities for  
2654 established purposes. Any moneys received from rentals of  
2655 facilities and properties managed by the department may be held  
2656 in a separate depository account in the name of the direct-  
2657 support organization and subject to the provisions of the letter  
2658 of agreement with the department. The letter of agreement must  
2659 provide that any funds held in the separate depository account  
2660 in the name of the direct-support organization must revert to  
2661 the department if the direct-support organization is no longer  
2662 approved by the department to operate in the best interests of  
2663 the state.

2664 (i) The department may adopt rules under s. 120.54 to  
2665 govern the use of administrative services, property, or  
2666 facilities of the department or office by the direct-support  
2667 organization.

2668 (j) The department may not permit the use of any  
2669 administrative services, property, or facilities of the state by  
2670 a direct-support organization if that organization does not  
2671 provide equal membership and employment opportunities to all  
2672 persons regardless of race, color, religion, gender, age, or  
2673 national origin.

2674 (k) This subsection is repealed October 1, 2027, unless  
2675 reviewed and saved from repeal by the Legislature.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2676           (16) The department shall adopt rules necessary to  
 2677 implement this section.

2678           Section 11. Section 893.0551, Florida Statutes, is amended  
 2679 to read:

2680           893.0551 Public records exemption for the prescription  
 2681 drug monitoring program.—

2682           (1) For purposes of this section, the terms used in this  
 2683 section have the same meanings as provided in s. 893.055.

2684           (2) The following information of a patient or patient's  
 2685 agent, a health care practitioner, a dispenser, an employee of  
 2686 the practitioner who is acting on behalf of and at the direction  
 2687 of the practitioner, a pharmacist, or a pharmacy that is  
 2688 contained in records held by the department under s. 893.055 is  
 2689 confidential and exempt from s. 119.07(1) and s. 24(a), Art. I  
 2690 of the State Constitution:

- 2691           (a) Name.
- 2692           (b) Address.
- 2693           (c) Telephone number.
- 2694           (d) Insurance plan number.
- 2695           (e) Government-issued identification number.
- 2696           (f) Provider number.
- 2697           (g) Drug Enforcement Administration number.
- 2698           (h) Any other unique identifying information or number.

2699           (3) The department shall disclose such ~~confidential and~~  
 2700 ~~exempt~~ information to the following persons or entities upon

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2701 request and after using a verification process to ensure the  
2702 legitimacy of the request as provided in s. 893.055:

2703 (a) A health care practitioner, or his or her designee,  
2704 who certifies that the information is necessary to provide  
2705 medical treatment to a current patient in accordance with ss.  
2706 893.04, 893.05, and 893.055.

2707 (b) An employee of the United States Department of  
2708 Veterans Affairs, the United States Department of Defense, or  
2709 the Indian Health Service who provides health care services  
2710 pursuant to such employment and who has the authority to  
2711 prescribe or dispense controlled substances shall have access to  
2712 the information in the program's system upon verification of  
2713 such employment.

2714 (c) The program manager and designated support staff for  
2715 administration of the program, and to provide relevant  
2716 information to the prescriber, dispenser, and appropriate law  
2717 enforcement agencies, in accordance with s. 893.055.

2718 (d) The department and its relevant health care regulatory  
2719 boards for investigations involving licensees authorized to  
2720 prescribe or dispense controlled substances. The department or  
2721 health care regulatory board may request information from the  
2722 program but may not have direct access to its system. The  
2723 department may provide to a law enforcement agency pursuant to  
2724 ss. 456.066 and 456.073 only information that is relevant to the  
2725 specific controlled substances investigation that prompted the

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2726 | request for the information.

2727 |       (e)~~(a)~~ The Attorney General or his or her designee when  
2728 | working on Medicaid fraud cases involving prescribed controlled  
2729 | substances ~~prescription drugs~~ or when the Attorney General has  
2730 | initiated a review of specific identifiers of Medicaid fraud or  
2731 | specific identifiers that warrant a Medicaid investigation  
2732 | regarding prescribed controlled substances ~~prescription drugs~~.  
2733 | The Attorney General's Medicaid fraud investigators may not have  
2734 | direct access to the department's system ~~database~~. The Attorney  
2735 | General or his or her designee may disclose to a criminal  
2736 | justice agency, as defined in s. 119.011, only the ~~confidential~~  
2737 | ~~and exempt~~ information received from the department that is  
2738 | relevant to an identified active investigation that prompted the  
2739 | request for the information.

2740 |       ~~(b) The department's relevant health care regulatory~~  
2741 | ~~boards responsible for the licensure, regulation, or discipline~~  
2742 | ~~of a practitioner, pharmacist, or other person who is authorized~~  
2743 | ~~to prescribe, administer, or dispense controlled substances and~~  
2744 | ~~who is involved in a specific controlled substances~~  
2745 | ~~investigation for prescription drugs involving a designated~~  
2746 | ~~person. The health care regulatory boards may request~~  
2747 | ~~information from the department but may not have direct access~~  
2748 | ~~to its database. The health care regulatory boards may provide~~  
2749 | ~~to a law enforcement agency pursuant to ss. 456.066 and 456.073~~  
2750 | ~~only information that is relevant to the specific controlled~~

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2751 ~~substances investigation that prompted the request for the~~  
 2752 ~~information.~~

2753 (f)~~(e)~~ A law enforcement agency that has initiated an  
 2754 active investigation involving a specific violation of law  
 2755 regarding prescription drug abuse or diversion of prescribed  
 2756 controlled substances and that has entered into a user agreement  
 2757 with the department. A law enforcement agency may request  
 2758 information from the department but may not have direct access  
 2759 to its system database. The law enforcement agency may disclose  
 2760 to a criminal justice agency, as defined in s. 119.011, only  
 2761 ~~confidential and exempt~~ information received from the department  
 2762 that is relevant to an identified active investigation that  
 2763 prompted the request for such information.

2764 (g) A district medical examiner or associate medical  
 2765 examiner, as described in s. 406.06, pursuant to his or her  
 2766 official duties, as required by s. 406.11, to determine the  
 2767 cause of death of an individual. Such medical examiners may  
 2768 request information from the department but may not have direct  
 2769 access to the system

2770 ~~(d) A health care practitioner, or his or her designee,~~  
 2771 ~~who certifies that the information is necessary to provide~~  
 2772 ~~medical treatment to a current patient in accordance with ss.~~  
 2773 ~~893.05 and 893.055.~~

2774 ~~(e) A pharmacist, or his or her designee, who certifies~~  
 2775 ~~that the requested information will be used to dispense~~

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2776 ~~controlled substances to a current patient in accordance with~~  
2777 ~~ss. 893.04 and 893.055.~~

2778 ~~(f) A patient or the legal guardian or designated health~~  
2779 ~~care surrogate for an incapacitated patient, if applicable,~~  
2780 ~~making a request as provided in s. 893.055(7)(c)4.~~

2781 ~~(g) The patient's pharmacy, prescriber, or dispenser, or~~  
2782 ~~the designee of the pharmacy, prescriber, or dispenser, who~~  
2783 ~~certifies that the information is necessary to provide medical~~  
2784 ~~treatment to his or her current patient in accordance with s.~~  
2785 ~~893.055.~~

2786 (h) An impaired practitioner consultant who has been  
2787 authorized in writing by a participant in, or by a referral to,  
2788 the impaired practitioner program to access and review  
2789 information as provided in s. 893.055(5)(e) ~~893.055(7)(e)5.~~

2790 (i) A patient or the legal guardian or designated health  
2791 care surrogate for an incapacitated patient, if applicable,  
2792 making a request as provided in s. 893.055(5)(f).

2793 (4) If the department determines consistent with its rules  
2794 that a pattern of controlled substance abuse exists, the  
2795 department may disclose such confidential and exempt information  
2796 to the applicable law enforcement agency in accordance with s.  
2797 893.055. The law enforcement agency may disclose to a criminal  
2798 justice agency, as defined in s. 119.011, only ~~confidential and~~  
2799 ~~exempt~~ information received from the department that is relevant  
2800 to an identified active investigation that is specific to a

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2801 violation of s. 893.13(7)(a)8., s. 893.13(8)(a), or s.  
 2802 893.13(8)(b).

2803 (5) Before disclosing ~~confidential and exempt~~ information  
 2804 to a criminal justice agency or a law enforcement agency  
 2805 pursuant to this section, the disclosing person or entity must  
 2806 take steps to ensure the continued confidentiality of all  
 2807 ~~confidential and exempt~~ information. At a minimum, these steps  
 2808 must include redacting any nonrelevant information.

2809 (6) An agency or person who obtains any ~~confidential and~~  
 2810 ~~exempt~~ information pursuant to this section must maintain the  
 2811 confidential and exempt status of that information and may not  
 2812 disclose such information unless authorized by law. Information  
 2813 shared with a state attorney pursuant to paragraph (3)(f) ~~(3)(a)~~  
 2814 or paragraph (3)(h) ~~(3)(e)~~ may be released only in response to a  
 2815 discovery demand if such information is directly related to the  
 2816 criminal case for which the information was requested. Unrelated  
 2817 information may be released only upon an order of a court of  
 2818 competent jurisdiction.

2819 (7) A person who willfully and knowingly violates this  
 2820 section commits a felony of the third degree, punishable as  
 2821 provided in s. 775.082, s. 775.083, or s. 775.084.

2822 Section 12. Paragraphs (a), (c), (d), (e), (f), and (h) of  
 2823 subsection (1), subsection (2), paragraphs (a) and (b) of  
 2824 subsection (4), and subsections (5) and (7) of section 893.13,  
 2825 Florida Statutes, are amended to read:

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2826           893.13 Prohibited acts; penalties.—  
 2827           (1) (a) Except as authorized by this chapter and chapter  
 2828 499, a person may not sell, manufacture, or deliver, or possess  
 2829 with intent to sell, manufacture, or deliver, a controlled  
 2830 substance. A person who violates this provision with respect to:  
 2831           1. A controlled substance named or described in s.  
 2832 893.03(1) (a), (1) (b), (1) (d), (2) (a), (2) (b), or (2) (c) 5.  
 2833 ~~(2) (e) 4.~~ commits a felony of the second degree, punishable as  
 2834 provided in s. 775.082, s. 775.083, or s. 775.084.  
 2835           2. A controlled substance named or described in s.  
 2836 893.03(1) (c), (2) (c) 1., (2) (c) 2., (2) (c) 3., ~~(2) (e) 5.,~~ (2) (c) 6.,  
 2837 (2) (c) 7., (2) (c) 8., (2) (c) 9., (2) (c) 10., (3), or (4) commits a  
 2838 felony of the third degree, punishable as provided in s.  
 2839 775.082, s. 775.083, or s. 775.084.  
 2840           3. A controlled substance named or described in s.  
 2841 893.03(5) commits a misdemeanor of the first degree, punishable  
 2842 as provided in s. 775.082 or s. 775.083.  
 2843           (c) Except as authorized by this chapter, a person may not  
 2844 sell, manufacture, or deliver, or possess with intent to sell,  
 2845 manufacture, or deliver, a controlled substance in, on, or  
 2846 within 1,000 feet of the real property comprising a child care  
 2847 facility as defined in s. 402.302 or a public or private  
 2848 elementary, middle, or secondary school between the hours of 6  
 2849 a.m. and 12 midnight, or at any time in, on, or within 1,000  
 2850 feet of real property comprising a state, county, or municipal

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2851 park, a community center, or a publicly owned recreational  
2852 facility. As used in this paragraph, the term "community center"  
2853 means a facility operated by a nonprofit community-based  
2854 organization for the provision of recreational, social, or  
2855 educational services to the public. A person who violates this  
2856 paragraph with respect to:

2857 1. A controlled substance named or described in s.  
2858 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5.  
2859 ~~(2)(c)4.~~ commits a felony of the first degree, punishable as  
2860 provided in s. 775.082, s. 775.083, or s. 775.084. The defendant  
2861 must be sentenced to a minimum term of imprisonment of 3  
2862 calendar years unless the offense was committed within 1,000  
2863 feet of the real property comprising a child care facility as  
2864 defined in s. 402.302.

2865 2. A controlled substance named or described in s.  
2866 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., ~~(2)(c)5.,~~ (2)(c)6.,  
2867 (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a  
2868 felony of the second degree, punishable as provided in s.  
2869 775.082, s. 775.083, or s. 775.084.

2870 3. Any other controlled substance, except as lawfully  
2871 sold, manufactured, or delivered, must be sentenced to pay a  
2872 \$500 fine and to serve 100 hours of public service in addition  
2873 to any other penalty prescribed by law.

2874

2875 This paragraph does not apply to a child care facility unless

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2876 | the owner or operator of the facility posts a sign that is not  
 2877 | less than 2 square feet in size with a word legend identifying  
 2878 | the facility as a licensed child care facility and that is  
 2879 | posted on the property of the child care facility in a  
 2880 | conspicuous place where the sign is reasonably visible to the  
 2881 | public.

2882 | (d) Except as authorized by this chapter, a person may not  
 2883 | sell, manufacture, or deliver, or possess with intent to sell,  
 2884 | manufacture, or deliver, a controlled substance in, on, or  
 2885 | within 1,000 feet of the real property comprising a public or  
 2886 | private college, university, or other postsecondary educational  
 2887 | institution. A person who violates this paragraph with respect  
 2888 | to:

2889 | 1. A controlled substance named or described in s.  
 2890 | 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5.  
 2891 | ~~(2)(c)4.~~ commits a felony of the first degree, punishable as  
 2892 | provided in s. 775.082, s. 775.083, or s. 775.084.

2893 | 2. A controlled substance named or described in s.  
 2894 | 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., ~~(2)(c)5.~~ (2)(c)6.,  
 2895 | (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a  
 2896 | felony of the second degree, punishable as provided in s.  
 2897 | 775.082, s. 775.083, or s. 775.084.

2898 | 3. Any other controlled substance, except as lawfully  
 2899 | sold, manufactured, or delivered, must be sentenced to pay a  
 2900 | \$500 fine and to serve 100 hours of public service in addition

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2901 to any other penalty prescribed by law.

2902 (e) Except as authorized by this chapter, a person may not  
 2903 sell, manufacture, or deliver, or possess with intent to sell,  
 2904 manufacture, or deliver, a controlled substance not authorized  
 2905 by law in, on, or within 1,000 feet of a physical place for  
 2906 worship at which a church or religious organization regularly  
 2907 conducts religious services or within 1,000 feet of a  
 2908 convenience business as defined in s. 812.171. A person who  
 2909 violates this paragraph with respect to:

2910 1. A controlled substance named or described in s.  
 2911 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5.  
 2912 ~~(2)(c)4.~~ commits a felony of the first degree, punishable as  
 2913 provided in s. 775.082, s. 775.083, or s. 775.084.

2914 2. A controlled substance named or described in s.  
 2915 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., ~~(2)(c)5.,~~ (2)(c)6.,  
 2916 (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a  
 2917 felony of the second degree, punishable as provided in s.  
 2918 775.082, s. 775.083, or s. 775.084.

2919 3. Any other controlled substance, except as lawfully  
 2920 sold, manufactured, or delivered, must be sentenced to pay a  
 2921 \$500 fine and to serve 100 hours of public service in addition  
 2922 to any other penalty prescribed by law.

2923 (f) Except as authorized by this chapter, a person may not  
 2924 sell, manufacture, or deliver, or possess with intent to sell,  
 2925 manufacture, or deliver, a controlled substance in, on, or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2926 | within 1,000 feet of the real property comprising a public  
 2927 | housing facility at any time. As used in this section, the term  
 2928 | "real property comprising a public housing facility" means real  
 2929 | property, as defined in s. 421.03(12), of a public corporation  
 2930 | created as a housing authority pursuant to part I of chapter  
 2931 | 421. A person who violates this paragraph with respect to:

2932 |         1. A controlled substance named or described in s.  
 2933 | 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5.  
 2934 | ~~(2)(e)4.~~ commits a felony of the first degree, punishable as  
 2935 | provided in s. 775.082, s. 775.083, or s. 775.084.

2936 |         2. A controlled substance named or described in s.  
 2937 | 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., ~~(2)(e)5.,~~ (2)(c)6.,  
 2938 | (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a  
 2939 | felony of the second degree, punishable as provided in s.  
 2940 | 775.082, s. 775.083, or s. 775.084.

2941 |         3. Any other controlled substance, except as lawfully  
 2942 | sold, manufactured, or delivered, must be sentenced to pay a  
 2943 | \$500 fine and to serve 100 hours of public service in addition  
 2944 | to any other penalty prescribed by law.

2945 |         (h) Except as authorized by this chapter, a person may not  
 2946 | sell, manufacture, or deliver, or possess with intent to sell,  
 2947 | manufacture, or deliver, a controlled substance in, on, or  
 2948 | within 1,000 feet of the real property comprising an assisted  
 2949 | living facility, as that term is used in chapter 429. A person  
 2950 | who violates this paragraph with respect to:

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2951           1. A controlled substance named or described in s.  
 2952 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5.  
 2953 ~~(2)(c)4.~~ commits a felony of the first degree, punishable as  
 2954 provided in s. 775.082, s. 775.083, or s. 775.084.

2955           2. A controlled substance named or described in s.  
 2956 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., ~~(2)(c)5.,~~ (2)(c)6.,  
 2957 (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a  
 2958 felony of the second degree, punishable as provided in s.  
 2959 775.082, s. 775.083, or s. 775.084.

2960           3. Any other controlled substance, except as lawfully  
 2961 sold, manufactured, or delivered, must be sentenced to pay a  
 2962 \$500 fine and to serve 100 hours of public service in addition  
 2963 to any other penalty prescribed by law.

2964           (2)(a) Except as authorized by this chapter and chapter  
 2965 499, a person may not purchase, or possess with intent to  
 2966 purchase, a controlled substance. A person who violates this  
 2967 provision with respect to:

2968           1. A controlled substance named or described in s.  
 2969 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5.  
 2970 ~~(2)(c)4.~~ commits a felony of the second degree, punishable as  
 2971 provided in s. 775.082, s. 775.083, or s. 775.084.

2972           2. A controlled substance named or described in s.  
 2973 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., ~~(2)(c)5.,~~ (2)(c)6.,  
 2974 (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a  
 2975 felony of the third degree, punishable as provided in s.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

2976 | 775.082, s. 775.083, or s. 775.084.

2977 |       3. A controlled substance named or described in s.  
2978 | 893.03(5) commits a misdemeanor of the first degree, punishable  
2979 | as provided in s. 775.082 or s. 775.083.

2980 |       (b) Except as provided in this chapter, a person may not  
2981 | purchase more than 10 grams of any substance named or described  
2982 | in s. 893.03(1)(a) or (1)(b), or any combination thereof, or any  
2983 | mixture containing any such substance. A person who violates  
2984 | this paragraph commits a felony of the first degree, punishable  
2985 | as provided in s. 775.082, s. 775.083, or s. 775.084.

2986 |       (4) Except as authorized by this chapter, a person 18  
2987 | years of age or older may not deliver any controlled substance  
2988 | to a person younger than 18 years of age, use or hire a person  
2989 | younger than 18 years of age as an agent or employee in the sale  
2990 | or delivery of such a substance, or use such person to assist in  
2991 | avoiding detection or apprehension for a violation of this  
2992 | chapter. A person who violates this subsection with respect to:

2993 |       (a) A controlled substance named or described in s.  
2994 | 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5.  
2995 | ~~(2)(e)4.~~ commits a felony of the first degree, punishable as  
2996 | provided in s. 775.082, s. 775.083, or s. 775.084.

2997 |       (b) A controlled substance named or described in s.  
2998 | 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., ~~(2)(e)5.,~~ (2)(c)6.,  
2999 | (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a  
3000 | felony of the second degree, punishable as provided in s.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3001 775.082, s. 775.083, or s. 775.084.

3002

3003 Imposition of sentence may not be suspended or deferred, and the  
3004 person so convicted may not be placed on probation.

3005 (5) A person may not bring into this state any controlled  
3006 substance unless the possession of such controlled substance is  
3007 authorized by this chapter or unless such person is licensed to  
3008 do so by the appropriate federal agency. A person who violates  
3009 this provision with respect to:

3010 (a) A controlled substance named or described in s.  
3011 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)5.  
3012 ~~(2)(c)4.~~ commits a felony of the second degree, punishable as  
3013 provided in s. 775.082, s. 775.083, or s. 775.084.

3014 (b) A controlled substance named or described in s.  
3015 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., ~~(2)(c)5.,~~ (2)(c)6.,  
3016 (2)(c)7., (2)(c)8., (2)(c)9., (2)(c)10., (3), or (4) commits a  
3017 felony of the third degree, punishable as provided in s.  
3018 775.082, s. 775.083, or s. 775.084.

3019 (c) A controlled substance named or described in s.  
3020 893.03(5) commits a misdemeanor of the first degree, punishable  
3021 as provided in s. 775.082 or s. 775.083.

3022 (7)

3023 (e) A person or health care practitioner who violates the  
3024 provisions of subparagraph (a)13. or paragraph (b) commits a  
3025 felony of the second ~~third~~ degree, punishable as provided in s.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3026 775.082, s. 775.083, or s. 775.084, if any controlled substance  
 3027 that is the subject of the offense is listed in Schedule II,  
 3028 Schedule III, or Schedule IV.

3029 Section 13. Section 893.147, Florida Statutes, is amended,  
 3030 to read:

3031 893.147 Use, possession, manufacture, delivery,  
 3032 transportation, advertisement, or retail sale of drug  
 3033 paraphernalia, specified machines, and materials.-

3034 (1) USE OR POSSESSION OF DRUG PARAPHERNALIA.—It is  
 3035 unlawful for any person to use, or to possess with intent to  
 3036 use, drug paraphernalia:

3037 (a) To plant, propagate, cultivate, grow, harvest,  
 3038 manufacture, compound, convert, produce, process, prepare, test,  
 3039 analyze, pack, repack, store, contain, or conceal a controlled  
 3040 substance in violation of this chapter; or

3041 (b) To inject, ingest, inhale, or otherwise introduce into  
 3042 the human body a controlled substance in violation of this  
 3043 chapter.

3044  
 3045 Any person who violates this subsection is guilty of a  
 3046 misdemeanor of the first degree, punishable as provided in s.  
 3047 775.082 or s. 775.083.

3048 (2) MANUFACTURE OR DELIVERY OF DRUG PARAPHERNALIA.—It is  
 3049 unlawful for any person to deliver, possess with intent to  
 3050 deliver, or manufacture with intent to deliver drug

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3051 paraphernalia, knowing, or under circumstances where one  
 3052 reasonably should know, that it will be used:

3053 (a) To plant, propagate, cultivate, grow, harvest,  
 3054 manufacture, compound, convert, produce, process, prepare, test,  
 3055 analyze, pack, repack, store, contain, or conceal a controlled  
 3056 substance in violation of this act; or

3057 (b) To inject, ingest, inhale, or otherwise introduce into  
 3058 the human body a controlled substance in violation of this act.

3059

3060 Any person who violates this subsection is guilty of a felony of  
 3061 the third degree, punishable as provided in s. 775.082, s.  
 3062 775.083, or s. 775.084.

3063 (3) DELIVERY OF DRUG PARAPHERNALIA TO A MINOR.—

3064 (a) Any person 18 years of age or over who violates  
 3065 subsection (2) by delivering drug paraphernalia to a person  
 3066 under 18 years of age is guilty of a felony of the second  
 3067 degree, punishable as provided in s. 775.082, s. 775.083, or s.  
 3068 775.084.

3069 (b) It is unlawful for any person to sell or otherwise  
 3070 deliver hypodermic syringes, needles, or other objects which may  
 3071 be used, are intended for use, or are designed for use in  
 3072 parenterally injecting substances into the human body to any  
 3073 person under 18 years of age, except that hypodermic syringes,  
 3074 needles, or other such objects may be lawfully dispensed to a  
 3075 person under 18 years of age by a licensed practitioner, parent,

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3076 or legal guardian or by a pharmacist pursuant to a valid  
 3077 prescription for same. Any person who violates the provisions of  
 3078 this paragraph is guilty of a misdemeanor of the first degree,  
 3079 punishable as provided in s. 775.082 or s. 775.083.

3080 (4) TRANSPORTATION OF DRUG PARAPHERNALIA.—It is unlawful  
 3081 to use, possess with the intent to use, or manufacture with the  
 3082 intent to use drug paraphernalia, knowing or under circumstances  
 3083 in which one reasonably should know that it will be used to  
 3084 transport:

3085 (a) A controlled substance in violation of this chapter;  
 3086 or

3087 (b) Contraband as defined in s. 932.701(2)(a)1.

3088  
 3089 Any person who violates this subsection commits a felony of the  
 3090 third degree, punishable as provided in s. 775.082, s. 775.083,  
 3091 or s. 775.084.

3092 (5) ADVERTISEMENT OF DRUG PARAPHERNALIA.—It is unlawful  
 3093 for any person to place in any newspaper, magazine, handbill, or  
 3094 other publication any advertisement, knowing, or under  
 3095 circumstances where one reasonably should know, that the purpose  
 3096 of the advertisement, in whole or in part, is to promote the  
 3097 sale of objects designed or intended for use as drug  
 3098 paraphernalia. Any person who violates this subsection is guilty  
 3099 of a misdemeanor of the first degree, punishable as provided in  
 3100 s. 775.082 or s. 775.083.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3101 (6) RETAIL SALE OF DRUG PARAPHERNALIA.—

3102 (a) It is unlawful for a person to knowingly and willfully  
 3103 sell or offer for sale at retail any drug paraphernalia  
 3104 described in s. 893.145(12) (a)-(c) or (g)-(m), other than a pipe  
 3105 that is primarily made of briar, meerschaum, clay, or corn cob.

3106 (b) A person who violates paragraph (a) commits a  
 3107 misdemeanor of the first degree, punishable as provided in s.  
 3108 775.082 or s. 775.083, and, upon a second or subsequent  
 3109 violation, commits a felony of the third degree, punishable as  
 3110 provided in s. 775.082, s. 775.083, or s. 775.084.

3111 (7) TABLETING MACHINES, ENCAPSULATING MACHINES, AND  
 3112 CONTROLLED SUBSTANCE COUNTERFEITING MATERIALS.—

3113 (a) Except as provided in paragraph (b), it is unlawful  
 3114 for any person to possess, purchase, deliver, sell, or possess  
 3115 with intent to sell or deliver a tableting machine, an  
 3116 encapsulating machine, or controlled substance counterfeiting  
 3117 materials knowing, intending, or having reasonable cause to  
 3118 believe that it will be used to manufacture a controlled  
 3119 substance or counterfeit controlled substance.

3120 (b)1. A regulated person may possess, purchase, deliver,  
 3121 sell, or possess with intent to deliver or sell a tableting  
 3122 machine or encapsulating machine as part of a regulated  
 3123 transaction with a regular customer or regular importer if he or  
 3124 she is in compliance with 21 U.S.C. s. 830. For purposes of this  
 3125 paragraph, the terms "regulated person," "regulated

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3126 transaction," "regular customer," and "regular importer" have  
3127 the same meanings as provided in 21 U.S.C. s. 802.

3128 2. A person registered under 21 U.S.C. s. 822 may possess,  
3129 purchase, deliver, sell, or possess with intent to deliver or  
3130 sell a tableting machine or encapsulating machine to manufacture  
3131 a controlled substance pursuant to such registration.

3132 3. A person who holds an active, unencumbered license or a  
3133 permit under s. 381.986 or chapter 465 may possess, purchase,  
3134 deliver, sell, or possess with intent to sell or deliver a  
3135 tableting machine or encapsulating machine to manufacture a  
3136 controlled substance, if such person is performing functions in  
3137 compliance with or under the authority of that license or  
3138 permit.

3139 (c) For purposes of this subsection, the term:

3140 1. "Controlled substance" has the same meaning as provided  
3141 in s. 893.02(4).

3142 2. "Controlled substance counterfeiting material" means a  
3143 punch, die, plate, stone, or other item designed to print,  
3144 imprint, or reproduce the trademark, trade name, or other  
3145 identifying mark, imprint, or device of another or any likeness  
3146 of any of the foregoing upon a drug or container or labeling  
3147 thereof so as to render such drug a counterfeit controlled  
3148 substance.

3149 3. "Counterfeit controlled substance" has the same meaning  
3150 as provided in s. 831.31(2).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3151 4. "Encapsulating machine" means manual, semiautomatic, or  
 3152 fully automatic equipment that can be used to fill shells or  
 3153 capsules with powdered or granular solids or semisolid material  
 3154 to produce coherent solid tablets.

3155 5. "Tableting machine" means manual, semiautomatic, or  
 3156 fully automatic equipment that can be used to compact or mold  
 3157 powdered or granular solids or semisolid material to produce  
 3158 coherent solid tablets.

3159 (d)1. Except as provided in subparagraph 2., a person who  
 3160 violates this subsection commits a felony of the third degree,  
 3161 punishable as provided in s. 775.082, s. 775.083, or s. 775.084.

3162 2. Any person who violates this subsection knowing,  
 3163 intending, or having reasonable cause to believe that such  
 3164 action will result in the unlawful manufacture of a controlled  
 3165 substance or counterfeit controlled substance that contains:

- 3166 a. A substance controlled under s. 893.03(1);
- 3167 b. Cocaine, as described in s. 893.03(2)(a)4.;
- 3168 c. Opium or any synthetic or natural salt, compound,  
 3169 derivative, or preparation of opium;
- 3170 d. Methadone;
- 3171 e. Alfentanil, as described in s. 893.03(2)(b)1.;
- 3172 f. Carfentanil, as described in s. 893.03(2)(b)6.;
- 3173 g. Fentanyl, as described in s. 893.03(2)(b)9.;
- 3174 h. Sufentanil, as described in s. 893.03(2)(b)30.; or
- 3175 i. A controlled substance analog, as described in s.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3176 | 893.0356, of any substance specified in sub-subparagraphs a.-h.,  
 3177 |  
 3178 | commits a felony of the second degree, punishable as provided in  
 3179 | s. 775.082, s. 775.083, or s. 775.084.

3180 | Section 14. Effective January 1, 2019, paragraphs (pp) and  
 3181 | (qq) of subsection (1) of section 458.331, Florida Statutes, are  
 3182 | amended to read:

3183 | 458.331 Grounds for disciplinary action; action by the  
 3184 | board and department.—

3185 | (1) The following acts constitute grounds for denial of a  
 3186 | license or disciplinary action, as specified in s. 456.072(2):

3187 | (pp) Applicable to a licensee who serves as the designated  
 3188 | physician of a pain-management clinic as defined in s. 458.3265  
 3189 | or s. 459.0137:

3190 | 1. Registering a pain-management clinic through  
 3191 | misrepresentation or fraud;

3192 | 2. Procuring, or attempting to procure, the registration  
 3193 | of a pain-management clinic for any other person by making or  
 3194 | causing to be made, any false representation;

3195 | 3. Failing to comply with any requirement of chapter 499,  
 3196 | the Florida Drug and Cosmetic Act; 21 U.S.C. ss. 301-392, the  
 3197 | Federal Food, Drug, and Cosmetic Act; 21 U.S.C. ss. 821 et seq.,  
 3198 | the Drug Abuse Prevention and Control Act; or chapter 893, the  
 3199 | Florida Comprehensive Drug Abuse Prevention and Control Act;

3200 | 4. Being convicted or found guilty of, regardless of

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3201 adjudication to, a felony or any other crime involving moral  
 3202 turpitude, fraud, dishonesty, or deceit in any jurisdiction of  
 3203 the courts of this state, of any other state, or of the United  
 3204 States;

3205 5. Being convicted of, or disciplined by a regulatory  
 3206 agency of the Federal Government or a regulatory agency of  
 3207 another state for, any offense that would constitute a violation  
 3208 of this chapter;

3209 6. Being convicted of, or entering a plea of guilty or  
 3210 nolo contendere to, regardless of adjudication, a crime in any  
 3211 jurisdiction of the courts of this state, of any other state, or  
 3212 of the United States which relates to the practice of, or the  
 3213 ability to practice, a licensed health care profession;

3214 7. Being convicted of, or entering a plea of guilty or  
 3215 nolo contendere to, regardless of adjudication, a crime in any  
 3216 jurisdiction of the courts of this state, of any other state, or  
 3217 of the United States which relates to health care fraud;

3218 8. Dispensing any medicinal drug based upon a  
 3219 communication that purports to be a prescription as defined in  
 3220 s. 465.003(14) or s. 893.02 if the dispensing practitioner knows  
 3221 or has reason to believe that the purported prescription is not  
 3222 based upon a valid practitioner-patient relationship; or

3223 9. Failing to timely notify the board of the date of his  
 3224 or her termination from a pain-management clinic as required by  
 3225 s. 458.3265(3) ~~458.3265(2)~~.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3226 (qq) Failing to timely notify the department of the theft  
 3227 of prescription blanks from a pain-management clinic or a breach  
 3228 of other methods for prescribing within 24 hours as required by  
 3229 s. 458.3265(3) ~~458.3265(2)~~.

3230 Section 15. Effective January 1, 2019, paragraphs (rr)  
 3231 and (ss) of subsection (1) of section 459.015, Florida Statutes,  
 3232 are amended to read:

3233 459.015 Grounds for disciplinary action; action by the  
 3234 board and department.—

3235 (1) The following acts constitute grounds for denial of a  
 3236 license or disciplinary action, as specified in s. 456.072(2):

3237 (rr) Applicable to a licensee who serves as the designated  
 3238 physician of a pain-management clinic as defined in s. 458.3265  
 3239 or s. 459.0137:

3240 1. Registering a pain-management clinic through  
 3241 misrepresentation or fraud;

3242 2. Procuring, or attempting to procure, the registration  
 3243 of a pain-management clinic for any other person by making or  
 3244 causing to be made, any false representation;

3245 3. Failing to comply with any requirement of chapter 499,  
 3246 the Florida Drug and Cosmetic Act; 21 U.S.C. ss. 301-392, the  
 3247 Federal Food, Drug, and Cosmetic Act; 21 U.S.C. ss. 821 et seq.,  
 3248 the Drug Abuse Prevention and Control Act; or chapter 893, the  
 3249 Florida Comprehensive Drug Abuse Prevention and Control Act;

3250 4. Being convicted or found guilty of, regardless of

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3251 adjudication to, a felony or any other crime involving moral  
 3252 turpitude, fraud, dishonesty, or deceit in any jurisdiction of  
 3253 the courts of this state, of any other state, or of the United  
 3254 States;

3255 5. Being convicted of, or disciplined by a regulatory  
 3256 agency of the Federal Government or a regulatory agency of  
 3257 another state for, any offense that would constitute a violation  
 3258 of this chapter;

3259 6. Being convicted of, or entering a plea of guilty or  
 3260 nolo contendere to, regardless of adjudication, a crime in any  
 3261 jurisdiction of the courts of this state, of any other state, or  
 3262 of the United States which relates to the practice of, or the  
 3263 ability to practice, a licensed health care profession;

3264 7. Being convicted of, or entering a plea of guilty or  
 3265 nolo contendere to, regardless of adjudication, a crime in any  
 3266 jurisdiction of the courts of this state, of any other state, or  
 3267 of the United States which relates to health care fraud;

3268 8. Dispensing any medicinal drug based upon a  
 3269 communication that purports to be a prescription as defined in  
 3270 s. 465.003(14) or s. 893.02 if the dispensing practitioner knows  
 3271 or has reason to believe that the purported prescription is not  
 3272 based upon a valid practitioner-patient relationship; or

3273 9. Failing to timely notify the board of the date of his  
 3274 or her termination from a pain-management clinic as required by  
 3275 s. 459.0137(3) ~~459.0137(2)~~.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3276 (ss) Failing to timely notify the department of the theft  
 3277 of prescription blanks from a pain-management clinic or a breach  
 3278 of other methods for prescribing within 24 hours as required by  
 3279 s. 459.0137(3) ~~459.0137(2)~~.

3280 Section 16. Paragraph (b) of subsection (4) of section  
 3281 463.0055, Florida Statutes, is amended to read:

3282 463.0055 Administration and prescription of ocular  
 3283 pharmaceutical agents.—

3284 (4) A certified optometrist shall be issued a prescriber  
 3285 number by the board. Any prescription written by a certified  
 3286 optometrist for an ocular pharmaceutical agent pursuant to this  
 3287 section shall have the prescriber number printed thereon. A  
 3288 certified optometrist may not administer or prescribe:

3289 (b) A controlled substance for the treatment of chronic  
 3290 nonmalignant pain as defined in s. 456.44(1)(f) ~~456.44(1)(e)~~.

3291 Section 17. Paragraph (a) of subsection (1) of section  
 3292 782.04, Florida Statutes, is amended to read:

3293 782.04 Murder.—

3294 (1)(a) The unlawful killing of a human being:

3295 1. When perpetrated from a premeditated design to effect  
 3296 the death of the person killed or any human being;

3297 2. When committed by a person engaged in the perpetration  
 3298 of, or in the attempt to perpetrate, any:

3299 a. Trafficking offense prohibited by s. 893.135(1),

3300 b. Arson,

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

- 3301 c. Sexual battery,
- 3302 d. Robbery,
- 3303 e. Burglary,
- 3304 f. Kidnapping,
- 3305 g. Escape,
- 3306 h. Aggravated child abuse,
- 3307 i. Aggravated abuse of an elderly person or disabled
- 3308 adult,
- 3309 j. Aircraft piracy,
- 3310 k. Unlawful throwing, placing, or discharging of a
- 3311 destructive device or bomb,
- 3312 l. Carjacking,
- 3313 m. Home-invasion robbery,
- 3314 n. Aggravated stalking,
- 3315 o. Murder of another human being,
- 3316 p. Resisting an officer with violence to his or her
- 3317 person,
- 3318 q. Aggravated fleeing or eluding with serious bodily
- 3319 injury or death,
- 3320 r. Felony that is an act of terrorism or is in furtherance
- 3321 of an act of terrorism, including a felony under s. 775.30, s.
- 3322 775.32, s. 775.33, s. 775.34, or s. 775.35, or
- 3323 s. Human trafficking; or
- 3324 3. Which resulted from the unlawful distribution by a
- 3325 person 18 years of age or older of any of the following

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3326 substances, or mixture containing any of the following  
 3327 substances, when such substance or mixture is proven to be the  
 3328 proximate cause of the death of the user:

- 3329 a. A substance controlled under s. 893.03(1);
- 3330 b. Cocaine, as described in s. 893.03(2)(a)4.;
- 3331 c. Opium or any synthetic or natural salt, compound,
- 3332 derivative, or preparation of opium;
- 3333 d. Methadone;
- 3334 e. Alfentanil, as described in s. 893.03(2)(b)1.;
- 3335 f. Carfentanil, as described in s. 893.03(2)(b)6.;
- 3336 g. Fentanyl, as described in s. 893.03(2)(b)9.;
- 3337 h. Sufentanil, as described in s. 893.03(2)(b)30.
- 3338 ~~893.03(2)(b)29.~~; or
- 3339 i. A controlled substance analog, as described in s.
- 3340 893.0356, of any substance specified in sub-subparagraphs a.-h.,
- 3341
- 3342 is murder in the first degree and constitutes a capital felony,
- 3343 punishable as provided in s. 775.082.

3344 Section 18. Paragraphs (c) and (f) of subsection (1) of  
 3345 section 893.135, Florida Statutes, are amended to read:

3346 893.135 Trafficking; mandatory sentences; suspension or  
 3347 reduction of sentences; conspiracy to engage in trafficking.—

3348 (1) Except as authorized in this chapter or in chapter 499  
 3349 and notwithstanding the provisions of s. 893.13:

3350 (c)1. A person who knowingly sells, purchases,

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3351 manufactures, delivers, or brings into this state, or who is  
 3352 knowingly in actual or constructive possession of, 4 grams or  
 3353 more of any morphine, opium, hydromorphone, or any salt,  
 3354 derivative, isomer, or salt of an isomer thereof, including  
 3355 heroin, as described in s. 893.03(1)(b), (2)(a), (3)(c)3., or  
 3356 (3)(c)4., or 4 grams or more of any mixture containing any such  
 3357 substance, but less than 30 kilograms of such substance or  
 3358 mixture, commits a felony of the first degree, which felony  
 3359 shall be known as "trafficking in illegal drugs," punishable as  
 3360 provided in s. 775.082, s. 775.083, or s. 775.084. If the  
 3361 quantity involved:

3362       a. Is 4 grams or more, but less than 14 grams, such person  
 3363 shall be sentenced to a mandatory minimum term of imprisonment  
 3364 of 3 years and shall be ordered to pay a fine of \$50,000.

3365       b. Is 14 grams or more, but less than 28 grams, such  
 3366 person shall be sentenced to a mandatory minimum term of  
 3367 imprisonment of 15 years and shall be ordered to pay a fine of  
 3368 \$100,000.

3369       c. Is 28 grams or more, but less than 30 kilograms, such  
 3370 person shall be sentenced to a mandatory minimum term of  
 3371 imprisonment of 25 years and shall be ordered to pay a fine of  
 3372 \$500,000.

3373       2. A person who knowingly sells, purchases, manufactures,  
 3374 delivers, or brings into this state, or who is knowingly in  
 3375 actual or constructive possession of, 14 grams or more of

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3376 hydrocodone, as described in s. 893.03(2)(a)1.k.  
 3377 ~~893.03(2)(a)1.j.~~, codeine, as described in s. 893.03(2)(a)1.g.,  
 3378 or any salt thereof, or 14 grams or more of any mixture  
 3379 containing any such substance, commits a felony of the first  
 3380 degree, which felony shall be known as "trafficking in  
 3381 hydrocodone," punishable as provided in s. 775.082, s. 775.083,  
 3382 or s. 775.084. If the quantity involved:  
 3383       a. Is 14 grams or more, but less than 28 grams, such  
 3384 person shall be sentenced to a mandatory minimum term of  
 3385 imprisonment of 3 years and shall be ordered to pay a fine of  
 3386 \$50,000.  
 3387       b. Is 28 grams or more, but less than 50 grams, such  
 3388 person shall be sentenced to a mandatory minimum term of  
 3389 imprisonment of 7 years and shall be ordered to pay a fine of  
 3390 \$100,000.  
 3391       c. Is 50 grams or more, but less than 200 grams, such  
 3392 person shall be sentenced to a mandatory minimum term of  
 3393 imprisonment of 15 years and shall be ordered to pay a fine of  
 3394 \$500,000.  
 3395       d. Is 200 grams or more, but less than 30 kilograms, such  
 3396 person shall be sentenced to a mandatory minimum term of  
 3397 imprisonment of 25 years and shall be ordered to pay a fine of  
 3398 \$750,000.  
 3399       3. A person who knowingly sells, purchases, manufactures,  
 3400 delivers, or brings into this state, or who is knowingly in

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3401 actual or constructive possession of, 7 grams or more of  
 3402 oxycodone, as described in s. 893.03(2)(a)1.g. ~~893.03(2)(a)1.e.~~,  
 3403 or any salt thereof, or 7 grams or more of any mixture  
 3404 containing any such substance, commits a felony of the first  
 3405 degree, which felony shall be known as "trafficking in  
 3406 oxycodone," punishable as provided in s. 775.082, s. 775.083, or  
 3407 s. 775.084. If the quantity involved:

3408       a. Is 7 grams or more, but less than 14 grams, such person  
 3409 shall be sentenced to a mandatory minimum term of imprisonment  
 3410 of 3 years and shall be ordered to pay a fine of \$50,000.

3411       b. Is 14 grams or more, but less than 25 grams, such  
 3412 person shall be sentenced to a mandatory minimum term of  
 3413 imprisonment of 7 years and shall be ordered to pay a fine of  
 3414 \$100,000.

3415       c. Is 25 grams or more, but less than 100 grams, such  
 3416 person shall be sentenced to a mandatory minimum term of  
 3417 imprisonment of 15 years and shall be ordered to pay a fine of  
 3418 \$500,000.

3419       d. Is 100 grams or more, but less than 30 kilograms, such  
 3420 person shall be sentenced to a mandatory minimum term of  
 3421 imprisonment of 25 years and shall be ordered to pay a fine of  
 3422 \$750,000.

3423       4.a. A person who knowingly sells, purchases,  
 3424 manufactures, delivers, or brings into this state, or who is  
 3425 knowingly in actual or constructive possession of, 4 grams or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3426 | more of:

3427 |       (I) Alfentanil, as described in s. 893.03(2)(b)1.;

3428 |       (II) Carfentanil, as described in s. 893.03(2)(b)6.;

3429 |       (III) Fentanyl, as described in s. 893.03(2)(b)9.;

3430 |       (IV) Sufentanil, as described in s. 893.03(2)(b)30.

3431 | ~~893.03(2)(b)29.~~;

3432 |       (V) A fentanyl derivative, as described in s.

3433 | 893.03(1)(a)62.;

3434 |       (VI) A controlled substance analog, as described in s.

3435 | 893.0356, of any substance described in sub-sub-subparagraphs

3436 | (I)-(V); or

3437 |       (VII) A mixture containing any substance described in sub-

3438 | sub-subparagraphs (I)-(VI),

3439 |

3440 | commits a felony of the first degree, which felony shall be

3441 | known as "trafficking in fentanyl," punishable as provided in s.

3442 | 775.082, s. 775.083, or s. 775.084.

3443 |       b. If the quantity involved under sub-subparagraph a.:

3444 |       (I) Is 4 grams or more, but less than 14 grams, such

3445 | person shall be sentenced to a mandatory minimum term of

3446 | imprisonment of 3 years, and shall be ordered to pay a fine of

3447 | \$50,000.

3448 |       (II) Is 14 grams or more, but less than 28 grams, such

3449 | person shall be sentenced to a mandatory minimum term of

3450 | imprisonment of 15 years, and shall be ordered to pay a fine of

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3451 \$100,000.

3452 (III) Is 28 grams or more, such person shall be sentenced  
 3453 to a mandatory minimum term of imprisonment of 25 years, and  
 3454 shall be ordered to pay a fine of \$500,000.

3455 5. A person who knowingly sells, purchases, manufactures,  
 3456 delivers, or brings into this state, or who is knowingly in  
 3457 actual or constructive possession of, 30 kilograms or more of  
 3458 any morphine, opium, oxycodone, hydrocodone, codeine,  
 3459 hydromorphone, or any salt, derivative, isomer, or salt of an  
 3460 isomer thereof, including heroin, as described in s.  
 3461 893.03(1)(b), (2)(a), (3)(c)3., or (3)(c)4., or 30 kilograms or  
 3462 more of any mixture containing any such substance, commits the  
 3463 first degree felony of trafficking in illegal drugs. A person  
 3464 who has been convicted of the first degree felony of trafficking  
 3465 in illegal drugs under this subparagraph shall be punished by  
 3466 life imprisonment and is ineligible for any form of  
 3467 discretionary early release except pardon or executive clemency  
 3468 or conditional medical release under s. 947.149. However, if the  
 3469 court determines that, in addition to committing any act  
 3470 specified in this paragraph:

3471 a. The person intentionally killed an individual or  
 3472 counseled, commanded, induced, procured, or caused the  
 3473 intentional killing of an individual and such killing was the  
 3474 result; or

3475 b. The person's conduct in committing that act led to a

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3476 natural, though not inevitable, lethal result,  
3477  
3478 such person commits the capital felony of trafficking in illegal  
3479 drugs, punishable as provided in ss. 775.082 and 921.142. A  
3480 person sentenced for a capital felony under this paragraph shall  
3481 also be sentenced to pay the maximum fine provided under  
3482 subparagraph 1.

3483         6. A person who knowingly brings into this state 60  
3484 kilograms or more of any morphine, opium, oxycodone,  
3485 hydrocodone, codeine, hydromorphone, or any salt, derivative,  
3486 isomer, or salt of an isomer thereof, including heroin, as  
3487 described in s. 893.03(1)(b), (2)(a), (3)(c)3., or (3)(c)4., or  
3488 60 kilograms or more of any mixture containing any such  
3489 substance, and who knows that the probable result of such  
3490 importation would be the death of a person, commits capital  
3491 importation of illegal drugs, a capital felony punishable as  
3492 provided in ss. 775.082 and 921.142. A person sentenced for a  
3493 capital felony under this paragraph shall also be sentenced to  
3494 pay the maximum fine provided under subparagraph 1.

3495         (f)1. Any person who knowingly sells, purchases,  
3496 manufactures, delivers, or brings into this state, or who is  
3497 knowingly in actual or constructive possession of, 14 grams or  
3498 more of amphetamine, as described in s. 893.03(2)(c)2., or  
3499 methamphetamine, as described in s. 893.03(2)(c)5.  
3500 ~~893.03(2)(c)4.~~, or of any mixture containing amphetamine or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3501 methamphetamine, or phenylacetone, phenylacetic acid,  
 3502 pseudoephedrine, or ephedrine in conjunction with other  
 3503 chemicals and equipment utilized in the manufacture of  
 3504 amphetamine or methamphetamine, commits a felony of the first  
 3505 degree, which felony shall be known as "trafficking in  
 3506 amphetamine," punishable as provided in s. 775.082, s. 775.083,  
 3507 or s. 775.084. If the quantity involved:

3508       a. Is 14 grams or more, but less than 28 grams, such  
 3509 person shall be sentenced to a mandatory minimum term of  
 3510 imprisonment of 3 years, and the defendant shall be ordered to  
 3511 pay a fine of \$50,000.

3512       b. Is 28 grams or more, but less than 200 grams, such  
 3513 person shall be sentenced to a mandatory minimum term of  
 3514 imprisonment of 7 years, and the defendant shall be ordered to  
 3515 pay a fine of \$100,000.

3516       c. Is 200 grams or more, such person shall be sentenced to  
 3517 a mandatory minimum term of imprisonment of 15 calendar years  
 3518 and pay a fine of \$250,000.

3519       2. Any person who knowingly manufactures or brings into  
 3520 this state 400 grams or more of amphetamine, as described in s.  
 3521 893.03(2)(c)2., or methamphetamine, as described in s.  
 3522 893.03(2)(c)5. ~~893.03(2)(c)4.~~, or of any mixture containing  
 3523 amphetamine or methamphetamine, or phenylacetone, phenylacetic  
 3524 acid, pseudoephedrine, or ephedrine in conjunction with other  
 3525 chemicals and equipment used in the manufacture of amphetamine

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3526 or methamphetamine, and who knows that the probable result of  
 3527 such manufacture or importation would be the death of any person  
 3528 commits capital manufacture or importation of amphetamine, a  
 3529 capital felony punishable as provided in ss. 775.082 and  
 3530 921.142. Any person sentenced for a capital felony under this  
 3531 paragraph shall also be sentenced to pay the maximum fine  
 3532 provided under subparagraph 1.

3533 Section 19. Paragraphs (b) through (e) and (g) of  
 3534 subsection (3) of section 921.0022, Florida Statutes, are  
 3535 amended to read:

3536 921.0022 Criminal Punishment Code; offense severity  
 3537 ranking chart.—

3538 (3) OFFENSE SEVERITY RANKING CHART

3539 (b) LEVEL 2

3540

3541

Florida Statute	Felony Degree	Description
379.2431 (1) (e) 3.	3rd	Possession of 11 or fewer marine turtle eggs in violation of the Marine Turtle Protection Act.
379.2431 (1) (e) 4.	3rd	Possession of more than 11 marine turtle eggs in violation

3542

3543

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			of the Marine Turtle Protection Act.
3544	403.413 (6) (c)	3rd	Dumps waste litter exceeding 500 lbs. in weight or 100 cubic feet in volume or any quantity for commercial purposes, or hazardous waste.
3545	517.07 (2)	3rd	Failure to furnish a prospectus meeting requirements.
3546	590.28 (1)	3rd	Intentional burning of lands.
3547	784.05 (3)	3rd	Storing or leaving a loaded firearm within reach of minor who uses it to inflict injury or death.
3548	787.04 (1)	3rd	In violation of court order, take, entice, etc., minor beyond state limits.
3549	806.13 (1) (b) 3.	3rd	Criminal mischief; damage \$1,000 or more to public communication

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			or any other public service.
3550	810.061 (2)	3rd	Impairing or impeding telephone or power to a dwelling; facilitating or furthering burglary.
3551	810.09 (2) (e)	3rd	Trespassing on posted commercial horticulture property.
3552	812.014 (2) (c) 1.	3rd	Grand theft, 3rd degree; \$300 or more but less than \$5,000.
3553	812.014 (2) (d)	3rd	Grand theft, 3rd degree; \$100 or more but less than \$300, taken from unenclosed curtilage of dwelling.
3554	812.015 (7)	3rd	Possession, use, or attempted use of an antishoplifting or inventory control device countermeasure.
3555	817.234 (1) (a) 2.	3rd	False statement in support of insurance claim.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3556	817.481 (3) (a)	3rd	Obtain credit or purchase with false, expired, counterfeit, etc., credit card, value over \$300.
3557	817.52 (3)	3rd	Failure to redeliver hired vehicle.
3558	817.54	3rd	With intent to defraud, obtain mortgage note, etc., by false representation.
3559	817.60 (5)	3rd	Dealing in credit cards of another.
3560	817.60 (6) (a)	3rd	Forgery; purchase goods, services with false card.
3561	817.61	3rd	Fraudulent use of credit cards over \$100 or more within 6 months.
3562	826.04	3rd	Knowingly marries or has sexual intercourse with person to whom

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			related.
3563	831.01	3rd	Forgery.
3564	831.02	3rd	Uttering forged instrument; utters or publishes alteration with intent to defraud.
3565	831.07	3rd	Forging bank bills, checks, drafts, or promissory notes.
3566	831.08	3rd	Possessing 10 or more forged notes, bills, checks, or drafts.
3567	831.09	3rd	Uttering forged notes, bills, checks, drafts, or promissory notes.
3568	831.11	3rd	Bringing into the state forged bank bills, checks, drafts, or notes.
3569	832.05 (3) (a)	3rd	Cashing or depositing item with intent to defraud.
3570			

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3571	843.08	3rd	False personation.
3572	893.13 (2) (a) 2.	3rd	Purchase of any s. 893.03(1) (c), (2) (c) 1., (2) (c) 2., (2) (c) 3., <del>(2) (c) 5.</del> , (2) (c) 6., (2) (c) 7., (2) (c) 8., (2) (c) 9., <u>(2) (c) 10.</u> , (3), or (4) drugs other than cannabis.
3573	893.147 (2)	3rd	Manufacture or delivery of drug paraphernalia.
3574			
3575			
3576			
3577	(c) LEVEL 3		
3578			
3579			
3580	Florida Statute	Felony Degree	Description
3581	119.10 (2) (b)	3rd	Unlawful use of confidential information from police reports.
	316.066	3rd	Unlawfully obtaining or using

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3582	(3) (b) - (d)		confidential crash reports.
3583	316.193 (2) (b)	3rd	Felony DUI, 3rd conviction.
3584	316.1935 (2)	3rd	Fleeing or attempting to elude law enforcement officer in patrol vehicle with siren and lights activated.
3585	319.30 (4)	3rd	Possession by junkyard of motor vehicle with identification number plate removed.
3586	319.33 (1) (a)	3rd	Alter or forge any certificate of title to a motor vehicle or mobile home.
3587	319.33 (1) (c)	3rd	Procure or pass title on stolen vehicle.
3588	319.33 (4)	3rd	With intent to defraud, possess, sell, etc., a blank, forged, or unlawfully obtained title or registration.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3589	327.35 (2) (b)	3rd	Felony BUI.
3590	328.05 (2)	3rd	Possess, sell, or counterfeit fictitious, stolen, or fraudulent titles or bills of sale of vessels.
3591	328.07 (4)	3rd	Manufacture, exchange, or possess vessel with counterfeit or wrong ID number.
3592	376.302 (5)	3rd	Fraud related to reimbursement for cleanup expenses under the Inland Protection Trust Fund.
3593	379.2431 (1) (e) 5.	3rd	Taking, disturbing, mutilating, destroying, causing to be destroyed, transferring, selling, offering to sell, molesting, or harassing marine turtles, marine turtle eggs, or marine turtle nests in violation of the Marine Turtle Protection Act.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

	379.2431 (1) (e) 6.	3rd	Possessing any marine turtle species or hatchling, or parts thereof, or the nest of any marine turtle species described in the Marine Turtle Protection Act.
3594	379.2431 (1) (e) 7.	3rd	Soliciting to commit or conspiring to commit a violation of the Marine Turtle Protection Act.
3595	400.9935 (4) (a) or (b)	3rd	Operating a clinic, or offering services requiring licensure, without a license.
3596	400.9935 (4) (e)	3rd	Filing a false license application or other required information or failing to report information.
3597	440.1051 (3)	3rd	False report of workers' compensation fraud or retaliation for making such a report.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3598	501.001 (2) (b)	2nd	Tampers with a consumer product or the container using materially false/misleading information.
3599	624.401 (4) (a)	3rd	Transacting insurance without a certificate of authority.
3600	624.401 (4) (b) 1.	3rd	Transacting insurance without a certificate of authority; premium collected less than \$20,000.
3601	626.902 (1) (a) & (b)	3rd	Representing an unauthorized insurer.
3602	697.08	3rd	Equity skimming.
3603	790.15 (3)	3rd	Person directs another to discharge firearm from a vehicle.
3604	806.10 (1)	3rd	Maliciously injure, destroy, or interfere with vehicles or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			equipment used in firefighting.
3605	806.10 (2)	3rd	Interferes with or assaults firefighter in performance of duty.
3606	810.09 (2) (c)	3rd	Trespass on property other than structure or conveyance armed with firearm or dangerous weapon.
3607	812.014 (2) (c) 2.	3rd	Grand theft; \$5,000 or more but less than \$10,000.
3608	812.0145 (2) (c)	3rd	Theft from person 65 years of age or older; \$300 or more but less than \$10,000.
3609	815.04 (5) (b)	2nd	Computer offense devised to defraud or obtain property.
3610	817.034 (4) (a) 3.	3rd	Engages in scheme to defraud (Florida Communications Fraud Act), property valued at less than \$20,000.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3611	817.233	3rd	Burning to defraud insurer.
3612	817.234 (8) (b) & (c)	3rd	Unlawful solicitation of persons involved in motor vehicle accidents.
3613	817.234 (11) (a)	3rd	Insurance fraud; property value less than \$20,000.
3614	817.236	3rd	Filing a false motor vehicle insurance application.
3615	817.2361	3rd	Creating, marketing, or presenting a false or fraudulent motor vehicle insurance card.
3616	817.413 (2)	3rd	Sale of used goods as new.
3617	828.12 (2)	3rd	Tortures any animal with intent to inflict intense pain, serious physical injury, or death.
3618	831.28 (2) (a)	3rd	Counterfeiting a payment instrument with intent to

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3619			defraud or possessing a counterfeit payment instrument.
	831.29	2nd	Possession of instruments for counterfeiting driver licenses or identification cards.
3620			
	838.021 (3) (b)	3rd	Threatens unlawful harm to public servant.
3621			
	843.19	3rd	Injure, disable, or kill police dog or horse.
3622			
	860.15 (3)	3rd	Overcharging for repairs and parts.
3623			
	870.01 (2)	3rd	Riot; inciting or encouraging.
3624			
	893.13 (1) (a) 2.	3rd	Sell, manufacture, or deliver cannabis (or other s. 893.03 (1) (c), (2) (c) 1., (2) (c) 2., (2) (c) 3., <del>(2) (c) 5.</del> , (2) (c) 6., (2) (c) 7., (2) (c) 8., (2) (c) 9., <u>(2) (c) 10.</u> , (3), or (4) drugs).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3625	893.13(1)(d)2.	2nd	Sell, manufacture, or deliver s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., <del>(2)(c)5.</del> (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., <u>(2)(c)10.</u> , (3), or (4) drugs within 1,000 feet of university.
3626	893.13(1)(f)2.	2nd	Sell, manufacture, or deliver s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., <del>(2)(c)5.</del> (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., <u>(2)(c)10.</u> , (3), or (4) drugs within 1,000 feet of public housing facility.
3627	893.13(4)(c)	3rd	Use or hire of minor; deliver to minor other controlled substances.
3628	893.13(6)(a)	3rd	Possession of any controlled substance other than felony possession of cannabis.
3629			

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3630	893.13(7)(a)8.	3rd	Withhold information from practitioner regarding previous receipt of or prescription for a controlled substance.
3631	893.13(7)(a)9.	3rd	Obtain or attempt to obtain controlled substance by fraud, forgery, misrepresentation, etc.
3632	893.13(7)(a)10.	3rd	Affix false or forged label to package of controlled substance.
3633	893.13(7)(a)11.	3rd	Furnish false or fraudulent material information on any document or record required by chapter 893.
3634	893.13(8)(a)1.	3rd	Knowingly assist a patient, other person, or owner of an animal in obtaining a controlled substance through deceptive, untrue, or fraudulent representations in or related to the practitioner's practice.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3635	893.13 (8) (a) 2.	3rd	Employ a trick or scheme in the practitioner's practice to assist a patient, other person, or owner of an animal in obtaining a controlled substance.
3636	893.13 (8) (a) 3.	3rd	Knowingly write a prescription for a controlled substance for a fictitious person.
3637	893.13 (8) (a) 4.	3rd	Write a prescription for a controlled substance for a patient, other person, or an animal if the sole purpose of writing the prescription is a monetary benefit for the practitioner.
3638	918.13 (1) (a)	3rd	Alter, destroy, or conceal investigation evidence.
3639	944.47 (1) (a) 1. & 2.	3rd	Introduce contraband to correctional facility.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3640	944.47(1)(c)	2nd	Possess contraband while upon the grounds of a correctional institution.
3641	985.721	3rd	Escapes from a juvenile facility (secure detention or residential commitment facility).
3642			
3643			
3644			
3645	(d) LEVEL 4		
3646			
3647	Florida Statute	Felony Degree	Description
3648	316.1935(3)(a)	2nd	Driving at high speed or with wanton disregard for safety while fleeing or attempting to elude law enforcement officer who is in a patrol vehicle with siren and lights activated.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3649	499.0051 (1)	3rd	Failure to maintain or deliver transaction history, transaction information, or transaction statements.
3650	499.0051 (5)	2nd	Knowing sale or delivery, or possession with intent to sell, contraband prescription drugs.
3651	517.07 (1)	3rd	Failure to register securities.
3652	517.12 (1)	3rd	Failure of dealer, associated person, or issuer of securities to register.
3653	784.07 (2) (b)	3rd	Battery of law enforcement officer, firefighter, etc.
	784.074 (1) (c)	3rd	Battery of sexually violent predators facility staff.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3654	784.075	3rd	Battery on detention or commitment facility staff.
3655	784.078	3rd	Battery of facility employee by throwing, tossing, or expelling certain fluids or materials.
3656	784.08 (2) (c)	3rd	Battery on a person 65 years of age or older.
3657	784.081 (3)	3rd	Battery on specified official or employee.
3658	784.082 (3)	3rd	Battery by detained person on visitor or other detainee.
3659	784.083 (3)	3rd	Battery on code inspector.
3660	784.085	3rd	Battery of child by throwing, tossing, projecting, or expelling certain fluids or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			materials.
3661	787.03 (1)	3rd	Interference with custody; wrongly takes minor from appointed guardian.
3662	787.04 (2)	3rd	Take, entice, or remove child beyond state limits with criminal intent pending custody proceedings.
3663	787.04 (3)	3rd	Carrying child beyond state lines with criminal intent to avoid producing child at custody hearing or delivering to designated person.
3664	787.07	3rd	Human smuggling.
3665	790.115 (1)	3rd	Exhibiting firearm or weapon within 1,000 feet of a school.
3666	790.115 (2) (b)	3rd	Possessing electric

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3667	790.115 (2) (c)	3rd	<p>weapon or device, destructive device, or other weapon on school property.</p> <p>Possessing firearm on school property.</p>
3668	800.04 (7) (c)	3rd	<p>Lewd or lascivious exhibition; offender less than 18 years.</p>
3669	810.02 (4) (a)	3rd	<p>Burglary, or attempted burglary, of an unoccupied structure; unarmed; no assault or battery.</p>
3670	810.02 (4) (b)	3rd	<p>Burglary, or attempted burglary, of an unoccupied conveyance; unarmed; no assault or battery.</p>
3671	810.06	3rd	Burglary; possession of tools.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3672	810.08 (2) (c)	3rd	Trespass on property, armed with firearm or dangerous weapon.
3673	812.014 (2) (c) 3.	3rd	Grand theft, 3rd degree \$10,000 or more but less than \$20,000.
3674	812.014 (2) (c) 4.-10.	3rd	Grand theft, 3rd degree, a will, firearm, motor vehicle, livestock, etc.
3675	812.0195 (2)	3rd	Dealing in stolen property by use of the Internet; property stolen \$300 or more.
3676	817.505 (4) (a)	3rd	Patient brokering.
3677	817.563 (1)	3rd	Sell or deliver substance other than controlled substance agreed upon, excluding s. 893.03(5)

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			drugs.
3678	817.568 (2) (a)	3rd	Fraudulent use of personal identification information.
3679	817.625 (2) (a)	3rd	Fraudulent use of scanning device, skimming device, or reencoder.
3680	817.625 (2) (c)	3rd	Possess, sell, or deliver skimming device.
3681	828.125 (1)	2nd	Kill, maim, or cause great bodily harm or permanent breeding disability to any registered horse or cattle.
3682	837.02 (1)	3rd	Perjury in official proceedings.
3683	837.021 (1)	3rd	Make contradictory statements in official proceedings.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3684	838.022	3rd	Official misconduct.
3685	839.13 (2) (a)	3rd	Falsifying records of an individual in the care and custody of a state agency.
3686	839.13 (2) (c)	3rd	Falsifying records of the Department of Children and Families.
3687	843.021	3rd	Possession of a concealed handcuff key by a person in custody.
3688	843.025	3rd	Deprive law enforcement, correctional, or correctional probation officer of means of protection or communication.
3689	843.15 (1) (a)	3rd	Failure to appear while on bail for felony (bond estreature or bond jumping).

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3690	847.0135 (5) (c)	3rd	Lewd or lascivious exhibition using computer; offender less than 18 years.
3691	874.05 (1) (a)	3rd	Encouraging or recruiting another to join a criminal gang.
3692	893.13 (2) (a) 1.	2nd	Purchase of cocaine (or other s. 893.03 (1) (a), (b), or (d), (2) (a), (2) (b), or <u>(2) (c) 5.</u> <del>(2) (c) 4.</del> drugs).
3693	914.14 (2)	3rd	Witnesses accepting bribes.
3694	914.22 (1)	3rd	Force, threaten, etc., witness, victim, or informant.
3695	914.23 (2)	3rd	Retaliation against a witness, victim, or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3696			informant, no bodily injury.
3697	918.12	3rd	Tampering with jurors.
3698	934.215	3rd	Use of two-way communications device to facilitate commission of a crime.
3700			
3701			
3702			
3703	(e)	LEVEL 5	
3704			
3705			
3706	Florida Statute	Felony Degree	Description
3707	316.027 (2) (a)	3rd	Accidents involving personal injuries other than serious bodily injury, failure to stop; leaving scene.
3708	316.1935 (4) (a)	2nd	Aggravated fleeing or eluding.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3709	316.80 (2)	2nd	Unlawful conveyance of fuel; obtaining fuel fraudulently.
3710	322.34 (6)	3rd	Careless operation of motor vehicle with suspended license, resulting in death or serious bodily injury.
3711	327.30 (5)	3rd	Vessel accidents involving personal injury; leaving scene.
	379.365 (2) (c) 1.	3rd	Violation of rules relating to: willful molestation of stone crab traps, lines, or buoys; illegal bartering, trading, or sale, conspiring or aiding in such barter, trade, or sale, or supplying, agreeing to supply, aiding in supplying, or giving away stone crab trap tags or certificates; making, altering, forging, counterfeiting, or reproducing stone crab trap tags; possession of forged, counterfeit, or imitation stone

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			crab trap tags; and engaging in the commercial harvest of stone crabs while license is suspended or revoked.
3712	379.367 (4)	3rd	Willful molestation of a commercial harvester's spiny lobster trap, line, or buoy.
3713	379.407 (5) (b) 3.	3rd	Possession of 100 or more undersized spiny lobsters.
3714	381.0041 (11) (b)	3rd	Donate blood, plasma, or organs knowing HIV positive.
3715	440.10 (1) (g)	2nd	Failure to obtain workers' compensation coverage.
3716	440.105 (5)	2nd	Unlawful solicitation for the purpose of making workers' compensation claims.
3717	440.381 (2)	2nd	Submission of false, misleading, or incomplete information with the purpose of avoiding or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			reducing workers' compensation premiums.
3718	624.401 (4) (b) 2.	2nd	Transacting insurance without a certificate or authority; premium collected \$20,000 or more but less than \$100,000.
3719	626.902 (1) (c)	2nd	Representing an unauthorized insurer; repeat offender.
3720	790.01 (2)	3rd	Carrying a concealed firearm.
3721	790.162	2nd	Threat to throw or discharge destructive device.
3722	790.163 (1)	2nd	False report of bomb, explosive, weapon of mass destruction, or use of firearms in violent manner.
3723	790.221 (1)	2nd	Possession of short-barreled shotgun or machine gun.
3724	790.23	2nd	Felons in possession of

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			firearms, ammunition, or electronic weapons or devices.
3725	796.05 (1)	2nd	Live on earnings of a prostitute; 1st offense.
3726	800.04 (6) (c)	3rd	Lewd or lascivious conduct; offender less than 18 years of age.
3727	800.04 (7) (b)	2nd	Lewd or lascivious exhibition; offender 18 years of age or older.
3728	806.111 (1)	3rd	Possess, manufacture, or dispense fire bomb with intent to damage any structure or property.
3729	812.0145 (2) (b)	2nd	Theft from person 65 years of age or older; \$10,000 or more but less than \$50,000.
3730	812.015 (8)	3rd	Retail theft; property stolen is valued at \$300 or more and one

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			or more specified acts.
3731	812.019 (1)	2nd	Stolen property; dealing in or trafficking in.
3732	812.131 (2) (b)	3rd	Robbery by sudden snatching.
3733	812.16 (2)	3rd	Owning, operating, or conducting a chop shop.
3734	817.034 (4) (a) 2.	2nd	Communications fraud, value \$20,000 to \$50,000.
3735	817.234 (11) (b)	2nd	Insurance fraud; property value \$20,000 or more but less than \$100,000.
3736	817.2341 (1), (2) (a) & (3) (a)	3rd	Filing false financial statements, making false entries of material fact or false statements regarding property values relating to the solvency of an insuring entity.
3737	817.568 (2) (b)	2nd	Fraudulent use of personal

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			identification information; value of benefit, services received, payment avoided, or amount of injury or fraud, \$5,000 or more or use of personal identification information of 10 or more persons.
3738	817.611(2)(a)	2nd	Traffic in or possess 5 to 14 counterfeit credit cards or related documents.
3739	817.625(2)(b)	2nd	Second or subsequent fraudulent use of scanning device, skimming device, or reencoder.
3740	825.1025(4)	3rd	Lewd or lascivious exhibition in the presence of an elderly person or disabled adult.
3741	827.071(4)	2nd	Possess with intent to promote any photographic material, motion picture, etc., which includes sexual conduct by a

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3742	827.071 (5)	3rd	child. Possess, control, or intentionally view any photographic material, motion picture, etc., which includes sexual conduct by a child.
3743	839.13 (2) (b)	2nd	Falsifying records of an individual in the care and custody of a state agency involving great bodily harm or death.
3744	843.01	3rd	Resist officer with violence to person; resist arrest with violence.
3745	847.0135 (5) (b)	2nd	Lewd or lascivious exhibition using computer; offender 18 years or older.
3746	847.0137 (2) & (3)	3rd	Transmission of pornography by electronic device or equipment.
3747			

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3748	847.0138 (2) & (3)	3rd	Transmission of material harmful to minors to a minor by electronic device or equipment.
3749	874.05(1)(b)	2nd	Encouraging or recruiting another to join a criminal gang; second or subsequent offense.
3750	874.05(2)(a)	2nd	Encouraging or recruiting person under 13 years of age to join a criminal gang.
3751	893.13(1)(a)1.	2nd	Sell, manufacture, or deliver cocaine (or other s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or <u>(2)(c)5.</u> <del>(2)(c)4.</del> drugs).
	893.13(1)(c)2.	2nd	Sell, manufacture, or deliver cannabis (or other s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., <del>(2)(c)5.</del> (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., <u>(2)(c)10.</u> , (3), or (4) drugs) within 1,000 feet of a

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3752	893.13(1)(d)1.	1st	<p>child care facility, school, or state, county, or municipal park or publicly owned recreational facility or community center.</p> <p>Sell, manufacture, or deliver cocaine (or other s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or <u>(2)(c)5.</u> <del>(2)(e)4.</del> drugs) within 1,000 feet of university.</p>
3753	893.13(1)(e)2.	2nd	<p>Sell, manufacture, or deliver cannabis or other drug prohibited under s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., <del>(2)(e)5.,</del> (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., <u>(2)(c)10.,</u> (3), or (4) within 1,000 feet of property used for religious services or a specified business site.</p>
3754	893.13(1)(f)1.	1st	<p>Sell, manufacture, or deliver cocaine (or other s.</p>

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3755			893.03(1)(a), (1)(b), (1)(d), or (2)(a), (2)(b), or <u>(2)(c)5.</u> <del>(2)(c)4.</del> drugs) within 1,000 feet of public housing facility.
	893.13(4)(b)	2nd	Use or hire of minor; deliver to minor other controlled substance.
3756			
	893.1351(1)	3rd	Ownership, lease, or rental for trafficking in or manufacturing of controlled substance.
3757			
3758			
3759			
3760			
3761	(g) LEVEL 7		
3762			
	Florida	Felony	
	Statute	Degree	Description
3763			
	316.027(2)(c)	1st	Accident involving death, failure to stop; leaving scene.
3764			

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3765	316.193 (3) (c) 2.	3rd	DUI resulting in serious bodily injury.
3766	316.1935 (3) (b)	1st	Causing serious bodily injury or death to another person; driving at high speed or with wanton disregard for safety while fleeing or attempting to elude law enforcement officer who is in a patrol vehicle with siren and lights activated.
3767	327.35 (3) (c) 2.	3rd	Vessel BUI resulting in serious bodily injury.
3767	402.319 (2)	2nd	Misrepresentation and negligence or intentional act resulting in great bodily harm, permanent disfiguration, permanent disability, or death.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3768	409.920 (2) (b) 1.a.	3rd	Medicaid provider fraud; \$10,000 or less.
3769	409.920 (2) (b) 1.b.	2nd	Medicaid provider fraud; more than \$10,000, but less than \$50,000.
3770	456.065 (2)	3rd	Practicing a health care profession without a license.
3771	456.065 (2)	2nd	Practicing a health care profession without a license which results in serious bodily injury.
3772	458.327 (1)	3rd	Practicing medicine without a license.
3773	459.013 (1)	3rd	Practicing osteopathic medicine without a license.
3774	460.411 (1)	3rd	Practicing chiropractic

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3775			medicine without a license.
3776	461.012 (1)	3rd	Practicing podiatric medicine without a license.
3777	462.17	3rd	Practicing naturopathy without a license.
3778	463.015 (1)	3rd	Practicing optometry without a license.
3779	464.016 (1)	3rd	Practicing nursing without a license.
3780	465.015 (2)	3rd	Practicing pharmacy without a license.
3781	466.026 (1)	3rd	Practicing dentistry or dental hygiene without a license.
3782	467.201	3rd	Practicing midwifery without a license.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3783	468.366	3rd	Delivering respiratory care services without a license.
3784	483.828 (1)	3rd	Practicing as clinical laboratory personnel without a license.
3785	483.901 (7)	3rd	Practicing medical physics without a license.
3786	484.013 (1) (c)	3rd	Preparing or dispensing optical devices without a prescription.
3787	484.053	3rd	Dispensing hearing aids without a license.
3788	494.0018 (2)	1st	Conviction of any violation of chapter 494 in which the total money and property unlawfully obtained exceeded \$50,000 and there were five or more victims.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3789	560.123 (8) (b) 1.	3rd	Failure to report currency or payment instruments exceeding \$300 but less than \$20,000 by a money services business.
3790	560.125 (5) (a)	3rd	Money services business by unauthorized person, currency or payment instruments exceeding \$300 but less than \$20,000.
3791	655.50 (10) (b) 1.	3rd	Failure to report financial transactions exceeding \$300 but less than \$20,000 by financial institution.
3792	775.21 (10) (a)	3rd	Sexual predator; failure to register; failure to renew driver license or identification card; other registration violations.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3793	775.21 (10) (b)	3rd	Sexual predator working where children regularly congregate.
3794	775.21 (10) (g)	3rd	Failure to report or providing false information about a sexual predator; harbor or conceal a sexual predator.
3795	782.051 (3)	2nd	Attempted felony murder of a person by a person other than the perpetrator or the perpetrator of an attempted felony.
3796	782.07 (1)	2nd	Killing of a human being by the act, procurement, or culpable negligence of another (manslaughter).
	782.071	2nd	Killing of a human being or unborn child by the operation of a motor vehicle in a

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3797			reckless manner (vehicular homicide).
3798	782.072	2nd	Killing of a human being by the operation of a vessel in a reckless manner (vessel homicide).
3799	784.045 (1) (a) 1.	2nd	Aggravated battery; intentionally causing great bodily harm or disfigurement.
3800	784.045 (1) (a) 2.	2nd	Aggravated battery; using deadly weapon.
3801	784.045 (1) (b)	2nd	Aggravated battery; perpetrator aware victim pregnant.
3802	784.048 (4)	3rd	Aggravated stalking; violation of injunction or court order.
3802	784.048 (7)	3rd	Aggravated stalking;

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3803			violation of court order.
	784.07 (2) (d)	1st	Aggravated battery on law enforcement officer.
3804			
	784.074 (1) (a)	1st	Aggravated battery on sexually violent predators facility staff.
3805			
	784.08 (2) (a)	1st	Aggravated battery on a person 65 years of age or older.
3806			
	784.081 (1)	1st	Aggravated battery on specified official or employee.
3807			
	784.082 (1)	1st	Aggravated battery by detained person on visitor or other detainee.
3808			
	784.083 (1)	1st	Aggravated battery on code inspector.
3809			

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3810	787.06 (3) (a) 2.	1st	Human trafficking using coercion for labor and services of an adult.
3811	787.06 (3) (e) 2.	1st	Human trafficking using coercion for labor and services by the transfer or transport of an adult from outside Florida to within the state.
3812	790.07 (4)	1st	Specified weapons violation subsequent to previous conviction of s. 790.07(1) or (2).
3813	790.16 (1)	1st	Discharge of a machine gun under specified circumstances.
3814	790.165 (2)	2nd	Manufacture, sell, possess, or deliver hoax bomb.
	790.165 (3)	2nd	Possessing, displaying, or threatening to use any hoax bomb while committing or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3815	790.166 (3)	2nd	<p>attempting to commit a felony.</p> <p>Possessing, selling, using, or attempting to use a hoax weapon of mass destruction.</p>
3816	790.166 (4)	2nd	<p>Possessing, displaying, or threatening to use a hoax weapon of mass destruction while committing or attempting to commit a felony.</p>
3817	790.23	1st, PBL	<p>Possession of a firearm by a person who qualifies for the penalty enhancements provided for in s. 874.04.</p>
3818	794.08 (4)	3rd	<p>Female genital mutilation; consent by a parent, guardian, or a person in custodial authority to a victim younger than 18 years of age.</p>

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3819	796.05 (1)	1st	Live on earnings of a prostitute; 2nd offense.
3820	796.05 (1)	1st	Live on earnings of a prostitute; 3rd and subsequent offense.
3821	800.04 (5) (c) 1.	2nd	Lewd or lascivious molestation; victim younger than 12 years of age; offender younger than 18 years of age.
3822	800.04 (5) (c) 2.	2nd	Lewd or lascivious molestation; victim 12 years of age or older but younger than 16 years of age; offender 18 years of age or older.
3823	800.04 (5) (e)	1st	Lewd or lascivious molestation; victim 12 years of age or older but younger than 16 years;

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3824	806.01 (2)	2nd	offender 18 years or older; prior conviction for specified sex offense. Maliciously damage structure by fire or explosive.
3825	810.02 (3) (a)	2nd	Burglary of occupied dwelling; unarmed; no assault or battery.
3826	810.02 (3) (b)	2nd	Burglary of unoccupied dwelling; unarmed; no assault or battery.
3827	810.02 (3) (d)	2nd	Burglary of occupied conveyance; unarmed; no assault or battery.
3828	810.02 (3) (e)	2nd	Burglary of authorized emergency vehicle.
3829	812.014 (2) (a) 1.	1st	Property stolen, valued at \$100,000 or more or a semitrailer deployed

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3830	812.014 (2) (b) 2.	2nd	<p>by a law enforcement officer; property stolen while causing other property damage; 1st degree grand theft.</p> <p>Property stolen, cargo valued at less than \$50,000, grand theft in 2nd degree.</p>
3831	812.014 (2) (b) 3.	2nd	<p>Property stolen, emergency medical equipment; 2nd degree grand theft.</p>
3832	812.014 (2) (b) 4.	2nd	<p>Property stolen, law enforcement equipment from authorized emergency vehicle.</p>
3833	812.0145 (2) (a)	1st	<p>Theft from person 65 years of age or older; \$50,000 or</p>

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			more.
3834	812.019 (2)	1st	Stolen property; initiates, organizes, plans, etc., the theft of property and traffics in stolen property.
3835	812.131 (2) (a)	2nd	Robbery by sudden snatching.
3836	812.133 (2) (b)	1st	Carjacking; no firearm, deadly weapon, or other weapon.
3837	817.034 (4) (a) 1.	1st	Communications fraud, value greater than \$50,000.
3838	817.234 (8) (a)	2nd	Solicitation of motor vehicle accident victims with intent to defraud.
3839	817.234 (9)	2nd	Organizing, planning, or participating in an

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3840	817.234 (11) (c)	intentional motor vehicle collision.
3841	817.2341 (2) (b) & (3) (b)	1st Insurance fraud; property value \$100,000 or more.  1st Making false entries of material fact or false statements regarding property values relating to the solvency of an insuring entity which are a significant cause of the insolvency of that entity.
3842	817.535 (2) (a)	3rd Filing false lien or other unauthorized document.
3843	817.611 (2) (b)	2nd Traffic in or possess 15 to 49 counterfeit credit cards or related documents.
3844	825.102 (3) (b)	2nd Neglecting an elderly person

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3845	825.103 (3) (b)	2nd	<p>or disabled adult causing great bodily harm, disability, or disfigurement.</p> <p>Exploiting an elderly person or disabled adult and property is valued at \$10,000 or more, but less than \$50,000.</p>
3846	827.03 (2) (b)	2nd	<p>Neglect of a child causing great bodily harm, disability, or disfigurement.</p>
3847	827.04 (3)	3rd	<p>Impregnation of a child under 16 years of age by person 21 years of age or older.</p>
3848	837.05 (2)	3rd	<p>Giving false information about alleged capital felony to a law enforcement officer.</p>
3849			

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3850	838.015	2nd	Bribery.
3851	838.016	2nd	Unlawful compensation or reward for official behavior.
3852	838.021 (3) (a)	2nd	Unlawful harm to a public servant.
3853	838.22	2nd	Bid tampering.
3854	843.0855 (2)	3rd	Impersonation of a public officer or employee.
3855	843.0855 (3)	3rd	Unlawful simulation of legal process.
3856	843.0855 (4)	3rd	Intimidation of a public officer or employee.
3857	847.0135 (3)	3rd	Solicitation of a child, via a computer service, to commit an unlawful sex act.
	847.0135 (4)	2nd	Traveling to meet a minor to commit an

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3858			unlawful sex act.
	872.06	2nd	Abuse of a dead human body.
3859			
	874.05 (2) (b)	1st	Encouraging or recruiting person under 13 to join a criminal gang; second or subsequent offense.
3860			
	874.10	1st, PBL	Knowingly initiates, organizes, plans, finances, directs, manages, or supervises criminal gang-related activity.
3861			
	893.13 (1) (c) 1.	1st	Sell, manufacture, or deliver cocaine (or other drug prohibited under s. 893.03 (1) (a), (1) (b), (1) (d), (2) (a), (2) (b), or <u>(2) (c) 5.</u> <del>(2) (e) 4.</del> ) within 1,000 feet of a child care facility, school, or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3862	893.13(1)(e)1.	1st	state, county, or municipal park or publicly owned recreational facility or community center.
3863	893.13(4)(a)	1st	Sell, manufacture, or deliver cocaine or other drug prohibited under s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or <u>(2)(c)5.</u> <del>(2)(c)4.</del> , within 1,000 feet of property used for religious services or a specified business site.
3864	893.135(1)(a)1.	1st	Trafficking in cannabis, more than 25 lbs., less than 2,000 lbs.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3865	893.135 (1) (b) 1.a.	1st	Trafficking in cocaine, more than 28 grams, less than 200 grams.
3866	893.135 (1) (c) 1.a.	1st	Trafficking in illegal drugs, more than 4 grams, less than 14 grams.
3867	893.135 (1) (c) 2.a.	1st	Trafficking in hydrocodone, 14 grams or more, less than 28 grams.
3868	893.135 (1) (c) 2.b.	1st	Trafficking in hydrocodone, 28 grams or more, less than 50 grams.
3869	893.135 (1) (c) 3.a.	1st	Trafficking in oxycodone, 7 grams or more, less than 14 grams.
3870	893.135 (1) (c) 3.b.	1st	Trafficking in oxycodone, 14 grams or more, less than 25 grams.
3871			

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3872	893.135 (1) (c) 4.b. (I)	1st	Trafficking in fentanyl, 4 grams or more, less than 14 grams.
3873	893.135 (1) (d) 1.a.	1st	Trafficking in phencyclidine, 28 grams or more, less than 200 grams.
3874	893.135 (1) (e) 1.	1st	Trafficking in methaqualone, 200 grams or more, less than 5 kilograms.
3875	893.135 (1) (f) 1.	1st	Trafficking in amphetamine, 14 grams or more, less than 28 grams.
3876	893.135 (1) (g) 1.a.	1st	Trafficking in flunitrazepam, 4 grams or more, less than 14 grams.
	893.135 (1) (h) 1.a.	1st	Trafficking in gamma- hydroxybutyric acid (GHB), 1 kilogram or more, less than 5

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

			kilograms.
3877	893.135 (1) (j) 1.a.	1st	Trafficking in 1,4- Butanediol, 1 kilogram or more, less than 5 kilograms.
3878	893.135 (1) (k) 2.a.	1st	Trafficking in Phenethylamines, 10 grams or more, less than 200 grams.
3879	893.135 (1) (m) 2.a.	1st	Trafficking in synthetic cannabinoids, 280 grams or more, less than 500 grams.
3880	893.135 (1) (m) 2.b.	1st	Trafficking in synthetic cannabinoids, 500 grams or more, less than 1,000 grams.
3881	893.135 (1) (n) 2.a.	1st	Trafficking in n-benzyl phenethylamines, 14 grams or more, less than 100 grams.
3882	893.1351 (2)	2nd	Possession of place for trafficking in or

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3883	896.101 (5) (a)	3rd	<p>manufacturing of controlled substance.</p> <p>Money laundering, financial transactions exceeding \$300 but less than \$20,000.</p>
3884	896.104 (4) (a) 1.	3rd	<p>Structuring transactions to evade reporting or registration requirements, financial transactions exceeding \$300 but less than \$20,000.</p>
3885	943.0435 (4) (c)	2nd	<p>Sexual offender vacating permanent residence; failure to comply with reporting requirements.</p>
3886	943.0435 (8)	2nd	<p>Sexual offender; remains in state after indicating intent to leave; failure to comply with reporting requirements.</p>

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3887	943.0435 (9) (a)	3rd	Sexual offender; failure to comply with reporting requirements.
3888	943.0435 (13)	3rd	Failure to report or providing false information about a sexual offender; harbor or conceal a sexual offender.
3889	943.0435 (14)	3rd	Sexual offender; failure to report and reregister; failure to respond to address verification; providing false registration information.
3890	944.607 (9)	3rd	Sexual offender; failure to comply with reporting requirements.
3891	944.607 (10) (a)	3rd	Sexual offender; failure to submit to the taking

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3892	944.607(12)	3rd	<p>of a digitized                      photograph.</p> <p>Failure to report or                      providing false                      information about a sexual                      offender; harbor or                      conceal a sexual offender.</p>
3893	944.607(13)	3rd	<p>Sexual offender; failure to                      report and reregister;                      failure to respond to address                      verification; providing false                      registration information.</p>
3894	985.4815(10)	3rd	<p>Sexual offender; failure                      to submit to the taking                      of a digitized                      photograph.</p>
3895	985.4815(12)	3rd	<p>Failure to report or                      providing false                      information about a                      sexual offender; harbor                      or conceal a sexual</p>

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3896 offender.

3897

3898

3899

3900 985.4815(13) 3rd Sexual offender; failure to

3901 report and reregister;

3902 failure to respond to

3903 address verification;

3904 providing false registration

3905 information.

3906

3907 Section 20. For the 2018-2019 fiscal year:

3908 (1) The nonrecurring sum of \$27,035,532 is appropriated

3909 from the Federal Grants Trust Fund to the Department of Children

3910 and Families for expenditure of funds related to the second year

3911 of the State Targeted Response to the Opioid Crisis grant, to

3912 increase access to treatment, reduce unmet treatment needs, and

3913 reduce opioid overdose-related deaths through prevention,

3914 treatment, and recovery activities.

3915 (2) To enhance the entire substance abuse continuum of

3916 care, the sum of \$14,626,911 in recurring funds is appropriated

3917 from the General Revenue Fund to the Department of Children and

3918 Families for community-based services to address the opioid

3919 crisis, including, but not limited to, outreach, addiction

3920 treatment, and recovery support services. Funding under this

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3914 subsection shall be used to expand capacity to increase access  
3915 to and reduce waitlists for treatment; increase efforts to  
3916 effectively engage and retain in treatment youth, pregnant  
3917 women, high-risk populations, and high utilizers of acute care  
3918 services; and further develop a recovery-based model of care.  
3919 Funding for specific services may include, but are not limited  
3920 to, case management, residential services, outpatient services,  
3921 aftercare services, and medication-assisted treatment.  
3922 Medication-assisted treatment may include, but is not limited  
3923 to, methadone, buprenorphine, and naltrexone extended release  
3924 injectable.

3925 (3) The recurring sum of \$5,000,000 from the General  
3926 Revenue Fund is appropriated to the Department of Health for the  
3927 purchase of emergency opioid antagonists to be made available to  
3928 emergency responders.

3929 (4) The recurring sum of \$6 million from the General  
3930 Revenue Fund is appropriated to the Office of State Court  
3931 Administrator for medication-assisted treatment of substance  
3932 abuse disorders in individuals involved in the criminal justice  
3933 system, individuals who have a high likelihood of becoming  
3934 involved in the criminal justice system, or individuals who are  
3935 in court-ordered, community-based drug treatment. Such  
3936 medication-assisted treatment may include, but is not limited  
3937 to, methadone, buprenorphine, and naltrexone extended release  
3938 injectable.

ENROLLED

CS/CS/HB 21, Engrossed 2

2018 Legislature

3939 |       (5) The sums of \$873,089 in recurring funds and \$117,700  
3940 | in nonrecurring funds are appropriated from the General Revenue  
3941 | Fund to the Department of Health for improvements to the  
3942 | Prescription Drug Monitoring Program system pursuant to s.  
3943 | 893.055, Florida Statutes.  
3944 |       Section 21. Except as otherwise expressly provided in this  
3945 | act, this act shall take effect July 1, 2018.